Efectos biológicos de la cardiolipina extracelular en pulmón. Acción antiviral frente a la infección por el virus respiratorio sincitial by Lorenzo Avilés, Alba de
UNIVERSIDAD COMPLUTENSE DE MADRID 
FACULTAD DE CIENCIAS QUÍMICAS 
Departamento de Bioquímica y Biología Molecular I 
 
 
 
 
 
TESIS DOCTORAL 
 
Efectos biológicos de la cardiolipina extracelular en pulmón. 
Acción antiviral frente a la infección por el virus respiratorio 
sincitial 
 
 
MEMORIA PARA OPTAR AL GRADO DE DOCTOR 
 
PRESENTADA POR 
 
Alba de Lorenzo Avilés 
 
Directora 
 
Cristina Casals Carro 
 
 
Madrid, 2018 
 
 
 
 
© Alba de Lorenzo Avilés, 2017 


UNIVERSIDAD COMPLUTENSE DE MADRID
FACULTAD DE CIENCIAS QUÍMICAS
Departamento de Bioquímica y Biología Molecular I
TESIS DOCTORAL
EFECTOS BIOLÓGICOS DE LA CARDIOLIPINA 
EXTRACELULAR EN PULMÓN. ACCIÓN ANTIVIRAL FRENTE A 
LA INFECCIÓN POR EL VIRUS RESPIRATORIO SINCITIAL.
MEMORIA PARA OPTAR AL GRADO DE DOCTOR 
Presentada por
Alba de Lorenzo Avilés
Directora
Dra. Cristina Casals Carro
Madrid, 2017

COMPLUTENSE UNIVERSITY OF MADRID
CHEMISTRY FACULTY
Department of Biochemistry and Molecular Biology I
BIOLOGICAL EFFECTS OF EXTRACELLULAR CARDIOLIPIN 
IN THE LUNG. ANTIVIRAL ACTION AGAINST RESPIRATORY 
SYNCYTIAL VIRUS INFECTION.
DOCTORAL THESIS OF
ALBA DE LORENZO AVILÉS
DIRECTOR
DRA. CRISTINA CASALS CARRO
Madrid, 2017

A mi familia.
A mis amigos.

The research for this doctoral thesis has been performed at the Department of 
Biochemistry and Molecular Biology I of the Complutense University of Madrid, 
under the supervision of Professor Cristina Casals Carro. 
Part of the experimental work was conducted in close collaboration with Dr. Isidoro 
Martínez González from the Institute of Health Carlos III and CIBER of Respiratory 
Diseases, at the National Center of Microbiology of Madrid. 
The completion of this thesis was possible thanks to a fellowship for initiation into 
investigation from CIBERES, the funding of the Ministry of Science and Innovation 
(SAF2012-32728 and SAF2015-65307-R) and the funding of CIBER of Respiratory 
Diseases (Institute of Health Carlos III-CB06/06/0002).

TABLE OF CONTENTS

LIST OF ABBREVIATIONS...................................................................19
RESUMEN.............................................................................................25
SUMMARY..............................................................................................35
1. INTRODUCTION...............................................................................45
1.1. The respiratory system.................................................................... 47 
1.1.1. Lung parenchyma............................................................... 48 
1.1.2. The respiratory tract and its role as a defensive barrier... 50
1.1.3. Lung surfactant....................................................................... 51 
1.1.3.1. Lung surfactant composition................................. 52 
1.1.3.2. Lung surfactant biological cycle............................ 53 
1.2. Respiratory infections and pulmonary pathogens....................... 54 
1.2.1 Respiratory syncytial virus.................................................. 59
1.2.1.1. Morphology.............................................................59 
1.2.1.2. Viral proteins.......................................................... 60
1.2.1.3. Replication cycle................................................... 62
1.2.1.4. Immune innate response against RSV................... 64
1.3. Immune innate system in the alveolar space............................... 65  
1.3.1. Soluble immune components............................................ 66 
1.3.2. Alveolar epithelial cells...................................................... 66 
1.3.3. Alveolar macrophages....................................................... 67 
1.3.4. Role of surfactant components in the immune innate 
defense......................................................................................... 69
1.3.4.1. Surfactant phospholipids...................................... 70 
1.3.4.2. Surfactant proteins................................................ 71 
1.4. Cardiolipin........................................................................................ 74 
2. HYPOTHESIS AND OBJECTIVES.................................................. 79
3. MATERIALS AND METHODS......................................................... 85
3.1. Biochemical and biophysical methods......................................... 87 
3.1.1. Isolation of rat lung surfactant from BAL.......................... 87 
3.1.2. Isolation of the lipid extract from native surfactant.......... 87 
3.1.3. Quantification of phospholipids......................................... 88  
3.1.4. Preparation of lipid vesicles from the lipid extract
of lung surfactant......................................................................... 88
3.1.5. Preparation of cardiolipin vesicles.................................... 88
3.1.6. Dynamic light scattering (DLS) analysis............................ 89 
3.1.7. Monolayer experiments..................................................... 89
3.1.8. Interfacial adsorption experiments....................................90 
3.1.9. Diferential scanning calorimetry (DSC)..............................91 
3.1.10. Fluorescence emission anisotropy experiments.............92 
TABLE OF CONTENTS
3.1.11. Binding studies................................................................. 93
3.2. Experiments with mouse and rat alveolar macrophages............ 93 
3.2.1. Isolation of rat alveolar macrophages from the 
bronchoalveolar lavage and culturing......................................... 93
3.2.2. Culture conditions of mouse alveolar macrophage 
cell line (MH-S)............................................................................. 94 
3.2.3. Stimulation of MH-S and rat alveolar macrophages........ 95
3.2.4. Cell viability assays ........................................................... 90
3.2.5. Immunofluorescence microscopy..................................... 95 
3.2.6. Quantification of TNF-α release........................................ 96 
3.2.7. Analysis of Akt, Erk and p38 by western blot....................97 
3.2.8. Determination of total protein amount by bicinchoninic 
acid (BCA) assay.......................................................................... 97 
3.2.9. Gene expression analysis by quantitative real-time 
polymerase chain reaction (qPCR).............................................. 98 
3.3. Experiments with human epithelial cells and respiratory 
syncytial virus (RSV) ............................................................................. 99
3.3.1. Culture conditions of human epithelial cells 
(A549 and Hep-2 cell line) ........................................................... 99
3.3.2. Cell viability assays............................................................ 101
3.3.3. RSV propagation and purification..................................... 101
3.3.4. Determination of viral titers............................................... 102
3.3.5. Gene expression analysis by quantitative real-time 
polymerase chain reaction (qPCR) Immunofluorescence 
microscopy.............................................................................. 103 
 3.3.6. Flow cytometry analysis of RSV binding to A549 cells. 104 
3.4. Experiments with murine epithelial cells and Haemophilus 
 influenzae (NTHi)................................................................................... 105
3.4.1. Culture conditions of murine epithelial cells 
(MLE-12 cell line)......................................................................... 105
3.4.2. Adhesion experiments of NTHi to pneumocytes 
MLE-12...................................................................................... 105
3.4.3. Experiments of internalization of NTHi in 
pneumocytes MLE-12.............................................................. 105
3.4.4. Analysis of Akt phosphorylation by western blot..........  106 
3.5. Statistics ....................................................................................... 106 
4. RESULTS AND DISCUSSION........................................................109
4.1. Anti-inflammatory effect of cardiolipin in alveolar 
macrophages stimulated with bacterial and fungal 
molecular patterns.................................................................... 111
4.1.1. Introduction...................................................................... 111
4.1.2. Experimental design........................................................ 112 
4.1.3.  Results............................................................................ 112 
4.1.3.1. Determination of the size and stability of
TABLE OF CONTENTS
cardiolipi vesicles..............................................................112 
4.1.3.2. Alveolar macrophages are able to 
internalize cardiolipin SUVs...............................................113 
4.1.3.3. Cardiolipin does not impair cell viability 
at the concentrations tested.............................................115
4.1.3.4. Cardiolipin inhibits LPS-elicited 
proinflammatory markers in MH-S macrophages.............116
4.1.3.5. Cardiolipin inhibits LPS-elicited signaling 
pathways in MH-S macrophages .....................................121
4.1.3.6. Cardiolipin inhibits LPS-elicited signaling 
pathways in primary rat alveolar macrophages.................124 
4.1.3.7. Cardiolipin immunomodulatory effect 
is not restricted to the LPS response................................124
4.1.4. Discussion.........................................................................127 
4.2. Antiviral and immunomodulatory effect of cardiolipin
vesicles against respiratory syncytial virus....................................... 136 
4.2.1. Introduction......................................................................  136
4.2.2. Experimental design........................................................ 136
4.2.3. Results.............................................................................. 137 
4.2.3.1. Cardiolipin does not impair epithelium 
viability at the tested concentrations................................137 
4.2.3.2. Cardiolipin inhibits viral replication......................138 
4.2.3.3. Cardiolipin inhibits RSV attachment 
to the epithelium surface.................................................. 139
4.2.3.4. Cardiolipin acts at a lower dose than POPG....... 140 
4.2.3.5. Cardiolipin vesicles inhibit the expression 
of RSV-induced infection markers in alveolar 
epithelial cells................................................................... 142 
4.2.3.6. Cardiolipin antiviral action is preserved 
regardless of the presence of pulmonary surfactant 
components..................................................................... 144 
4.2.3.7. Internalized CL vesicles did not affect viral 
replication but inhibit TNF-α production in RSV-infected 
A549 AECs....................................................................... 145 
4.2.4. Discussion........................................................................ 147 
4.3. Cardiolipin cells against Haemophilus influenzae infection 
of murine alveolar epithelial cells....................................................... 151 
4.3.1. Introduction................................................................................. 151
4.3.2. Experimental design................................................................... 153 
4.3.3.  Results....................................................................................... 153
4.3.3.1. Cardiolipin inhibits NTHi internalization into epithelial cells 
without affecting bacterial adhesion to the cell surface.............. 154 
4.3.3.2. Cardiolipin inhibits NTHi-induced Akt phosphorylation..154
4.3.4. Discussion....................................................................................154
4.4. Cardiolipin effects on pulmonary surfactant...............................157 
TABLE OF CONTENTS
4.4.1. Introduction......................................................................157
4.4.2. Experimental design........................................................158 
4.4.3.  Results............................................................................159 
4.4.3.1. Surfactant inhibition by cardiolipin......................159 
4.4.3.2. SP-A binds cardiolipin.........................................161
4.4.3.3 Cardiolipin is able to insert into surfactant 
monolayers.......................................................................162 
4.4.3.4. Cardiolipin effect on the physical properties 
of surfactant membranes in the absence and  
presence of SP-A.............................................................164 
4.4.4. Discussion........................................................................165 
5. CONCLUSIONS....................................................................................... 171
6. REFERENCES.......................................................................................... 175
TABLE OF CONTENTS


ABBREVIATIONS

21
LIST OF ABBREVIATIONS
ΔH  Enthalpy of the gel-to-liquid phase transition
T1/2  Temperature width at half-height of the DSC peak
γ  Surface tension
ABCA3 ATP-binding cassette transporter A3
AEC  Alveolar epithelial cell
ALI  Acute lung injury
AM  Alveolar macrophage
ARDS  Acute respiratory distress syndrome
ATCC  American Type Culture Collection
BCA  Bicinchoninic acid
cAMP  Cyclic adenosine monophosphate
CD  Cluster of differentiation
CD200R Cluster of differentiation 200 receptor
cDNA  Complementary deoxyribonucleic acid
CL  Cardiolipin
COX2  Cyclooxygenase 2
Cp  Excess heat capacity
CRD  Carbohydrate recognition domain
CXCL10 C-X-C motif chemokines 10 
DAMPs Damage-associated molecular patterns
DAPI  4’,6-diamidino-2-phenylindole
DiI  1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine   perchlorate
DLS  Dynamic Light Scattering
DMEM Dulbecco’s modified Eagle’s medium
DMSO Dimethyl sulfoxide
DNA  Deoxyribonucleic acid
DNase I Deoxyribonuclease I
dNTP  Deoxynucleotide triphosphate
DPPC  Dipalmitoylphosphatidylcholine
DSC  Differential scanning calorimetry
dsRNA Double-stranded ribonucleic acid
ECL  Enhanced chemiluminescent
EDTA  Ethylenediaminetetraacetic acid
ELISA  Enzyme-linked immune sorbent assay
ERK  Extracellular signal-regulated kinase
FBS  Fetal bovine serum
FCS  Fetal calf serum
FITC  Fluorescein isothiocyanate
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GM-CSF Granulocyte macrophage colony stimulation factor
HRP  Horseradish peroxidase
IFN  Interferon
IL  Interleukin
ABBREVIATIONS
22
ABBREVIATIONS
iNOS  Inducible nitric oxide synthase
IRF  Interferon regulatory factor
ISG15  Interferon-stimulated gene 15
ISGF3  Interferon-stimulated gene factor 3
ISRE  Interferon-stimulated response element
JAK  Janus kinase
JNK  c-Jun N-terminal kinase
Lα  Liquid-crystalline phase
Lβ  Gel phase
LB  Lamellar body
LBP  Lipopolysaccharide-binding protein
Lo  Liquid-ordered phase
LPS  Lipopolysaccharide
MAPK  Mitogen-activated protein kinase
MCP-1 Monocyte chemoattractant protein-1
MLV  Multilamellar vesicle
moi  Multiplicity of infection
MVB  Multivesicular body
NF-AT  Nuclear factor of activated T cells
NF-kB  Nuclear factor-kB
NMR  Nuclear magnetic resonance
PA  Palmitic acid
PAMPs Pathogen-associated molecular patterns
PBS  Phosphate buffered saline
PC  Phosphatidylcholine
PE  Phosphatidylethanolamine
pfu  Plaque-forming units
PG  Phosphatidylglycerol
PGE2  Prostaglandin E2
PI  Phosphatidylinositol
PI3K  Phosphatidylinositol-3-kinase
PKC  Protein kinase C
PMSF  Phenylmethylsulfonyl fluoride
POPC  Palmitoyloleoylphosphatidylcholine
POPG  Palmitoyloleoylphosphatidylglycerol
PRRs  Pattern recognition receptors
PVDF  Polyvinylidene difluoride
qPCR  Quantitative real-time polymerase chain reaction
RANTES Regulated on activation normal T cell expressed and secreted
RDS  Respiratory distress syndrome
RIG-I  Retinoic acid-inducible gene I
RLRs  RIG-I-like receptors
RNA  Ribonucleic acid
RNase Ribonuclease
ROS  Reactive oxygen species
23
RPMI   Roswell Park Memorial Institute
RSV   Respiratory syncytial virus
SDS    Sodium dodecyl-sulphate
SDS-PAGE   Sodium dodecyl-sulphate polyacrylamide gel electrophoresis
S.E                 Standard error
SP-A, -B, -C, -D  Surfactant protein A, B, C, D
sPL    Synthetic surfactant without human recombinant SP-C
STAT    Signal transducer and activator of transcription
SUV    Small Unilamellar Vesicle
TBS    Tris buffered saline
TGF-β   Transforming growth factor beta
TH    Helper T cell
TLR    Toll-like receptor
Tm    Phase transition temperature
TM    Tubular myelin
TMB    Tetramethylbenzidine
TNF-α   Tumor necrosis factor alpha
ABBREVIATIONS

RESUMEN

27
1. INTRODUCCIÓN E HIPÓTESIS
Para facilitar el intercambio gaseoso, el pulmón presenta la mayor área del cuerpo en 
contacto con el medio externo, lo que facilita la oxigenación pero aumenta el riesgo 
de infección e inflamación por patógenos y endotoxinas presentes en el aire que 
respiramos. El epitelio alveolar (neumocitos tipo I y II) y los macrófagos alveolares 
están cubiertos por un fluido acuoso que contiene membranas extracelulares, 
sintetizadas y secretadas por los neumocitos tipo II, denominadas surfactante 
pulmonar.
El surfactante pulmonar está compuesto por un 90% en peso de lípidos 
(mayoritariamente fosfolípidos) y un 10% en peso de proteínas, dentro de las 
cuales encontramos las cuatro proteínas específicas del surfactante pulmonar SP-
A, SP-B, SP-C y SP-D. La principal función del surfactante pulmonar es reducir la 
tensión superficial en la interfase aire-líquido al final de la espiración, evitando así 
el colapso alveolar. Además, el surfactante pulmonar, juega un papel fundamental 
en la defensa inmune innata del alveolo [Cañadas and Casals, 2012]. Se ha 
descrito que las proteínas del surfactante SP-A y SP-D, denominadas colectinas 
pulmonares, actúan como opsoninas incrementando la fagocitosis de bacterias 
[McCormack and Whitsett, 2002] y son capaces de modular la respuesta inmune 
innata desencadenada por LPS [Stamme et al., 2002; Yamazoe et al., 2008]. Los 
fosfolípidos aniónicos del surfactante, principalmente POPG, presentan efecto 
anti-inflamatorio en macrófagos estimulados con LPS [Kuronuma et al., 2009] y 
Mycoplasma pneumoniae [Kandasamy et al., 2011], bloqueando la unión de LPS a 
TLR4 o de M. pneumoniae a TLR2 [Kuronuma et al., 2009; Kandasamy et al., 2011]. 
Además, se ha descrito que POPG es capaz de neutralizar los virus respiratorios, 
influenza A y virus respiratorio sincitial (VRS), in vitro e in vivo [Numata et al., 2010; 
Numata et al., 2012]. Sin embargo, su acción anti-inflamatoria y antiviral desaparece 
al estar inmersos en las estructuras membranosas que forman el surfactante 
pulmonar.
La cardiolipina (CL) es un fosfolípido aniónico que presenta cuatro cadenas de 
acilo en vez de dos, lo cual le otorga una estructura molecular voluminosa, en 
comparación con el resto de fosfolípidos. CL se encuentra en la membrana externa 
de bacterias Gram- negativas y -positivas (~ 10% y ~25%, respectivamente) [Barák 
y Muchová, 2013]. En células eucariotas se localiza principalmente en la membrana 
mitocondrial interna (~ 20 %) [Krebs et al., 1979; Zinser et al., 1991; Paradies et al., 
2013]. Sin embargo, también se encuentra en la membrana mitocondrial externa (~ 
5%), especialmente en los sitios de contacto entre las membranas externa e interna 
[Daum 1985; Zinser et al., 1991; Kroon et al., 1997]. En la mitocondria, CL tiene 
RESUMEN
28
un papel crucial en la estructura y función mitocondrial. Durante la apoptosis, las 
cadenas de acilo insaturadas de CL sufren una extensiva oxidación y el contenido 
en CL en la membrana externa aumenta. Así, CL actúa como patrón molecular de 
daño específico de la muerte celular por apoptosis [Maguire et al., 2017].
Se ha descrito que existen altos niveles de cardiolipina en el fluido alveolar de 
humanos y ratones infectados con bacterias causantes de neumonía [Ray et al., 
2010].  Las especies moleculares de CL encontradas en el fluido alveolar de ratones 
y humanos con neumonía indican que la CL es de origen mitocondrial más que 
bacteriano. Además, se ha detectado una alta concentración de este fosfolípido 
en el lavado broncoalveolar de ratones con neumonía causada por Haemophilus 
influenzae que carece de CL en su membrana. Se ha descrito que concentraciones 
elevadas de CL en el fluido alveolar alteran la función pulmonar y se ha sugerido 
que dicha alteración podría deberse a la inhibición de la actividad tensoactiva del 
surfactante pulmonar [Ray et al., 2010].
Recientemente, se ha sugerido que la cardiolipina podría tener un papel dual 
en el contexto de las interacciones huésped-huésped y huésped-patógeno 
[Balasubramanian et al., 2015]. La presencia de CL aumenta la fagocitosis de 
membranas que contienen CL mitocondrial o bacteriana por parte de los macrófagos 
(RAW 264.7, THP-1 tratadas con ésteres de forbol, macrófagos peritoneales 
de ratón y macrófagos humanos derivados de monocitos). La fagocitosis de 
membranas que contienen CL es dependiente del receptor tipo “scavenger” CD36. 
Por otra parte, CL atenúa la respuesta inflamatoria de macrófagos peritoneales de 
ratón RAW 264.7 estimulados con LPS a través del bloqueo del TLR4, receptor 
del LPS. Estos autores proponen que CL podría tener un efecto beneficioso para 
ambos, huésped y patógeno. Así, el aumento de la fagocitosis a través de CD36 
favorecería la eliminación de los patógenos bacterianos sin embargo, la atenuación 
de la respuesta inflamatoria de las células del huésped dificultaría la lucha contra la 
infección [Balasubramanian et al., 2015]. No obstante, los efectos biológicos de CL 
en el alveolo son desconocidos. No se ha investigado anteriormente el efecto de CL 
sobre la respuesta inmune de las células alveolares ni sobre la estructura y función 
de las membranas del surfactante. 
Teniendo en cuenta esta información previa, nuestra primera hipótesis es que la 
liberación de CL en el fluido alveolar por parte de las células del huésped, podría 
ser un mecanismo protector frente a la infección y/o inflamación. La segunda 
hipótesis que nos planteamos es si la secreción de altas cantidades de CL como 
resultado de daño celular exacerbado podría alterar la estructura y función de las 
membranas del surfactante pulmonar. 
RESUMEN
29
2. OBJETIVOS
El objetivo principal de esta tesis ha sido determinar las propiedades anti-
infecciosas y anti-inflamatorias de bajas concentraciones de CL utilizando células 
alveolares y patógenos respiratorios. Además, se ha estudiado el efecto de altas 
concentraciones de CL en la estructura y función de las membranas del surfactante 
pulmonar.
Esta tesis está compuesta por cuatro apartados con los siguientes 
objetivos concretos:
1.  Estudiar el papel inmunomodulador de bajas concentraciones de 
 vesículas de CL en la respuesta inflamatoria de macrófagos alveolares 
 murinos estimulados con LPS o zymosan.
2.  Determinar el papel antiviral y anti-inflamatorio de bajas dosis de 
 vesículas de CL frente a la infección causada por el virus respiratorio 
 sincitial en células epiteliales alveolares humanas, profundizando en 
 el mecanismo subyacente a la acción antiviral de CL y la influencia de 
 los componentes del surfactante pulmonar en las propiedades 
 antivirales de CL. 
3.  Investigar el efecto protector de CL frente a la infección por 
 Haemophilus influenzae en células epiteliales alveolares murinas.
4.  Evaluar el efecto inhibitorio de altas concentraciones CL en la 
 estructura y función biofísica del surfactante pulmonar.
3. RESULTADOS Y CONCLUSIONES
3.1. Efecto anti-inflamatorio de cardiolipina en macrófagos 
alveolares estimulados con patrones moleculares bacterianos y 
fúngicos
Para estudiar el efecto inmunomodulador de bajas concentraciones de CL (≥0.07 
nmol/ml) sobre la respuesta inflamatoria de macrófagos alveolares murinos (MH-S) 
y aislados de rata, se emplearon dos estímulos pro-inflamatorios: 
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o LPS o endotoxina: componente de la membrana externa de bacterias 
Gram-negativas que induce daño pulmonar agudo o ARDS como 
consecuencia de infecciones bacterianas o sepsis [Matute-Bello et al., 
2008]. 
o Zymosan: componente particulado complejo presente en la superficie de 
hongos y levaduras tradicionalmente empleado como estímulo fagocítico 
y pro-inflamatorio tanto in vitro como in vivo [Pillemer and Ecker, 1941, Di 
Carlo and Fiore, 1958].
Para estudiar el efecto de CL sobre la respuesta inmune celular, se emplearon 
dos aproximaciones experimentales distintas: las vesículas de CL se añadieron 
simultáneamente con el estímulo pro-inflamatorio (CL extracelular) o bien las 
células fueron preincubadas durante 18 horas con CL antes de la estimulación (CL 
intracelular).
En ambos casos, CL, inhibió las rutas de señalización activadas por LPS o zymosan 
(MAPKs, la ruta PI3K/Akt y la activación NFkB). Como consecuencia, inhibió la 
producción de los mediadores pro-inflamatorios TNF-α e iNOS, tanto a nivel de 
mRNA como de proteína. Además, disminuyó la producción del mRNA inducida 
por LPS de los marcadores pro-inflamatorios IL1-β, CXCL10 y de un mediador 
que puede tener actividad pro- o anti-inflamatoria en función del contexto, COX2. 
Además, empleando macrófagos alveolares primarios de rata, observamos que CL 
tiene un efecto inhibitorio en la fosforilación de Akt y Erk inducida por LPS, similar 
a lo obtenido con macrófagos murinos.
Conclusiones: bajas dosis de vesículas de CL añadidas junto con el estímulo pro-
inflamatorio y preincubadas con las células antes de la estimulación, presentan 
un extraordinario efecto anti-inflamatorio en la respuesta immune de macrófagos 
alveolares. Además, hemos comprobado que el efecto anti-inflamatorio de CL no 
está restringido a un único estímulo. 
3.2. Efecto antiviral e inmunomodulador de vesículas de cardiolipina 
frente al virus respiratorio sincitial
El virus respiratorio sincitial es el principal agente causante de neumonía y 
bronquiolitis en niños menores de dos años, ancianos e individuos inmunodeprimidos 
[Collins and Mellero, 2011]. Se ha sugerido que durante la infección, la cardiolipina 
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podría ser liberada al fluido alveolar procedente de células alveolares dañadas [Ray 
et al., 2010]. Nuestra hipótesis es que CL, a bajas concentraciones, podría actuar 
como factor de defensa para proteger al huésped frente a la infección por el virus 
respiratorio sincitial. 
En experimentos con células epiteliales alveolares humanas, hemos observado que 
la coadministración de pequeñas dosis de CL con VRS, inhibe la replicación viral 
y la consiguiente respuesta celular inducida por VRS. Así, CL inhibió la expresión 
de los receptores celulares para VRS (TLR3 y RIG-I), ISG-15 y TNF-α en células 
epiteliales alveolares infectadas con VRS. Sin embargo, la preincubación de las 
células con CL previo a la infección no produjo ningún efecto en la replicación viral 
pero inhibió la expresión de TNF-α. A nivel mecanístico, CL bloquea la infección por 
RSV impidiendo la unión de las partículas virales a la superficie celular, evitando así la 
entrada y replicación del VRS en las células epiteliales. Además, hemos comparado 
las propiedades antivirales de CL con las de fosfatidilglicerol, un componente del 
surfactante pulmonar con actividad antiviral. A bajas concentraciones de lípido, CL 
tiene una actividad antiviral mucho más potente que fosfatidilglicerol.
Por último, hemos comprobado que la presencia de surfactante pulmonar nativo, 
que cubre el epitelio pulmonar, o de sus componentes aislados (SP-A y la fracción 
hidrofóbica del surfactante, formada por lípidos y las proteínas hidrofóbicas SP-B y 
SP-C) no reduce el efecto antiviral de CL.
Conclusiones: nuestros resultados indican que CL podría tener un papel importante 
durante la infección por VRS, previniendo la interacción huésped-VRS y atenuando 
la replicación viral y respuesta inflamatoria. Estos hallazgos sugieren que CL podría 
ser un agente antiviral prometedor frente a VRS. 
3.3. Efecto protector de cardiolipina frente a la infección por 
Haemophilus influenzae no tipable 
Haemophilus influenzae no tipable es una bacteria Gram-negativa que carece de 
CL en la composición de su membrana [Ray et al., 2010]. NTHi se encuentra en la 
nasofaringe de la mayoría de individuos sanos como comensal pero cuando alcanza 
las vías respiratorias inferiores actúa como agente patógeno [Murphy, 2005]. NTHi 
es la principal causa de exacerbación en pacientes con enfermedades pulmonares 
subyacentes como enfermedad pulmonar obstructiva crónica (EPOC) [Sethi and 
Murphy, 2008]. 
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NTHi es capaz de causar infecciones crónicas debido a su capacidad de internarse 
en el epitelio alveolar y sobrevivir en estado no replicativo [Clementi and Murphy, 
2011]. El mecanismo de internación requiere la integridad de las balsas lipídicas 
y del citoesqueleto de actina, así como la fosforilación de Akt mediada por PI3K 
[Morey et al., 2011]. 
Nuestros resultados indicaron, que la coadministración de vesículas de CL con 
NTHi, disminuye la invasión pero no la adhesión en células epiteliales alveolares de 
ratón (línea MLE-12). Los resultados fueron similares para las dos cepas bacterianas 
clínicas estudiadas, aisladas de individuos con EPOC y otitis. Estos resultados 
sugieren que CL actúa bloqueando rutas de señalización implicadas en la invasión 
bacteriana. Como se ha indicado antes, la fosforilación de Akt inducida por NTHi 
es esencial para la internación de NTHi, y hemos observado que la presencia de CL 
drásticamente disminuye la fosforilación de Akt inducida por NTHi. 
Conclusiones: muchos patógenos se refugian en el interior de las células del 
huésped durante la infección. Una terapia basada en CL podría suponer un 
beneficio clínico en infecciones persistentes debido a la capacidad de CL para 
inhibir la internación de la bacteria en el epitelio.
3.4. Efecto de la cardiolipina en la estructura y función del 
surfactante pulmonar
Para determinar el efecto de CL en la estructura y función del surfactante pulmonar, 
se empleó surfactante pulmonar nativo (SPN) de rata que contiene las proteínas 
hidrofóbicas SP-B y SP-C y la colectina pulmonar SP-A, así como vesículas de 
extracto lipídico de surfactante pulmonar de rata (ELS), que carece de SP-A. 
Para evaluar el efecto de CL en la función del surfactante, se determinó su 
capacidad para adsorberse a una interfase aire-liquido empleando una balanza de 
Langmuir que consta de una subfase acuosa acoplada a un sensor de presión. 
Los experimentos se realizaron empleando tres aproximaciones experimentales 
distintas: A) las vesículas de CL se inyectaron en la subfase acuosa simultáneamente 
o 10 minutos antes de la inyección de SPN o ELS; B) CL se encontraba presente 
en la composición de las vesículas de ELS a distintos porcentajes molares (3,6 y 
12 %), y se determinó su capacidad de adsorberse a la interfase aire-líquido. Los 
resultados indicaron que CL inhibe la función tensoactiva del surfactante tanto si se 
encuentra libre en la subfase acuosa como formando parte de la composición de 
las vesículas de surfactante. 
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El efecto inhibitorio de las vesículas de CL es mucho mayor si se inyectan 10 minutos 
antes que ELS comparado con la inyección simultánea de ELS. Esta inhibición es 
debida a adsorción competitiva, ya que las vesículas de CL presentan actividad 
interfacial. Sin embargo, la adsorción de CL a la interfase es más lenta que la de 
LES. A destacar, la co-inyección de CL con SPN no afecta a la adsorción interfacial 
de NPS, mientras que la pre-inyección de CL inhibe la adsorción de NPS. Hemos 
demostrado que SP-A se une a CL (Kd=2.2 ± 0.4 nM) y sugerimos que la SP-A 
presente en NPS podría unir vesículas de CL libres protegiendo a las membranas del 
surfactante frente a la inhibición cuando SPN y las vesículas de CL se coinyectan. 
Por otra parte, hemos observado que CL es capaz de insertarse en las membranas 
de ELS y afecta a las propiedades físicas de las membranas de surfactante, tanto 
en ausencia como en presencia de SP-A. En presencia de CL, las membranas 
del surfactante son más fluidas y menos ordenadas. Observamos un aumento de 
fluidez y disminución del orden lipídico de las membranas de ELS a medida que 
aumentaba la cantidad de CL incorporada en las membranas ELS. Este efecto 
podría deberse a la estructura molecular voluminosa de CL que dificulta el correcto 
empaquetamiento de las moléculas de dipalmitoilfosfatidilcolina, un fosfolípido 
esencial para la función biofísica del surfactante.
Conclusiones: Nuestros resultados demuestran la acción inhibitoria de altas dosis 
de CL sobre la función surfactante pulmonar. CL actúa a través de dos mecanismos 
distintos: (i) adsorción competitiva, en la cual CL compite con el surfactante por la 
adsorción a la interfase aire-líquido; (ii) un efecto fluidificante sobre las membranas 
del surfactante. Por otra parte, SP-A es capaz de contrarrestar el ligero efecto 
inhibitorio de vesículas de CL libres en la subfase acuosa en la función del surfactante. 
Sin embargo, si CL se encuentra formando parte de la composición del LES, SP-A 
no es capaz de revertir el efecto de CL en las propiedades físicas del LES.
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1. INTRODUCTION AND HYPOTHESIS
To facilitate gas exchange, the lung has the largest area of the body in contact 
with the external environment. This extensive surface in contact with the external 
medium aids oxygenation but increases the risk of infection and inflammation by 
pathogens and endotoxins present in the air we breathe. The alveolar epithelium 
(type I and type II pneumocytes) and alveolar macrophages are covered by an 
aqueous fluid containing extracellular membranes called pulmonary surfactant that 
are synthesized and secreted by type II pneumocytes.
Pulmonary surfactant is composed of approximately 90 wt.% lipids (mainly 
phospholipids) and 10 wt.% proteins, among which are four specific surfactant 
proteins: SP-A, SP-B, SP-C, and SP-D. The main function of pulmonary surfactant 
is to reduce the surface tension at the air-liquid interface at the end of exhalation, 
preventing alveolar collapse. In addition, pulmonary surfactant plays a key role in 
innate immune defense in the alveolus [Cañadas and Casals, 2012]. Pulmonary 
collectins (SP-A and SP-D) act as opsonins, increasing the phagocytosis of bacteria 
[McCormack and Whitsett, 2002], and are able to modulate the LPS-triggered innate 
immune response [Stamme et al., 2002; Yamazoe et al., 2008]. Anionic surfactant 
phospholipids, mainly POPG, have anti-inflammatory actions on macrophages 
stimulated with bacterial lipopolysaccharide (LPS) [Kuronuma et al., 2009] and 
Mycoplasma pneumoniae [Kandasamy et al., 2011], blocking the binding of either 
LPS to TLR4 or M. pneumoniae to TLR2 [Kuronuma et al., 2009; Kandasamy et 
al., 2011]. Moreover, POPG is capable of neutralizing respiratory viruses such as 
influenza and respiratory syncytial virus, in vitro and in vivo [Numata et al., 2010; 
Numata et al., 2012]. However, its anti-inflammatory and antiviral actions disappear 
when POPG forms part of  pulmonary surfactant membranes.
Cardiolipin (CL) is an anionic phospholipid carrying four acyl chains instead of two, 
which gives it a bulky molecular structure, compared with other phospholipids. CL 
is found in the inner membrane of Gram-negative  and –positive bacteria (~ 10% and 
~25%, respectively) [Barák and Muchová, 2013]. In eukaryotic cells, CL is mainly 
located in the inner mitochondrial membrane (~ 20 %) [Krebs et al., 1979; Zinser et 
al., 1991; Paradies et al., 2013]. However, CL is also found in the outer mitochondrial 
membrane (~ 5%), preferably in the contact sites between the outer and the inner 
membrane [Daum 1985; Zinser et al., 1991; Kroon et al., 1997]. In the mitocondria, 
CL plays a key role in the structure and function of mitochondrial membranes. During 
apoptosis, the unsaturated acyl chains of CL suffer extensive oxidation and CL levels 
in the outer mitochondrial membrane increase. Thus, CL acts as molecular pattern 
of specific damage of cell death by apoptosis [Maguire et al., 2017].
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High levels of CL have been found in the bronchoalveolar lavage (BAL) of humans 
and mice infected with bacteria causing pneumonia [Ray et al., 2010]. These 
molecular species of CL appear to be from human rather than bacterial origin. 
Furthermore, high levels of this phospholipid have been detected in the BAL of 
mice with pneumonia caused by Haemophilus influenzae, which lacks CL on its 
membrane. High levels of CL in the alveolar fluid alter lung function; it has been 
suggested that this alteration might be due to impairment of the surfactant function 
[Ray et al., 2010].
Recently, it has been suggested that CL might have a dual role in the context of host-
host and host-pathogen interactions [Balasubramanian et al., 2015]. The presence of 
CL increases the phagocytosis of membranes containing mitochondrial or bacterial 
CL by macrophages (RAW 264.7, THP1 treated with phorbol esters, mouse peritoneal 
macrophages, and human macrophages derived from monocytes). Phagocytosis of 
CL containing membranes is dependent on  the scavenger receptor CD36. On the 
other hand, CL attenuates the inflammatory response of mouse peritoneal RAW 
264.7 macrophages stimulated with LPS by blocking the LPS receptor TLR4. These 
authors propose that CL could have beneficial effects for both host and pathogen. 
Thus, increased phagocytosis through CD36 would favor bacterial clearance; 
however, an attenuated inflammatory response by host cells would hamper the fight 
against infection [Balasubramanian et al., 2015]. However, the biological role of CL 
in the alveolus is unknown. Its effect on the immune response of alveolar cells or on 
the structure and function of surfactant membranes still remains unknown.
Taking all this into consideration, our first hypothesis is that the release of low 
amounts of CL in the alveolar fluid by host cells could be a protective mechanism 
against infection and/or inflammation. Our second hypothesis is that the secretion 
of high amounts of CL as a result of exacerbated cellular damage could alter the 
structure and function of pulmonary surfactant membranes.
2. OBJECTIVES
The main objective of this thesis was to determine the anti-infectious and anti-
inflammatory properties of low concentrations of CL using alveolar cells and 
respiratory pathogens. In addition, to study the effect of high concentrations of CL 
on the structure and function of pulmonary surfactant membranes was an objective 
of this thesis.
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This doctoral thesis consists of four sections with the following 
specific objectives:
1.  To investigate the immunomodulatory role of CL on the immune innate 
 response of alveolar macrophages stimulated with LPS or zymosan.
2.  To determine the antiviral and anti-inflammatory effect of CL against 
 respiratory syncytial virus infection on human alveolar epithelial cells, 
 as well as to obtain deeper insight into the mechanism underlying CL 
 antiviral action and the influence of lung surfactant components on CL 
 antiviral properties.
3.  To study CL protective action against alveolar epithelial cell infection 
 with Haemophilus influenzae.
4.  To evaluate the inhibitory effect of high amounts of CL on lung 
 surfactant structure and biophysical function.
3. RESULTS AND CONCLUSIONS
3.1. Anti-inflammatory effects of cardiolipin on alveolar 
macrophages stimulated with bacterial and fungal molecular 
patterns 
To study the immunomodulatory effects of low concentrations of CL (≥0.07 nmol/ ml) 
on the inflammatory response of murine alveolar macrophages (MH-S) and isolated 
alveolar macrophages from rats, we employed two proinflammatory stimuli:
o LPS or endotoxin: component of the outer membrane of Gram-
negative bacteria that induces acute lung injury or ARDS [Matute-Bello et 
al., 2008].
o Zymosan: complex particulate component present on the surface of 
fungi and yeasts traditionally used as phagocytic and proinflammatory 
stimulus both in vitro and in vivo [Pillemer and Ecker, 1941; Di Carlo and 
Fiore, 1958].
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To study the effect of CL on the immune response of alveolar macrophages, 
two different experimental approaches were employed: CL vesicles were added 
simultaneously with the proinflammatory stimulus (extracellular CL) or cells were 
preincubated with CL for 18 hours previous to stimulation (intracellular CL). 
In both cases, CL inhibited LPS- or zymosan-elicited signaling pathways (MAPK 
cascade, the PI3K/Akt pathway, and NF-κB activation). As a consequence, CL 
inhibited the production of the proinflammatory markers TNF-α and iNOS at both 
mRNA and protein level. Moreover, CL reduced mRNA production of proinflammatory 
cytokines IL1-β and CXCL10, as well as COX2, a mediator that can have pro- or 
anti-inflammatory activity depending on the environment. Furthermore, employing 
primary rat AMs, we found that  CL have an inhibitory effect on LPS-elicited Akt and 
Erk phosphorylation, similar to that obtained with murine AMs.
CONCLUSIONS: CL vesicles simultaneously added with the proinflammatory 
stimulus and preincubated with cells before stimulation present a strong 
immunomodulatory effect at low doses on the inflammatory response of AMs. 
Moreover, we have proved that the anti-inflammatory action of CL is not restricted 
to a particular stimulus.
3.2. Antiviral and immunomodulatory effects of cardiolipin against 
respiratory syncytial virus
Respiratory syncytial virus is the main causal agent of pneumonia and bronchilitis 
in children under the age of two, the elderly, and immunocompromised individuals 
[Collins and Mellero, 2011]. It has been suggested that during infection, CL could 
be released to the alveolar fluid from damaged host cells [Ray et al., 2010]. We 
propose that CL, at low concentrations, could act as a defensive factor against RSV 
infection.  
In experiments with human alveolar epithelial cells, we found that the coadministration 
of low amounts of CL with RSV inhibited viral replication and the subsequent RSV-
elicited cellular responses such as expression of RSV cellular receptors (TLR3 and 
RIG-I), ISG-15, and TNF-α by RSV-infected alveolar epithelial cells (AECs). However, 
preincubation of the cells with CL previous infection did not inhibit viral replication but 
inhibited TNF-α expression. Mechanistically, CL blocks RSV infection by inhibition 
of RSV attachment to the cell surface, preventing RSV entry and replication inside 
the epithelial cells. We have further compared the antiviral properties of Cl with 
that of phosphatidylglycerol (PG), a component of lung surfactant with reported 
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antiviral activity. At low lipid concentrations, CL had much stronger antiviral activity 
than PG. Finally, we found that the presence of native lung surfactant or its isolated 
components (SP-A and the hydrophobic fraction of lung surfactant, composed by 
lipids and the hydrophobic proteins SP-B and SP-C) did not diminish CL antiviral 
effects.
CONCLUSIONS: Our results indicate that CL might play a significant role during 
RSV infection, preventing host-RSV interaction and attenuating virus replication 
and inflammatory responses. These findings raise CL as a promising antiviral agent 
against RSV.
3.3. Cardiolipin protective effects against non-typeable Haemophilus 
influenzae (NTHi) infection
Non-typeable Haemophilus influenzae is a Gram-negative bacteria lacking CL in the 
composition of its membrane [Ray et al., 2010]. NTHi is present in the nasopharynx 
of the vast majority of healthy individuals as a commensal, but when it reaches the 
lower airways, it acts as a pathogen [Murphy, 2005]. NTHi is the leading cause of 
exacerbation in patients with underlying lung diseases such as COPD [Sethi and 
Murphy, 2008].
NTHi is capable of causing chronic infections due to their ability to penetrate into 
the alveolar epithelium and survive in a non-replicative state [Clementi and Murphy, 
2011]. The mechanism requires the integrity of the lipid rafts and actin cytoskeleton, 
as well as Akt phosphorylation mediated by PI3K [Morey et al., 2011].
Our results indicated that CL addition simultaneous with NTHi infection reduces 
the internalization of NTHi by murine AECs (cell line MLE-12) without affecting 
NTHi adhesion to the epithelium surface. Results were similar for two clinical 
bacterial strains studied, isolated from individuals with COPD and otitis. These 
results suggest that CL acts by blocking signaling pathways involved in bacterial 
internalization. As noted above, Akt phosphorylation induced by NTHi is essential 
for NTHi internalization, and we found that the presence of CL drastically decreased 
NTHi-induced Akt phosphorylation.
CONCLUSIONS: Many pathogens seek refuge inside host cells during infection. A 
therapy based on CL might be beneficial in persistent infections due to the ability of 
CL to inhibit bacterial internalization by the epithelium.
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3.4 Cardiolipin effects on pulmonary surfactant structure and 
function
To determine the effect of CL on surfactant structure and function, we employed rat 
native pulmonary surfactant (NPS) containing the hydrophobic proteins SP-B and 
SP-C and the lung collectin SP-A as well as vesicles prepared from the lipid extract 
of  surfactant (LES) that lacks SP-A.
To evaluate the effect of CL on surfactant function, we determined its capacity to 
adsorb and spread onto an air-liquid interface using a Langmuir balance consisting 
of an aqueous subphase coupled to a pressure sensor. Experiments were performed 
using different experimental approaches: A) CL vesicles were injected into the 
aqueous subphase simultaneously or 10 minutes before NPS or LES injection; B) 
CL was present in LES vesicles at different molar percentages (3, 6, and 12%), and 
the ability of CL-containing LES vesicles to adsorb to the air-liquid interface was 
determined. The results indicated that CL was able to inhibit surfactant function 
if CL vesicles were free in the aqueous subphase or CL was forming part of the 
composition of surfactant vesicles. 
The inhibitory effect of CL vesicles was much greater if CL vesicles were injected 
in the subphase 10 minutes before LES injection compared to simultaneous LES 
injection. This inhibition was due to competitive adsorption since CL vesicles 
showed interfacial activity, but CL adsorption to the interface was slower than 
that of LES. Interestingly, co-injection of CL with NPS did not affect the interfacial 
adsorption of NPS, whereas preinjection of CL strongly hampered the adsorption of 
NPS. We found that SP-A bound to CL (Kd = 2.2 ± 0.4 nM) and suggest that SP-A 
present in NPS would bind to CL free vesicles protecting surfactant membranes 
from inhibition when NPS and CL vesicles were co-inyected.
On the other hand, we found that CL was capable of inserting into LES membranes 
and affected the physical properties of surfactant membranes both in the absence 
and presence of SP-A. The presence of CL rendered surfactant membranes more 
fluid and less ordered. There was an increase of fluidity and decrease of lipid order of 
LES membranes as the amount of CL incorporated into LES membranes increased. 
This effect might be due to the bulky molecular structure of CL that impairs the 
correct packing of DPPC molecules, an essential phospholipid for surfactant 
biophysical function.
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CONCLUSIONS: In summary, our results highlight an inhibitory action for CL at 
high doses on lung surfactant function. CL action takes place by two different 
mechanisms: (i) competitive adsorption, in which CL competes with surfactant 
for the air-liquid interface, (ii) a fluidizing effect of CL on surfactant membranes. 
Furthermore, we proved that SP-A is able to counteract the slight inhibitory effect 
caused by free CL vesicles in the aqueous subphase but did not show any effect 
when CL forms part of the composition of LES vesicles.
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1.1. THE RESPIRATORY SYSTEM
Respiration is the act of breathing, namely inhaling (inspiration) oxygen (O2) from the 
atmosphere into the lungs and exhaling (expiration) into the atmosphere the waste 
product, carbon dioxide (CO2).
Figure 1.1. Diagram of the upper and lower respiratory airways.
The respiratory system can be divided into main parts: the upper and lower airways 
(Figure 1.1). The upper respiratory tract includes the oral cavity, the nasal cavity, 
the pharynx and the larynx. Its primary function consists in trapping larger dust 
particles, warming and humidifying the inhaled air before it reaches the conducting 
airways of the lower respiratory tract, which is composed of the tracheo-bronchial 
tree and the lungs. Over the course of 23 divisions, the bronchial tree descends 
from the trachea to the alveolar sacs (Figure 1.2). The first 16 branches form the 
conducting zone of the airways which transport the air to and from the outside 
(bronchi and bronchioles). The remaining seven branches form the transition zone 
(respiratory bronchioles and alveolar ducts) and the respiratory zone, where are 
found the alveoli. There are approximately 300 million of alveoli in the lung and 
their alveolar-capillary membrane provides a large surface area (130 cm2) for gas 
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exchange [Weibel, 1984].            
Figure 1.2. Schematic representation of the human adult airways (re-drawn 
from Weibel, 1984).
1.1.1.Lung parenchyma
The alveolar-capillary unit consists of three layers: epithelial, interstitial and 
endothelial (Figure 1.3).
The alveolar epithelium is composed by two different cell types:
-Alveolar type I pneumocytes cover over 95% of the alveolar surface while 
comprising only 8% of the total cells in the normal adult human lung [Crapo et al., 
1982]. These cells are derived from the type II pneumocytes during alveolar repair 
[Evans and Hackney, 1972]. They are able to stretch into flattened cells with very 
little depth (approximately 0.1 µm), but with a large surface area which minimizes the 
distance between the alveolar air space and pulmonary capillaries, thus maximizing 
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gas exchange [Castranova et al., 1988]. 
-Alveolar type II pneumocytes are typically secretory cells and present polarized 
morphology, with cuboid appearance and microvilli on the apical side [Whitsett et 
al., 1985]. They only comprise 4% of the alveolar surface, however, they constitute 
60% of alveolar epithelial cells and 10-15% of all lung cells. These cells play 
several roles on the alveolar unit. Therefore, they are responsible for regeneration 
of damaged alveolar epithelium, metabolism of toxic compounds and the trans-
epithelial movement of water. Nevertheless, their most important function is to 
synthesize and secrete lung surfactant, which is a unique feature of these cells 
[Castranova et al., 1988, Herzog et al., 2008].
Above the alveolar surface, there is a thin film of liquid which is secreted and absorbed 
by antagonistic processes: absorption is due to an osmotic process that requires 
active sodium transport, whereas fluid secretion requires active chlorine transport 
outward of alveolar epithelial cells. This alveolar fluid needs of the presence of lung 
surfactant, a lipoprotein complex that reduces the surface tension into the air-liquid 
interface, thus avoiding alveolar collapse.
In the alveolus there are also found the alveolar macrophages (AMs). They are 
tissue-resident cells found in the inner epithelial surface close to the epithelium. 
AMs are professional phagocytes that contribute to the clearance of infectious 
agents such as bacteria, viruses and pollutants that reach the alveolar space. 
AMs need further specialization than other types of macrophages because lungs 
suffer marked environmental fluctuations. Thus, the partial oxygen pressure in the 
alveoli in normal conditions is 100–110 mm Hg, but this value will vary after the 
exposure to environmental agents, lung infection or chronic inflammatory diseases. 
AMs activation is tightly controlled by interacting with epithelial, stromal and other 
immune cells and soluble mediators that creates a regulatory environment to limit 
unwanted inflammatory responses. This cell-cell contact will be lost when AMs 
receptors interact with their respective ligands [Hussel and Bell, 2014]. Another 
important function of AMs is to internalize and tdegrade altered surfactant, thus 
helping to maintain surfactant homeostasis [Trapnell and Whitsett, 2002].
Beneath the epithelium it is found the interstitial layer which is constituted of 
connective tissue composed of elastic and collagen fibers, where are present 
mesenchymal cells and fibroblasts which support the alveolar structure through the 
secretion of extracellular matrix proteins and immune cells (lymphocytes, interstitial 
macrophages and mast cells) [Herzog et al., 2008]. 
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Finally, under the interstitial layer it is found the alveolar endothelium, which forms 
a barrier between the blood and the air. It is composed of a single continuous layer 
of squamous epithelial cells of mesenchymal origin called endothelial cells, which in 
human lungs occupy a surface area of 130 m2. This extensive area allows filtering 
the blood before it enters in the systemic circulation [Simionescu et al., 1991].
Figure 1.3. Schematic diagram of the alveolar-capillary unit. The three layers 
and their components are represented: alveolar epithelium, interstitial layer and 
alveolar endothelium.
1.1.2. The respiratory tract and its role as a defensive barrier
The first lines of defense in the respiratory system are structural and mechanical 
barriers which hamper the entry of pathogens, allergens and foreign particles into 
the lung. Physical defenses mainly comprise the upper airways filtering system, the 
airway epithelium and the mucociliary system.
The upper airway filtering system is constituted by the nose and the nasopharynx. 
Particles with a diameter > 10µm are found within these structures. They are able to 
remove airborne particles and water soluble gases from inspired air. This anatomical 
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mechanism of defense is augmented by sneezing and coughing reflexes which 
remove unwanted particles from the nose, pharynx and large airways [Nishino et 
al., 2000].
The airway epithelium is another physical barrier between the external environment 
and the internal milieu [Ganesan et al., 2013]. This barrier presents three components 
that contribute significantly to the defense of the respiratory tract: the mucociliary 
escalator which traps and clear foreign particles from airways, intercellular tight 
and adherent junctions which regulate epithelial paracellular permeability, and 
secreted antimicrobial peptides which aid to kill inhaled pathogens. The mucus 
is secreted by globet cells and submucosal glands present in the upper and 
lower airways. It contains micromolecules such as electrolytes and amino acids 
as well as macromolecules including lipids, carbohydrates, nucleic acids, mucins, 
immunoglobulins, enzymes and albumin. The function of the mucus is to trap 
particles, absorb gases and facilitate their removal by the cilia which sweeps the 
trapped material from the lungs towards the pharynx [Knowles et al., 2002].
1.1.3. Lung surfactant
Pulmonary surfactant is a lipoprotein complex of extracellular membranes placed 
in the alveoli aqueous layer covering alveolar cells. Its main function is to reduce 
the surface tension at the air water interface that exerts a collapsing pressure, thus 
avoiding alveolar collapse [Perez-Gil, 2008; Casals and Cañadas, 2012]. Moreover, 
surfactant plays a key role in the innate immune defense in the lung, forming together 
with AMs the first barrier against inhaled pathogens or pollutants. Both surfactant 
properties-lowering surface tension and immune innate defense- depend on its lipid 
and proteic components [Whitsett and Weaver, 2002; Wright, 2005].
Pulmonary surfactant is crucial for lung physiology, given that deficiency or 
dysfunction of surfactant components causes impaired lung performance which 
leads to develop respiratory diseases [Ballard et al., 1995; Skelton et al., 1999; 
Gower and Nogee, 2011]. The first described and commonest cause of morbidity in 
neonates is respiratory distress syndrome, pathology due to surfactant deficiency 
in which preterm newborns are not able to synthesize enough lung surfactant. They 
can be treated with exogenous surfactant replacement [Avery and Mead, 1959; 
Robertson and Halliday, 1998; Jobe, 2006].  
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 1.1.3.1. Lung surfactant composition
Pulmonary surfactant is a highly conserved complex mixture of lipids (90 wt.%), and 
proteins (10 wt.%). The lipid fraction consists mainly of phospholipids (PL) (~90-95 
wt.%) with a small amount of neutral lipids (~5-10 wt.%), mainly cholesterol. The 
proteic fraction mainly consists of surfactant specific apolipoproteins: SP-A, SP-B, 
SP-C and SP-D, as well as non-specific surfactant proteins, mainly serum-derived 
proteins. 
Phospholipids are amphipathic molecules that form bilayers in aqueous 
environment and monolayers at the air-water interface. At the air-water interface, 
phospholipids polar head group is toward the water and the acyl chains are 
facing to the air. Phosphatidylcholine (PC), which is the major phospholipid (70-
80%) is primarily disaturated, being the predominant molecular species of PC, 
dipalmitoylphosphatidylcholine (DPPC) (16:0/16:0-PC) accounting for ~55 mol% 
(in human, rat, pig, and mouse) to ~40 mol % (in goat, caw, and rabbit). DPPC 
provides tightly membrane packing due to its saturated acyl chains being, by this 
reason, responsible of lowering the surface tension at the air-liquid interface during 
compression. The remaining forms of PC are unsaturated being 1-palmitoyl-2-
oleoyl phosphatidylcholine (POPC) (16:0/18:1-PC) the most abundant among them. 
Primarily unsaturated forms of anionic phospholipids, mainly phosphatidylglycerol 
(PG) and phosphatidylinositol (PI) (~8–15 wt. %) are also found in mammals. Other 
phospholipids are present in surfactant at very low levels such as unsaturated 
phosphatidylethanolamine (PE), sphingomyelin (SM), lyso-PC, and choline 
plasmalogens [Goerke, 1988; Veldhuizen et al., 1998; Casals and Cañadas, 2012].
Apart of the lipid component, there are four specific surfactant proteins (SP-) 
designated as SP-A, SP-B, SP-C and SP-D according to the nomenclature proposed 
by Possmayer [Possmayer, 1988], which have a distribution in mass of 5.0, 0.7, 0.8 
and 0.5%, respectively, and are classified in two groups: hydrophobic (SP-B and 
SP-C) and hydrophilic (SP-A and SP-D). The small hydrophobic proteins, SP-B and 
SP-C, together with DPPC, are responsible of surfactant tensoactive properties. 
The large hydrophilic surfactant proteins, SP-A and SP-D, participate in pulmonary 
host defense and modulate immune responses. SP-A, SP-B and SP-C are obtained 
together with surfactant membranes by ultracentrifigation of BAL, whereas SP-D is 
not associated with membranes [Casals and Cañadas, 2012].
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Figure 1.4. Cartoon illustrating the composition of pulmonary surfactant in 
percentages by weight (A). Three-dimensional models of hydrophobic (SP-B 
and SP-C) and hydrophilic (SP-A and SP-D) specific surfactant proteins (B) 
(adapted from Cañadas and Casals, 2012). PL: Phospholipid; DPPC: dipalmito-
ylphosphatidylcholine; PC: phosphatidylcholine; PG: phosphatidylglicerol; SP-: 
surfactant protein-.
 1.1.3.2. Lung surfactant biological cycle
Pulmonary surfactant is synthesized in the endoplasmic reticulum of type II 
pneumocytes [Agassandian and Mallampali, 2013]. Life cycle of pulmonary 
surfactant comprises the following established steps (Figure 1.5):
1.   Synthesis of pulmonary surfactant components by type II pneumocytes.
2.  Assembly and storage of surfactant and regulated surfactant secretion 
 into the alveolar fluid.
3.  Rapid adsorption of surfactant into air-liquid interface, forming a   
 monolayer. The monolayer will be compressed to reach low surface  
 tension in order to prevent alveolar collapse.
4.  Degradation and/or retrieval of surfactant components by alveolar 
 macrophages and/or type II pneumocytes.
I. INTRODUCTION
54
Figure 1.5. Schematic representation of pulmonary surfactant biological cycle. 
Pulmonary surfactant is synthesized by type II epithelial cells and then stored as 
closely packed bilayer membranes called lamellar bodies (LB) (a) which will be 
secreted into alveolar fluid by exocytosis forming a highly organized lattice-li-
ke membrane structure termed tubular myelin (TM) (c). These large extracellu-
lar membranes, called large surfactant aggregates (LA), adsorb quickly to the 
air-liquid interface thereby allowing to reduce surface tension values along the 
alveolar epithelium at the end of expiration thus avoiding alveolar collapse. The-
se surface-active monolayer presents bilayer structures attached to it (d). Upon 
several surface compression and expansion cycles, small surfactant aggregates 
(SA) are generated (E) and present poor surface activity. Small aggregates are 
taken up and degraded by alveolar macrophages and type II cells. Taken from 
Cañadas and Casals, 2012.
1.2. RESPIRATORY INFECTIONS AND PULMONARY PATHOGENS
During breathing, respiratory airways are continuously exposed to contaminated 
air. In spite of the lung defense barriers cited above, many respiratory pathogens 
have evolved to successfully colonize and grow on or within lung epithelial cells, 
occasionally causing life-threatening diseases.
Respiratory infections are usually classified as upper and lower tract respiratory 
infections. Upper respiratory tract infections comprise common cold, sinusitis, 
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pharyngitis, epiglottitis and laryngotracheitis. The causative agents are mainly viruses 
but also bacteria, mycoplasma and fungi. Organisms gain entry into the respiratory 
tract by inhalation and invade the mucosa. Lower respiratory tract infections include 
bronchitis, bronchiolitis and pneumonia and are usually more severe than the upper 
ones. The etiological agents are usually viruses or bacteria but also mycoplasma and 
fungi. The pathogens reach the lower respiratory airways by inhalation or aspiration. 
They grow in the epithelium causing inflammation, increased mucus secretion and 
impared mucociliary function. In severe bronchiolitis, inflammation and necrosis of 
the epithelium may block small airways leading to airway obstruction [Dasaraju and 
Liu, 1966]. 
Pneumonia is a common and serious illness and represents the major cause of 
morbility and mortality in humans. Pneumonia may manifest as a wide range of 
possible outcomes because of different disease severities and pathogenic features. 
For critically ill patients, community-acquired pneumonia and ventilator-associated 
pneumonia are associated with high mortality [Mizgerd, 2008]. Moreover, in 
immunocompromised individuals, pneumonia might derive in sepsis, thus pathogen 
enters into the bloodstream and rapidly disseminates to and infect other organs.
 Bacteria are the most common cause of pneumonia, however it also can be produced 
by viruses, such as respiratory syncytial virus (RSV) and fungi. Bacterial pathogens 
causing pneumonia include Gram-negative bacteria, such as Pseudomonas 
aeruginosa, Escherichia coli, Klebsiella pneumoniae and Haemophilus influenzae 
and Gram-positive bacteria, mainly Staphylococcus aureus and Streptococcus 
pneumoniae [Woodhead, 2011]. 
When pathogens reach the lungs, the innate immune system is crucial to eliminate 
them. As stated above, the first step is the recognition of PAMPs by phagocytic 
cells, mainly AMs. One of the best known bacterial PAMPs is endotoxin (LPS), 
which is the major component of the outer membrane of Gram negative bacteria 
and a potent stimulator of inflammatory processes [O´Brien et al. 1980, Ulevitch and 
Tobias, 1995].
LPS is a complex glycolipid consisting of a polysaccharide fraction covalently 
bound to a hydrophobic moiety designated as lipid A, which gives its character of 
endotoxin [Lüderitz et al., 1978].                 
LPS recognition by AMs requires the intervention of extracellular and plasma 
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membrane proteins, including serum LPS-binding protein (LBP) [Tobias et al., 1986]. 
LBP monomerizes LPS and transfers LPS molecules to cluster of differentiation 14 
(CD14) [Wright et al., 1990, Tobias et al., 1993], a GPI-anchored protein which is 
found in lipid rafts, membrane microdomains with a lower degree of fluidity [Pugin 
et al., 1998]. CD14 activation triggers the mobilization of myeloid differentiation 
protein 2 (MD-2), Toll-like receptor 4 (TLR4) and other molecules into lipid rafts, 
thereby forming the LPS receptor complex that results in the presentation of the 
endotoxin to TLR4 [Triantafilou et al., 2002]. Following to the recognition of LPS by 
its receptor, intracellular signaling pathways are activated. TLR4 activation triggers 
the activation of phosphatidylinositol-3-kinase (PI3K) [O’Toole and Peppelenbosch 
2007] and the two major downstream signaling pathways, one that depends on the 
adaptor protein myeloid differentiation factor 88 (MyD88) and the other that requires 
recruitment of Toll-interleukin-1 (IL-1) receptor (TIR)-domain–containing adaptor 
inducing interferon-β (TRIF) [Kawai and Akira, 2005] (Figure 1.7). Activation of the 
MyD88-dependent signaling pathway requires of the recruitment of the adaptor 
proteins TIRAP and MyD88. The clustering of the interleukin-1 receptor-associated 
(IRAK) 4 on MyD88 facilitates IRAK1 phosphorylation and activation, recruitment of 
TNF receptor-associated factor (TRAF) 6 and engagement of Transforming growth 
factor beta-activated kinase (TAK)  1 [Commane et al., 2001]. TAK1 activates 
extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 
mitogen-activated protein kinases (MAPKs) and the transcription factor activator 
protein (AP)-1 as well as nuclear factor- κB (NF-κB). AP-1 and NF-κB translocate to 
the nucleus to facilitate transcription of proinflammatory cytokines such as tumor 
necrosis factor α (TNFα) and interleukin-12 (IL-12), chemokines (CCL2, CXCL10, 
and CXCL11), inducible nitric oxide synthase (iNOS), among others [Akira and Sato, 
2003].
After activation of the MyD88-associated pathway, the LPS/MD-2/TLR4 complex 
translocates to endosomes and associates with the adaptor proteins TRIF and 
TRAF3 (Figure 1.6). TRIF facilitates the delayed activation of the MAPKs/AP-1 and 
NF-κB signaling pathways through engagement of TRAF-6 and Receptor-interacting 
protein (RIP) 1, respectively [Kagan et al., 2008]. The tank-binding kinase (TBK)/
interferon regulatory factor 3 (IRF3) pathway is activated by TRAF3 and results in 
the production of type I interferons (IFNα/β), which are important for generating 
an effective host response to viral and bacterial [Jiang et al., 2004]. Finally, the 
endotoxin receptor complex is sorted to late endosomes/lysosomes for degradation 
and signal termination [Husebye et al., 2006]. 
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Figure 1.6. Schematized LPS signaling pathway. Activation of the LPS receptor 
complex induces TLR4 dimerization/oligomerization with rapid activation of the 
MyD88-depedent signaling pathways. Activated TLR4 is then endocytosed and 
the TRIF-dependent signaling pathway is induced. Re-drawn from Bohannon et 
al., 2013.
LPS-elicited inflammatory response activates host defense mechanisms to fight 
infection. However, an exacerbated inflammatory response can contribute to the 
development of respiratory diseases such as pneumonia, acute lung injury, acute 
respiratory distress syndrome or multiple organ failure associated with severe sepsis 
[Hardaway, 2000; Cohen, 2002; Piantadosi and Schwartz, 2004].
Concerning to fungal pathogens, Aspergillus fumigatus is considered as one of the 
most common airborne fungal pathogens able to produce severe to fatal invasive 
infections in immunocompromised individuals [Dixon et al., 1996; Lehrnbecher 
et al., 2010]. Immunosuppressed individuals infected with A.fumigatus lead to 
develop respiratory diseases, such as community-acquired pneumonia or allergic 
bronchopulmonary aspergillosis. Furthermore, sensitivity to A.fumigatus has been 
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associated with severe persistent asthma in adults [Knutsen et al., 2012].
The small conidia of A.fumigatus enter into the terminal respiratory airways by 
inhalation and reach the alveoli [Ben-Ami et al., 2010]. In healthy individuals, inhaled 
conidia are efficiently cleared by the lung innate immune system [Margalit and 
Kavanagh, 2015]. If not, they will germinate into hyphal structures, which could 
damage lung tissue [Dagenais and Keller, 2009]. 
Fungal cell wall presents several PAMPs that allow the immune cells to recognize 
them and mount the inflammatory response to fight infection. Zymosan is a 
complex fungal cell wall particle which contains multiple PAMPs and has been 
traditionally used as a phagocytic and inflammatory stimulus in vivo and in vitro 
[Pillemer and Ecker, 1941, Di Carlo and Fiore, 1958]. Zymosan is mainly composed 
by polysaccharides, of which β-glucan and mannan are the major constituents. 
Zymosan triggers immune response in AMs through TLR2, eliciting similar pathways 
to those described above for LPS. TLR2 could form heteromers with TLR1 or TLR6 
in order to expand the spectrum of ligand recognition [Farhat et al., 2008]. TLR2 
cooperates with TLR6 and CD14 in response to zymosan [Ozinsky et al., 2000; Lee 
et al., 2012], however CD14 participate to a lesser extent in signaling mediated by 
the TLR2-TLR6 complex than in signaling mediated by TLR4, because the TLR2-
TLR6 complex was also shown to associate with the scavenger receptor B (CD36) 
[Hoebe et al., 2004], which is also implicated in atherosclerosis by its ability to bind 
oxidized lipoproteins [Silverstein et al., 2010].Moreover, it is known that TLR2 alone, 
in contrast to TLR4, can interact with bacterial peptidoglycan regardless or whether 
CD14 is present, nonetheless CD14 enhances peptidoglycan signaling [Sato et al., 
2003]. During phagocytosis processes, zymosan is recognized by another receptor, 
Dectin-1, that cooperates with TLR2 to trigger the appropriate inflammatory 
response against the pathogen [Goodridge and Underhill, 2008].
Finally, viral infections of the lower respiratory tract cause an enormous disease 
burden in children, and the role of respiratory viruses in serious lower respiratory 
tract infections in older adults is increasingly appreciated. A variety of viruses have 
been associated with clinical syndromes ranging from mild illnesses, such as the 
common cold, to more severe devastating conditions, such as pneumonia [Hamelin 
et al., 2004].  Most viruses that infect humans enter into the body through the 
respiratory tract as in aerosols produced by coughing or sneezing of other infected 
hosts. Large particles are usually trapped in the sinuses and could cause upper 
respiratory infections. Smaller particles can reach the alveolar spaces and cause 
infections in the lower respiratory tract. After virus entrance, they could cause local 
respiratory infections as with most respiratory viruses such as influenza, rhinovirus, 
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respiratory syncytial virus, parainfluenza virus, coronavirus and metapneumovirus, 
occasionally causing lower respiratory infections [Flint et al., 2000]. 
1.2.1. Respiratory Syncytial Virus
Respiratory syncytial virus is a member of the Paramyxoviridae family, subfamily 
Pneumovirinae. Discovered in 1956 [Morris et al., 1956], RSV was quickly identified 
as a human virus and shown to be the leading cause of pediatric lower respiratory 
tract infections, mainly bronchiolitis and pneumonia, as well as an important cause 
of lower respiratory tract infections in adults underlying cardiopulmonary disease or 
immunosuppressed individuals. Most children are infected by RSV during the first 
year of life and virtually all are infected by the age of two. Re-infection is frequent 
during the first years of life and can occur multiple times throughout life, seriously 
impacting adults with chronic pulmonary diseases. Furthermore, severe RSV 
infection early in life is commonly associated with persistent abnormalities in airway 
function, such as recurrent wheezing, allergic sensitization and asthma. There is 
still no licensed vaccine against RSV infection and the therapeutic options are not 
effective or controversial [Collins and Mellero, 2011].
 1.2.1.1. Morphology
RSV is a non-segmented negative-sense RNA virus consisting of 15,2 kb [Collins 
and Crowe, 2007]. The virion of the RSV is enveloped with a lipid bilayer, which 
is obtained from the host plasma membrane [Collins et al., 2013]. The genome is 
found in the helical nucleocapsid. Ten genes encode for eleven proteins named 
non-structural protein 1 (NS1), non-structural protein 2 (NS2), nucleoprotein (N), 
phosphoprotein (P), matrix protein (M), SH, glycoprotein (G), fusion protein (F), matrix 
protein 1 (M2-1), matrix protein 2 (M2-2) and polymerase (L) [Collins and Graham, 
2013]. The virion is relatively large, of about 150-300 nm in diameter [Collins et al., 
2013]. (Figure 1.7).
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Figure 1.7. Particle of RSV.
 
 1.2.1.2. Viral proteins
Five of the eleven RSV proteins are involved in nucleocapsid structure and/or RNA 
synthesis [Collins and Crowe, 2007]. In RSV-infected cells, the viral RNA with the L, 
N, P and M2-1 proteins form the polymerase complex in which the transcription of 
mRNA and genomic RNA occurs [Li et al., 2008]. 
The nucleocapsid protein (N) tightly encapsidates genomic RNA as well as it 
positive-sense replicative intermediate, called the antigenome [Collins and Crowe, 
2007]. This probably reduces detection of viral RNAs by host cell toll-like receptors 
(TLRs) and intracellular RNA recognition helicases that initiate innate immune 
responses through IFN regulatory factors and NF-κB [Akira et al., 2006; Liu et al., 
2007]. 
The Large subunit of the polymerase complex (L) is the RNA-dependent RNA 
polymerase which replicates the viral RNA genome and transcribe mRNAs, the 
capping enzyme to cap the mRNA 5′ end, and the methylase to methylate the cap 
[Dochow et al., 2012]. Given that the enzymatic activities of the polymerase complex 
are primarily associated with L, this protein is an attarctive drug target  [Morin et al., 
2012]. 
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The phosphoprotein (P) is an essential cofactor in RNA synthesis and also is thought 
to associate with free N and L to maintain them in soluble form for assembly of and 
interaction with nucleocapsids [Dupuy et al., 1999].
The Matrix protein 1 (M2-1) and matrix protein 2 (M2-2) are found only in 
close relatives of RSV [Collins and Graham, 2008]. M2-1 protein is necessary for 
processive transcription and is essential for viral viability [Fearns and Collins, 1999]. 
In its absence, transcription terminates nonspecifically within several hundred 
nucleotides and results in reduced expression of NS1 and NS2 alone [Fearns and 
Collins, 1999]. The other product of the M2 gene, the M2-2 protein, is not essential 
but appears to downregulate transcription in favor of RNA replication as infection 
progresses [Bermingham and Collins, 1999; Beyer et al., 2004].
The four other RSV proteins associate with the lipid bilayer to form the viral envelope 
[Collins and Crowe, 2007]. The M matrix protein lines the inner envelope surface 
and is important in virion morphogenesis [Teng and Collins, 1998]. The heavily 
glycosylated G, fusion F, and small hydrophobic SH proteins are transmembrane 
surface glycoproteins. G and F are the only virus neutralization antigens and are the 
two major protective antigens [Collins and Crowe, 2007].
The M matrix protein is a non-glycosylated inner virion protein, plays a central role 
in infection [Collins and Crowe, 2007]. M protein is mainly located in the cytoplasm 
where RSV replication occurs, but M also is present in the nucleus at particular 
stages of infection. RSV M plays a crucial role in virus assembly, budding and the 
formation of virus particles. The assotiation of this protein with the ribonucleoprotein 
complex inhibits viral transcription [Ghildyal et al., 2002]. The M protein has also 
been implicated in viral protein trafficking. This protein is also capable of associating 
with the plasma membrane, F and G proteins at the cell surface. This probably 
contributes to the transport of the ribonucleoprotein complex to the cell surface 
[Mitra et al., 2012; Shaikh and Crowe, 2013]. 
The G glycoprotein is produced, both, as a type II transmembrane protein that 
is incorporated into virions and as a soluble form lacking the signal/membrane-
anchor region that is secreted from infected cells [Hendricks et al., 1988]. G protein 
plays a crutial role in RSV binding to the cell surface through interaction with 
glycosaminoglycans, C-X3-C motif chemokine receptor 1 (CX3CR1) and the C type 
lectins, L-SIGN and DC-SIGN, on the cell surface [Bourgeois et al., 1998; Malhotra 
et al., 2003; Tripp R et al., 2001; Johnson et al., 2012]. The G protein also modulates 
the host immune response via the CX3C motif that mimics fractalkine/C-X3-C motif 
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ligand 1. The G protein containing CX3C motif binds to CX3CR1 and has leukocyte 
chemoattractant activity, thereby inducing disease pathogenesis [Fong et al., 1998; 
Tripp et al., 2001; Chirkova et al., 2013].
The F protein is a transmembrane protein of the surface of the viral envelope. The 
F protein has two cleavage sites, however, activation seems to be readily achieved 
by ubiquitous celular proteases [Collins and Graham, 2008]. F protein binds to the 
host cell membranes through GAGs and fuses irreversibly the viral and host cell 
membranes through changes in its conformation [Techaarpornkul et al., 2002]. In 
later stages of the infective cycle, F protein is involved in the dissemination of the 
virus by fusion of an infected cells with neighboring cells leading to the formation of 
syncytia [Walsh and Hruska, 1983].
During infection, the SH protein has been shown to exist in several forms as 
full-length truncated protein (4.5 kDa), and post-translationally modified by 
glycosylation and phosphorylation [Olmsted and Collins, 1989; Rixon et al., 2005], 
although the full-length unmodified form are the major species [Collins and Mottet, 
1993]. SH permeabilizes membranes [Carter et al., 2010]. SH absence leads to 
viral attenuation in the context of whole organisms and it prevents apoptosis in 
infected cells [Gan et al., 2012]. SH does not seem to play a key role role in RSV 
replication and pathogenesis. Thus, deletion of SH from recombinant RSV had little 
effect on virus production in vitro and resulted in only a small decrease in replication 
in chimpanzees [Collins and Graham, 2008].
The remaining two RSV proteins, NS1 and NS2, are nonessential proteins solely found 
in the pneumovirus genus [Buchholz et al., 1999]. Both interfere with the induction 
and signaling of IFNI and IFNIII, thus suppressing one of the main pathways of the 
immune innate response [Elliott et al., 2007; Barik, 2013]. They are not necessary for 
virus replication in vitro whereas deletion of either NS gene severely attenuates RSV 
in vivo, indicating important defects in virus-host interplay [Bossert et al., 2003]. 
 1.2.1.3. Replication cycle
The infection cycle begins with the interaction of RSV with receptor at the cell 
surface and the fusion of its envelope with the plasma membrane [Collins et al., 
2013]. Subsequently, the viral nucleocapsid is released into the cytoplasm of the 
cell. The nucleocapsid consists of the viral RNA, encapsidated along its length with 
the N nucleoprotein to form a helical structure [Bakker et al., 2013; Maclellan et al., 
2007; Tawar et al., 2009], and associated with the viral RNA-dependent polymerase, 
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a complex comprising proteins L, P and M2-1 [Garcia et al., 1993]. In the cytoplasm, 
the polymerase complex transcribes the viral mRNAs and replicates the genome by 
generating a positive-sense RNA intermediate, named antigenome, which acts as 
a template for further viral RNA synthesis [Collins et al., 1984; Collins and Wertz, 
1983]. Genomes and antigenomes are encapsidated with N nucleoprotein as they 
are synthesized and associate with the polymerase proteins to form nucleocapsids. 
Nucleocapsids are transported to the plasma membrane where they associate with 
other viral structural proteins. The virions will be released by budding [Fearns and 
Dewal, 2016]. (Figure 1.8).
Figure 1.8. Schema of RSV replication cycle. Re-drawn from Fearns and Dewal, 
2016. The attachment glycoprotein (G protein, red circle) binds to the chemokine 
receptor, CX3CR1, on the apical surface of epithelial cells and the fusion protein 
(F) (blue cylinder) mediates entry of the nucleocapsid into the cytoplasm. The 
complex consists of N nucleoprotein and viral RNA (chain of blue circles) ser-
ves as a template for the RSV polymerase complex, consisting of the L and P 
proteins (brown and black ovals, respectively), to synthesize viral mRNAs. The 
transcription process also requires the M2-1 protein (yellow circle). The surfa-
ce glycoproteins are synthesized, post-translationally modified, and transported 
through the endoplasmic reticulum and exocytic pathway. The M matrix protein 
(orange rod) associates with replication complexes in the cytoplasm and inte-
racts with the cytoplasmic tail of the F protein to elicit formation of viral filaments. 
This allows nucleocapsids to be packaged into filamentous virus particles, which 
are released by budding from the cell plasma membrane.
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 1.2.1.4. Immune innate response against RSV
Airway epithelial cells are the prime targets for RSV replication, thus these cells 
play a key role in regulating the respiratory tract inflammation that occurs upon viral 
infection [Lotz and Peebles, 2012]. The initial sensor for RSV infection is retinoic 
acid-inducible gene I (RIG-I), an intracellular RNA helicase that recognizes viral 
double-stranded RNA (dsRNA) [Liu et al. 2007]. Cells also sense RSV through toll-
like receptors. RSV commonly activates TLR2 and TLR6 [Murawski et al., 2009], 
TLR3 [Groskreutz et al., 2006], TLR4 [Haynes et al., 2001] and TLR7 [Lukacs et 
al., 2010]. Nevertheless, RIG-I and TLR3 are the main receptors for RSV [Liu et 
al., 2007]. RIG-I mediates RSV-induced early signaling events whereas TLR3, 
which is also a viral dsRNA sensor, acts later in the course of the viral infection 
[Alexopolou et al., 2001, Liu et al., 2007]. The activation of these receptors triggers 
the phosphorylation and degradation of IκB, thereby allowing nuclear translocation 
of transcription factors NFκB, IRF3 or IRF7 for the induction of type-I IFNs and 
proinflammatory cytokines [Kubota et al., 2008]. IFN-I (IFN-α and β) is produced by 
most nucleated cells whereas IFN-II is produced mainly by T cells and natural killer 
cells as IFN-ɣ [Katze et al., 2002]. IFN-I plays an important defensive role in many 
respiratory virus infections by limiting viral replication until the host develops its own 
defense mechanisms [Le Bon and Tough, 2002]. IFN-I bind to their extracellular 
receptors activating JAK-STAT pathway, which promotes the expression of IFN-
stimulated gene (ISG) [Horvath et al. 1996, Kong et al., 2003, Ramaswamy et al., 
2004]. (Figure 1.9).
(legend continued on next page
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Figure 1.9. Major signaling pathways activated in alveolar epithelial cells after 
RSV infection. TLR3 is expressed in intracellular endosomes and recognizes vi-
ral ssRNAs, such as those of rhinovirus, RSV, and influenza virus. TLR3 activates 
IRF-3 via the Toll/IL-1 receptor domain-containing adaptor (TRIF), resulting in 
IFN-β production. TLR3 also activates IRF-7 and NFκB through MyD88 activa-
tion. Activation of NFκB and IRF-7 leads to the production of proinflammatory 
cytokines such as TNF-α and the production of IFN-α, respectively. The RNA 
helicases RIG-I detect viral replication products in the cytosol to activate IRF-
3. IFNs-α/-β bind to their receptor on the epithelial cell surface and promote 
the phosphorylation and activation of STAT1/2 that lead to the transcription of 
IFN-stimulated gene such as ISG15.
ISG15 is one of the earliest and most important ISG induced by type I IFN after viral 
infection. This gene encodes an ubiquitin-like protein that exerts its antiviral action 
by conjugation with host and viral proteins [Kunzi et al., 2003]. ISG15 promotes an 
antiviral state by subverting proteosome-mediated degradation of IRF3 in infected 
cells [Pitha-Rowe and Pitha, 2007]. ISG15 can also be released to the extracellular 
medium by lysis of infected cells where activates the production and secretion of 
IFN-ɣ from B-cell-depleted lymphocytes, thus acting also as a proinflammatory 
mediator [Recht et al., 1991; Jeon et al., 2010]. It has been reported that TLR3 
expression in the context of RSV infection, depends on RIG-I-induced IFN-β 
secretion [Liu et al., 2007]
It has been postulated that RSV-elicited TLR3 activation leads to the production of 
chemokines, mainly CXCL8 and CCL5 [Rudd et al., 2005], which recruit and activate 
immune cells that produce high levels of proinflammatory cytokines including TNF-α 
and IFN-I that triggers inflammatory processes [Tian et al., 2002]. TNF-α secretion 
is necessary to develop the innate immune response against the virus. In this way, 
TNF-α was shown to promote neutrophil activation and migration to the lungs 
[Noah et al., 2002, Abraham, 2003] that will help to kill RSV. Nevertheless, TNF-α 
can induce lung injury due to an exacerbated proinflammatory response through 
excessive recruitment of inflammatory cells or direct cytotoxic effects on alveolar 
epithelial cells [Zhao et al., 2000].
1.3. INNATE IMMUNE SYSTEM IN THE ALVEOLAR SPACE 
The innate immune system in respiratory mucosa acts as first line of lung defense 
against inhaled microbes. Once pattern recognition receptors sense the microbes, 
inflammatory responses are triggered immediately. These inflammatory responses 
must be regulated to prevent tissue damage caused by an exacerbated inflammation. 
The innate immune system consists of an array of soluble components which bind 
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microbial products and phagocytic cells which travel through the blood and migrate 
into the sites of inflammation in the lung, or reside in the lung waiting to fight infection 
[Martin and Frevert, 2005]. 
1.3.1. Soluble immune components
The presence of soluble components in the alveolar space is very important to fight 
infection and clear inhaled pathogens from the lung. In the conducting airways, 
aqueous fluids contain lysozyme, which present lytic activity against several bacterial 
membranes, lactoferrin which is an iron binding protein that reduce the availability 
of iron (essential for bacterial grow) and defensins, which are antimicrobial peptides 
released from leukocytes and respiratory epithelial cells [Becker et al., 2000]. IgG, 
the most abundant immunoglobulin in alveolar fluids, complement proteins and 
surfactant-associated proteins act as additional microbial opsonins. In particular, 
SP-A and SP-D, members of the collectin family, promote phagocytosis by AMs. 
Lung collectins bind LPS and hamper their interaction with LBP in alveolar fluid and 
the TLR4 complex on alveolar macrophages [Borron et al., 2000; Sano et al., 2000]. 
Alveolar fluid contains high levels of LBP and soluble CD14 (sCD14), which are key 
molecules in the recognition of LPS by AMs and other immune cells [Martin and 
Frevert, 2005]. sCD14 is released from the surface of AMs by proteases, and this is 
augmented by IL-6, which is abundant in the BAL of patients with lung injury [Park 
et al., 2001; Lin et al., 2004]. AMs produce inflammatory cytokines and orchestrate 
a local inflammatory response by recruiting neutrophils from the blood into the 
alveolar space.
1.3.2. Alveolar epithelial cells
The pulmonary epithelium is involved in lung defense in different ways. Firstly, it acts 
as a structural barrier and contributes to the clearance of foreign inhaled particles 
and pathogens by the muco-ciliary escalator. Lung epithelial cells are attached 
to their neighbouring cells by intercellular junctions that divide the epithelium into 
apical and basal surfaces and restrict the passive movement of particles across 
the epithelium. In addition, alveolar epithelial cells participate in the immune innate 
response in the lung. Type II cells appear to be the primary alveolar epithelial cells 
(AECs) responsible for this part of innate immunity, but it is highly probable that type 
I cells are also involved. AECs are able to recruit inflammatory cells by releasing 
arachidonic acid derivates [Holtzman, 1992], chemokines in response to diverse 
stimuli such as bacterial and viral products [Lin et al., 1998; Vareille M et al., 2011]. 
AECs up-regulate adhesion molecules in response to inflammatory stimuli, allowing 
the adhesion of neutrophils and mononuclear cells to an inflamed area. AECs are 
also able to secrete antimicrobial substances, such as SP-A and SP-D, antimicrobial 
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proteins such as lysozyme, β-defensins, lactoferrins, cathelicidins, lipocalins 
and antioxidants such as reduced glutathione, which contribute to host defense. 
AECs II express toll-like receptors (TLR), mainly TLR2 and TLR4. Hence, they can 
recognize Gram-positive and Gram-negative bacteria. AECs II also express TLR3 to 
recognize some viruses such as Respiratory Syncytial Virus (RSV). In response to 
a viral infection, AECs secrete IL-6, IL-8, and RANTES as well as type I interferons 
(IFN-α, IFN-β). These interferons in turn will increase the production of chemokines 
and surface expression of ICAM-1, which is crucial to induce the migration of 
inflammatory cells [Mason, 2006].
1.3.3. Alveolar macrophages
Alveolar macrophages are the primary resident macrophages in the alveolar space. 
These cells constitute the major cell type recovered by bronchoalveolar lavage 
(BAL). AMs account approximately for 95% of the cell burden in BAL, with the 
remainder being lymphocytes (1-4%) and only about 1% of neutrophils [Gordon 
and Read, 2002]. 
Figure 1.10. Scanning electron micrograph of a rat lung showing the images 
of erythrocytes in the alveolar wall capillaries and two ruffled alveolar 
macrophages (MP) in the alveolar space (ALV). Taken from Martin and Frevert, 
2005.
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AMs are derived from hematopoietic precursors and then specialized in the lungs 
into AMs. They are distributed in different tissues where they develop a key role in 
homeostasis, tissue remodeling and host defense [Lambretch et al., 2006]. AMs, 
typically exhibit a lobulated nucleus surrounded by vacuolated cytoplasm containing 
abundant mitochondria and electron-dense secondary lysosomes. They are usually 
observed protruding from the alveolar epithelial walls into the lumen of the lungs 
[Laskin et al., 2001].
In the lung, AMs are exposed to high oxygen levels and are also bathed in high 
concentrations of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) 
and surfactant proteins (SP-A and SP-D) which present immunomodulatory actions. 
This particular environment made them to show certain unique features. The high 
levels of GM-CSF in the alveolar space favor the increase of CD11c expression, 
which is the most important difference between AMs and the rest of macrophage 
populations [Guth et al., 2009].
In the steady state, AMs produce little amounts of proinflammatory cytokines and 
exhibit poor phagocytic activity. They are responsible of maintaining an immunological 
tolerant environment in order to prevent an exacerbated immune response against 
the vast repertoire of environmental antigens at which are continuously exposed. 
This fact avoids T-cell mediated lung damage by lymphocytostatic signals released 
by AMs such as immunosuppressive prostaglandins, TGF-β and IL-1 receptor 
antagonist [Roth and Golub, 1993]. It has also been described that AMs abrogate 
immune responses through the inhibition of dendritic cell-mediated activation of T 
cells [Holt, 1993]. 
Interestingly, under homeostatic conditions, AMs are in close contact with the 
alveolar epithelium. This mechanism aids to limit unwanted inflammatory responses. 
AMs express high levels of CD200 receptor (CD200R), a type I transmembrane 
glycoprotein of the immunoglobulin superfamily and the alveolar epithelium express 
its ligand (CD200). The interaction between CD200R and CD200 inhibits the activation 
of MAPK pathways elicited by TLRs in AMs [Hussel and Bell, 2014]. Additionally, 
in the healthy lung, AMs are in close contact with type AECs II and induce the 
expression of the integrin αvβ6 on the surface of these cells. This integrin activates 
TGF-β which restricts the inflammatory response of AMs [Lambretch, 2006].
Despite their quiescent state in healthy lungs, following antigenic challenge, 
AMs lose their contact with the alveolar epithelium and trigger an inflammatory 
response to fight infection. AMs present several pattern recognition receptors, such 
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as TLRs, nucleotide-binding oligomerization domain-like receptors, and retinoic 
acid-inducible gene-I-like receptors. These PRRs allow them to sense pathogen-
associated molecular patterns (PAMPs) such as bacterial LPS, viral nucleic acids 
and components of the fungal cell wall, among others, or host-derived damage-
associated molecular patterns (DAMPs) by triggering activation of NF-kB, AP1, 
CREB, c/EBP, and IRF transcription factors which in turn activates the expression 
of proinflammatory mediators [Newton and Dixit, 2012].
Moreover, the proinflammatory cytokines produced by AMs, mainly IL-8 and related 
C-X-C chemokines trigger an inflammatory response by recruiting neutrophils into 
the alveolar space. AMs also produce and secrete CC chemokines, such as MCP-1 
and RANTES, which recruits monocytes and lymphocytes into the inflamed regions 
of the lung [Martin and Frevert, 2005].
In spite of an appropriate inflammatory response is necessary to combat inhaled 
pathogens, an aberrant proinflammatory response could induce lung injury through 
excessive recruitment of inflammatory cells or direct cytotoxic effects on AECs. For 
this reason, it is necessary the development of new therapies that aid to limit AMs 
responses during disease.
1.3.4. ROLE OF SURFACTANT COMPONENTS IN THE INNATE 
IMMUNE DEFENSE
Pulmonary surfactant has been proved to play a pivotal role in the immune innate 
system in the lung, helping to clear inhaled pathogens and to modulate inflammatory 
responses [Wright, 2005].
Firstly, pulmonary surfactant acts as a structural barrier hampering the entrance of 
pathogens in the lung. Moreover, there is mounting evidence indicating that both, 
surfactant phospholipids and proteins, play an indispensable role in lung defense 
[Chroneos et al., 2010].
Several evidences have linked disorders in surfactant levels or composition with 
inflammation in acute lung injury, pulmonary fibrosis, emphysema, cystic fibrosis 
and chronic obstructive pulmonary disease, among others [Gunther et al., 1999; 
Lewis and Veldhuizen, 2003; Chroneos et al., 2010].
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Results from in vivo experiments support the concept that genetic polymorphisms 
in one or more surfactant proteins genes are correlated with increased susceptibility 
to pulmonary inflammatory disease in humans [Chroneos et al., 2010].
 1.3.4.1 Surfactant phospholipids
There is growing evidence that support an important function for surfactant 
phospholipids in modulating innate immune response in the alveoli. This may 
represent a control mechanism to limit prolonged inflammation that could damage 
lung tissue.
Dipalmitoylphosphatidylcholine
DPPC is the most predominant phospholipid in the composition of pulmonary 
surfactant and has been demonstrated to be crucial to reduce surface tension to low 
levels at the end of expiration, thereby preventing alveolar collapse [Cañadas and 
Casals, 2012]. Interestingly, it has been described immunomodulatory properties 
for DPPC in the lung [Chroneos et al., 2010].
Firstly, it has been described that DPPC inhibits platelet-activating factor (PAF) 
biosynthesis, which has a major role in the inflammatory response in the lung. The 
proposed mechanism is via perturbation of the cell membrane, which becomes 
more rigid, thereby inhibiting the action of the enzymes involved in PAF biosynthesis 
[Tonks et al., 2003]. Moreover, it has been reported that preincubation of cells with 
DPPC inhibited the respiratory burst in response to LPS and zymosan through 
inhibition of protein kinase (PKC) δ [Tonks et al., 2005]. In addition, it has been 
described that DPPC is able to up-regulate COX2 via CREB transcription factor, 
which in turn implies an increased expression of the anti-inflammatory prostaglandin 
PGE2 [Morris et al., 2008]. All these experiments where performed using human 
monocytic cell lines. 
Finally, it has been proved that DPPC is able to reduce IL-8 secretion in the human 
A549 AECs by impairing TLR4 translocation into specific membrane domains 
designated as lipid rafts [Abate et al., 2010].
Anionic phospholipids
Several studies have postulated a potentially important role for anionic phospholipids 
in modulating the immune response with special emphasis on POPG.
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POPG has been reported to compete with LPS for the positively charged LPS-
binding site on LBP through electrostatic interactions [Hashimoto et al., 2003]. 
Furthermore, POPG has been demonstrated to bind to CD14 and MD-2 thus 
inhibiting LPS-elicited NO and TNF-α production from rat and human AMs and 
U937 cells [Kuronuma et al., 2009]. In addition, POPG is able inhibit the production 
of inflammatory mediators through TLR2 activation by Micoplasma pneumoniae 
[Kandasamy et al., 2011]. 
Interestingly, it has been described that anionic phospholipids carrying acyl chains 
with a higher degree of unsaturated bonds exhibit stronger immunomodulatory 
properties. Thus, DPPG did not show inhibitory effect on TLR4-elicited NFκB 
activation, whereas POPG and DOPG, did. It is plausible that the transfer of a 
phospholipid to LBP or CD14 from fluid phospholipid vesicles occurs more readily 
than the transference from those more rigid [Hashimoto et al., 2003]. 
In addition, anionic phospholipids have been proved to exhibit antiviral properties. 
It has been described that anionic pulmonary surfactant phospholipids such as 
POPG and PI, are able to bind RSV and block viral attachment to the epithelium, 
thereby suppressing RSV-induced replication and inflammation in vitro and in vivo 
and to provide short-term prophylaxis against RSV infection in mice [Numata et al., 
2010; Numata et al., 2013a; Numata et al., 2013b, Numata et al., 2015]. POPG also 
has been proved to protect against Influenza A virus infection by suppressing viral 
attachment to the plasma membrane and subsequent replication and inflammation 
[Numata et al., 2012].
1.3.4.2 Surfactant proteins
Among surfactant proteins, lung collectins (SP-A and SP-D) have been proved to 
play a significant role in lung defense. On the other hand, hydrophobic proteins (SP-
B and SP-C) are mainly involved in respiratory dynamics. Nevertheless, increasing 
evidence indicate that SP-B and SP-C present immunomodulatory function [Glasser 
and Mallampali, 2012].
Lung collectins
Hydrophilic surfactant proteins SP-A and SP-D, belong to the C-type collectin 
superfamily and are called lung surfactant collectins. Concerning to their structure, 
they present four domains that consist of an N-terminus involved in interchain 
disulfide bonding, a collagen-like domain, a coiled coil neck domain and a lectin 
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or carbohydrate recognition domain (CRD). Each monomeric protein is assembled 
to form a triple helix at the collagenous domain. These trimers are oligomerized to 
form a bouquet-like octadecamer for SP-A and a cruciform dodecamer for SP-D 
[Ariki et al., 2012]. 
Lung collectins are able to recognize a wide range of pathogens by PAMPs on their 
surface. For example, LPS on Gram-negative bacteria, lipoteichoic acid on Gram-
positive bacteria, glycoprotein on fungi, lipoarabinomannan on mycobacteria, 
phospholipids on mycoplasma, and viral surface glycoproteins have been identified 
as ligands for pulmonary collectins [Hogenkamp et al., 2007].
Upon recognition, they can act as opsonins agglutinating microorganisms [Sano 
and Kuroki, 2005] or directly inhibit the growth of microbes such as Histoplasma 
capsulatum yeast and some strains of Gram-negative bacteria, by increasing the 
permeability of the microbial cell membrane [McCormack et al., 2003; Wu et al., 
2003]. 
Genetic elimination of lung collectins in mice has provided compelling evidence of 
its important role against infectious agents of the respiratory tract. These knockout 
mice show slower clearance of microbes including Haemophilus influenzae [Levine 
et al., 2000] and respiratory syncytial virus [Levine et al., 1999; Levine et al., 2004], 
among others. Moreover, deficiency of these lectins has been associated with 
increased inflammation after infection with certain pathogens such as group B 
Streptococcus, Haemophilus influenzae and influenza A virus [Levine et al., 2000; 
Levine et al., 2002].
Lung collectins could augment the uptake of particles and infectious agents by 
different mechanisms. One mechanism described is opsonization. In this way, C1q 
receptor mediates the phagocytosis of SP-A-opsonized Staphylococcus aureus by 
monocytes [Geertsma et al., 1994]. SP-A opsonizes Bacillus Calmette-Guerin and 
Staphylococcus aureus enhancing their phagocytosis by alveolar macrophages 
via SP-R210, which is a specific receptor for SP-A [Weikert et al., 1997; Sever-
Chroneos et al. 2011].
Another mechanism by which lung collectins promote uptake of pathogens is 
by increasing the expression of cell surface receptors. SP-A up-regulates the 
expression of scavenger receptor A and mannose receptor on the surface of alveolar 
macrophages, thereby favoring the phagocytosis of Streptococcus pneumoniae 
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and Mycobacterium avium, respectively [Kuronuma et al., 2004; Kudo et al., 2004].
In the context of inflammation, lung collectins have been shown to modulate the 
inflammatory response elicited by different infectious agents. Thus, SP-A interacts 
with CD14 on alveolar macrophages and avoids smooth LPS (s-LPS) binding to 
CD14 and inhibiting as a consequence s-LPS-induced TNF-α expression [Sano et 
al., 1999]. In agree with this finding, it has been proved that intratracheal instillation 
of s-LPS into SP-A-deficient mice leads to an increased lung inflammation in 
comparison to wild-type mice and that co-instillation of s-LPS with SP-A attenuates 
inflammation in SP-A knockout mice [Borron et al., 2000]. Similarly, by binding to 
TLR2, SP-A inhibits the interactions of peptidoglycan and zymosan with TLR2 
[Murakami et al., 2002; Sato et al., 2003].
Surfactant protein B
SP-B is a small hydrophobic peptide crucial for sustaining respiratory physiology. 
Newborns with mutations that lead to deficiency of SP-B develop respiratory 
distress syndrome and die after birth due to the impossibility of inflate their lungs 
[Nogee et al., 1994; Perez-Gil, 2008]. Despite of its main function on surfactant 
physiology, increasing data indicate that an immunomodulatory role for SP-B 
cannot be ruled out [Chroneos et al., 2010]. Experiments with conditional knockout 
mice of SP-B indicate that SP-B deficiency was associated with increased levels 
of proinflammatory markers such as IL-6, IL1-β and MIP-2 in AMs and AECs. 
Restoration of SP-B levels decreased lung inflammation. This fact highlights a role 
for SP-B in the control of the inflammatory response in the lung [Ikegami et al., 
2005]. 
Moreover, it has been reported that SP-B reduces nitric oxide production by rat AMs 
by decreasing iNOS levels [Miles et al., 1999]. Furthermore, in vivo experiments have 
proved that SP-B protects against lung injury induced by intratracheal administration 
of endotoxin. 
In addition, SP-B has been proved to exhibit antimicrobial properties. Thus, a 
synthetic SP-B peptide is capable of inhibiting E. Coli growth in vitro [Kaser et al., 
1997]. Interestingly, it has been demonstrated that SP-B is able to aggregate and 
kill Klebsiella pneumonia, Pseudomonas aeruginosa, Staphylococcus aureus and 
group B streptococcus by increasing bacterial membrane permeability [Ryan et al., 
2006].
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Surfactant protein C
The surface-tension reducing properties of SP-C have been exhaustively studied. 
Recently, it has been described that in addition to lung collectins, SP-C presents 
immunomodulatory properties. SP-C interacts with lipid A and CD14 [Augusto et 
al., 2001; Augusto et al., 2002; Chaby et al., 2005]. These findings imply that SP-C 
neutralizes LPS to induce inflammatory stimuli in the alveoli.
Interestingly, it has been demonstrated that SP-C-deficient mice are more 
susceptible to bacterial and viral infections. In fact, it has been demonstrated 
that SP-C knockout mice are more vulnerable to pulmonary infection caused by 
Pseudomonas aeruginosa. Lower bacterial clearance and increased pulmonary 
inflammation were reported in mice lacking SP-C [Glasser et al., 2008]. Moreover, 
in the absence of SP-C, RSV infection augmented lung inflammation due at least 
in part by SP-C-mediated inhibitory effect on TLR3 signaling [Glasser et al., 2009]..
1.4. CARDIOLIPIN
Cardiolipin (1,3-diphosphatidyl-sn-glycerol, CL) is present in the outer membrane 
of Gram-negative bacteria and the membrane of Gram-positive bacteria (~ 10 and 
~25%, respectively) [Barák and Muchová, 2013]. In eukaryotic cells, CL is mainly 
located in the inner mitochondrial membrane (~20 %), where fits perfectly due 
to its molecular structure [Krebs 
et al., 1979; Zinser et al., 1991 
Paradies et al., 2013; Mayr, 2015]. 
Nevertheless, CL is also present in 
the outer mitochondrial membrane 
(~5%) and is enriched at contact 
sites between the inner and outer 
membrane [Daum, 1985; Zinser 
et al., 1991; Kroon et al., 1997]. 
Cardiolipin is a dimeric phosphatidic 
acid with a glycerol backbone 
containing two phosphates and 
four acyl chains, thus differing from 
the rest of phospholipids (Figure 
1.11) [Lecocq and Ballou, 1964]. 
CL belongs to non-bilayer forming 
phospholipids since the head group 
is significantly smaller than the tail 
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that is formed by four fatty acids [Mayr, 2015]. The two phosphates are ionized at 
physiological pH resulting in CL being a doubly-negatively charged amphiphilic lipid 
[Few et al., 1960]. 
In bacteria, CL is synthesized from two molecules of phosphatidylglicerol whereas in 
the mitochondria is synthesized from phosphatidylglicerol and cytidine diphosphate 
diacilglycerol (CDP-DAG) [Tian et al., 2012]. In the mitochondria, two molecules of 
CDP-DAG are required to attach the two phosphatidyl groups to the positions 1 and 
3 of the glycerol backbone.Two enzymes are required in CL synthesis: phosphatidyl-
glycerol-phosphate synthetase and CL synthetase [Schlame et al., 2005]. 
Interestingly, molecular species of CL found in eukaryotic and prokaryotes organisms 
are different: shorter acyl chains and saturated or mono-unsaturated CL species are 
typical of bacteria whereas longer chain polyunsaturated CL are mainly found in 
the mitochondria [Schlame, 2008]. Furthermore, bacterial CLs undergo limited acyl 
chain modifications, including formation of plasmalogen acyl chains which contain 
an alk-1´-enyl ether linkage as described in Clostridium difficile [Guan et al., 2014]. 
Nevertheless, mitochondrial CLs undergo an extensive acyl chain remodeling to 
generate cell and tissue-especfific CL molecular species. The enzymes involved 
in these post-translational modifications are: (i) a CL specific phospholipase which 
produces monolyso-CL [Baile et al., 2013]; (ii) An acyl transferase (tafazzin) that is 
located in the intermembrane space of the mitochondria and reversibly exchange 
acyl chains between phospholipids and monolyso-CL [Schlame, 2008; Claypool 
and Koehler 2012; Lu et al., 2016]; (iii) A monolyso-CL acyltransferase-1 that 
is located in the mitochondrial matrix [Lu and Claypool, 2015] and (iv) An acyl-
CoA:lyso-CL-acyltransferase-1 which is beyond the outer side of the mitochondrial 
outer membrane, in the mitochondria associated membranes of the endoplasmic 
reticulum [Zhao et al., 2009; Lu and Claypool, 2015].
In the mitochondria, CL is essential for its function and structural integrity. After 
remodeling, CL is mainly concentrated in the inner leaftet of the inner mitochondrial 
membrane where CL bind to several mitochondrial proteins and, among them, 
the respiratory super-complexes [Bazan et al., 2013; Mejia et al., 2014]. Thus, this 
phospholipid is essential for ATP production by oxidative phosphorylation and also 
participates in mitochondrial fusion and fission processes [Claypool and Koehler, 
2012; Mayr, 2015].
Moreover, CL acts as a DAMP in damaged mitochondria changing its localization 
from the inner to the outer membrane thus promoting mitophagy [Chu et al., 2013; 
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Kagan et al., 2017]. Externalized CL binds to microtubule-associated protein 1 light 
chain 3 which forms part of the autophagy machinery [Hsu and Shi, 2017; Maguire 
et al., 2017]. CL is also involved in apoptosis. To trigger apoptosis, CL should be 
externalized but also undergo peroxidation of its polyunsaturated acylchains by 
cytochrome c [Kuwana et al., 2002; Kagan et al., 2017; Maguire et al., 2017].  CL 
enables tBid recruitment to the mitochondrial membrane and Bax activation, a pore-
forming pro-apoptotic protein involved in mitochondrial membrane permeabilization 
[Claypool and Koehler, 2012]. 
The relevance of CL on cell function has been demonstrated by the existence 
of several diseases (heart failure, diabetes or Barth syndrome) associated with 
deficiency in CL biosynthesis and/or alteration in the remodeling mechanisms of CL 
acyl chains [Claypool and Koehler 2012; Acehan et al., 2011; Chatfield et al., 2014]. 
Nevertheless, outside of the mitochondrial scenario, the effect of CL on cell function 
remains poorly understood. The role of secreted CL into the extracellular medium 
on the immune response of alveolar cells or molecular effects of CL on membrane 
structure and dynamics have been poorly investigated.
It has been reported that in humans with pneumonia or mice infected with bacterial 
pathogens, CL is released into the alveolar fluid. CL could be released into the 
alveolar fluid from either dying host lung cells or from bacterial membranes. The 
molecular characteristics of the CL found in the alveolar fluid of patients or mice 
with pneumonia suggest a mitochondrial rather than bacterial origin. In fact, in 
pneumonias caused by Haemophilus influenzae, which lacks CL on its membrane 
composition, high levels of CL have been detected in BAL of infected mice. High 
concentrations of CL in the alveolar fluid impair lung function as it might damage 
the surface activity of pulmonary surfactant, a lipoprotein complex that prevents 
alveolar collapse and is involved in the innate immune defense of the lung [Ray et 
al., 2010].
Recently, it has been described a dual role for CL in the context of host-host 
and host-pathogens interactions. Balasubramanian and co-workers found that 
the presence of CL increases the phagocytosis of membranes with externalized 
mitochondrial or bacterial CLs by macrophages (RAW 264.7, THP1 treated with 
phorbol esters, mouse peritoneal macrophages and human macrophages derived 
from monocytes) in a CD36 scavenger receptor dependent manner. On the other 
hand, CL attenuates the inflammatory response of mouse peritoneal RAW 264.7 
macrophages stimulated with LPS by blocking the LPS receptor, TLR4. Given that 
bacteria externalize CL during host encounter, these investigators propose that 
externalization of CL might be an evasion strategy to avoid its recognition by the 
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innate immune system. Nevertheless, the presence of CL on the bacterial surface 
favors the pathogen clearance mediated by macrophages dependent on CD36. 
Therefore, these investigators propose that extracellular CL could be used by both, 
host and pathogen, for their own benefit [Balasubramanian et al., 2015].
I. INTRODUCTION

II. HYPOTHESIS AND OBJECTIVES

81
II. HYPOTESIS AND OBJECTIVES
Cardiolipin is an unusual anionic tetra-acylated phospholipid [Lecocq and Ballou, 
1964] which is mainly located in the mitochondrial membranes of eukaryotic cells 
and in Gram-negative and Gram-positive bacteria [Paradies et al., 2013; Barak 
and Muchová, 2013]. In the mitochondria, CL develops a crucial role in membrane 
structure and function [Mayr, 2015]. Moreover, its implication in apoptosis is well-
known [Kagan et al., 2017; Maguire et al., 2017]. However, little is known about the 
biological function of CL outside the cellular environment. 
It has been reported that in mice and humans infected with bacteria that cause 
pneumonia, cardiolipin, presumably from the host, is released to the alveolar fluid. 
High levels of CL in the alveolar fluid impair lung function [Ray et al., 2010]. It has been 
suggested that damaged lung function might be a consequence of CL-dependent 
inhibition of the tensoactive properties of pulmonary surfactant [Ray et al., 2010]. On 
the other hand, it was recently postulated that extracellular CL could be beneficial 
for the host since membranes presenting mitochondrial or bacterial CLs on their 
surface are avidly phagocytosed by macrophages, which could facilitate clearance 
of host damaged membranes [Balasubramanian et al., 2015]. At the same time 
CL, as well as other anionic lipids, can block LPS binding to TLR4 [Kuronuma et 
al., 2009; Balasubramanian et al., 2015], which limits inflammation. However, the 
potential anti-inflammatory action of CL could also be beneficial for pathogens in 
evading the host immune response.
We hypothesize that CL actions must depend on the CL concentrations in the 
extracellular medium. We aim to understand the biological actions of extracellular 
CL in the alveolar microenvironment in which these particles can interact with 
surfactant membranes, the alveolar epithelium, alveolar macrophages, and invading 
microorganisms (virus and bacteria).
The focus of this doctoral thesis is to understand how extracellular CL exerts its 
action in the alveolus during infection. To this end, we have studied whether low 
doses of cardiolipins are able to control inflammation and/or infection using cell 
culture models of inflammation and infection with respiratory pathogens. On the 
other hand, we studied whether high doses of CL might have any impact on the 
structure and function of pulmonary surfactant, and the mechanism by which this 
might occur.
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Accordingly, this thesis comprises four sections of results with the following specific 
objectives:
1.  To investigate the immunomodulatory role of CL on the immune innate 
 response of alveolar macrophages stimulated with LPS or zymosan.
2.  To determine the antiviral and anti-inflammatory effect of CL against 
 respiratory syncytial virus infection on human alveolar epithelial cells,  
 as well as to obtain deeper insight into the mechanism underlying CL  
 antiviral action and the influence of lung surfactant components on CL 
 antiviral properties.
3.  To study CL protective action against non-typeable Haemophilus 
 influenzae (NTHi) infection on alveolar epithelial cells.
4. To evaluate the inhibitory effect of high amounts of CL on lung 
 surfactant structure and biophysical function.
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3.1. BIOCHEMICAL AND BIOPHYSICAL METHODS
3.1.1. Isolation of native rat pulmonary surfactant.
Male Sprague Dawley rats (Charles River, USA) were anesthetized with an 
intraperitoneal injection of Ketamine (80 mg/kg) and Xylazine (10 mg/kg). BALs were 
performed with 40 ml of NaCl 0.9% (p/v), instilling into the trachea 10 ml each time. 
The BAL recovered was centrifuged for 7 min at 250 g to obtain cell-free BAL, which 
was stored at -80ºC in order to isolate pulmonary surfactant.
BALs from five rats were pooled and centrifuged at 48000g for 1h at 4ºC in a 
centrifuge XL-90 model (Beckman Coulter, Fullerton, USA) to separate LA from 
SA which remain in the pellet and supernatant, respectively. LA presents high 
surface activity and consists of surfactant lipids and apolipoproteins SP-A, SP-B, 
and SP-C, but not SP-D. SA represents the non-functional surfactant fraction that 
is generated due to respiratory dynamics. Given that SP-D is not able to bind to 
surfactant membranes, remains in the SA fraction [Casals and Cañadas, 2012]. 
After the centrifugation step, supernatant (SA) was discarded. The pellet (LA) was 
recovered and homogenized in 1ml of NaCl (0.9% p/v) using a potter and stored at 
-80ºC until its use.
3.1.2. Isolation of lipid extract from native surfactant
A lipid extraction from the LA fraction of pulmonary surfactant using organic 
solvents was performed according to the method described by Bligh and Dyer [Bligh 
and Dyer, 1959]. For this purpose, 1 ml of LA was transferred into conical tubes 
previously delipidized with CHCl3:CH3OH (2:1, v/v). Then, 2 ml of CH3OH and 1 ml 
of CHCl3 were added and the mixture was stirred using vortex for 30 seconds to 
form a monophasic system CHCl3:CH3OH:H2O (1:2:1, v/v). Subsequently, samples 
were incubated for 30 minutes at 37 ºC in a 320 Unitronic OR bath with continuous 
stirring to produce protein flocculation. After that, 1 ml of CHCl3 and 1 ml of H2O 
were added and samples were shaken for 30 seconds and centrifuged at 3000 rpm 
for 5 minutes to form a biphasic system CHCl3:CH3OH: H2O (2:2:2). After that, the 
organic layer was separated and transferred into a delipidized B20 tubes (Afora, 
Spain). Then, 2 ml of CHCl3 were added to the remaining aqueous phase. After 
shaking and centrifugation as explained above, the organic layer was transferred 
into a B20 tube. This last step was repeated once, in order to recover as much 
possible hydrophobic material.
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Finally, the organic phase contained into the B20 tube was evaporated with a rotary 
evaporator (Buchi, Flawil, Switzerland) and resuspended in 1ml of CHCl3:CH3OH 
(3:1, v/v). The samples were kept at -20 until use.
3.1.3. Quantification of total amount of phospholipid 
Total phospholipid amount in the lipid extract of the LA fraction was performed 
by the phosphorus method described by Rouser and co-workers [Rouser et al., 
1966]. Samples (2µl) and standards (calibration curve of KH2PO4 0.05 mg/ml) 
each in duplicate, were taken to complete evaporation. Phosphorus present in 
phospholipids was mineralized by adding 0.45 ml of 70% HClO4 into each tube and 
incubated covered with glass ampoules in a sand bath at 260ºC for 30 minutes. After 
hydrolysis, the phosphorus liberated was quantitated by a colorimetric reaction by 
adding to each tube 3.5 ml of H2O, 0.5 ml of ammonium molybdate (2.5% w/v) and 
0.5 ml ascorbic acid (10% w/v). Molybdate forms a complex with phosphorus which 
is reduced by ascorbic acid and that results in a colored compound. The reaction 
was developed for 7 minutes in boiling water and stopped by immersing the tubes 
in ice. The amount of phosphorus was determined by measuring absorbances at 
820 nm in a DU.800 spectrophotometer (Beckman Coulter, Fullerton, USA).
3.1.4. Preparation of liposomes of lipid extract of pulmonary 
surfactant
Multilamellar vesicles (MLVs) of lipid extract of rat pulmonary surfactant (LES) in 
the absence or presence of CL, were formed upon hydration in HEPES 25 mM pH 
7.0, NaCl 150 mM (buffer A) for interfacial adsorption experiments, or in Tris-HCl 
5mM pH=7.4, NaCl 150 mM (buffer B) for Differential Scanning Calorimetry (DSC) 
and emission anisotropy of DPH experiments. MLVs were prepared by hydrating 
the dry proteolipid film, with or without the fluorescent probe DPH, in the suitable 
buffer, and allowing it to swell for 1 h at 55°C. After that, MLVs were used directly or 
sonicated at the same hydration temperature for 4 min at 390 W/cm2 (burst of 0.6 
s, with 0.4 s between bursts) in a UP 200S sonifier with a 2 mm microtip [Canadas 
O et al., 2004] to perform fluorescence experiments. Vesicles were prepared freshly 
each day, just before the experiment was started.
3.1.5. Preparation of cardiolipin vesicles. 
Cardiolipin (1’,3’-Bis-(1,2-dilinolenil-sn-glycero-3-phospho)-sn-glycerol)) was 
dissolved in HPLC grade chloroform/methanol (Scharlau, Spain) (2:1 v/v) and was 
carried first to total evaporation under a nitrogen stream and subsequently, in a 
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vacuum centrifuge to remove any traces of organic solvent. Then, the dry lipid film 
was hydrated in 1 ml of 20 mM Tris pH = 7.4 containing 150 mM NaCl, for 1 h at 10°C 
in a Thermomixer (Eppendorf, Hamburg, Germany) with constant stirring. Afterthat, 
the vesicles formed upon hydration were sonicated to obtain small unilamellar 
vesicles (SUVs) at the same temperature of hydration for 3 minutes at 390 W/cm2 
(burst of 0.6 s, with 0.4 s between bursts) in a UP 200S sonifier with a 2 mm microtip 
(Hielscher Ultrasonics, Teltow, Germany).
3.1.6. Dynamic Light Scattering analysis 
CL was prepared as described in section 3.1.5 at a final concentration of 1mg/
ml. The size of the vesicles obtained upon sonication and its stability over time 
were determined at 37°C in a Zetasizer Nano S (Malvern Instruments, Malvern, UK) 
equipped with a 633-nm HeNe laser. Three scans were performed for each sample. 
The hydrodynamic diameter was calculated using the general purpose algorithm 
available from the Malvern software for dynamic light scattering (DLS) analysis, 
which correlates the diffusion coefficient to the hydrodynamic diameter through the 
Stokes-Einstein equation, Eq.3.1:
where kB is the Boltzmann constant, T is the temperature, ɳ is the viscosity, and D 
is the translational diffusion coefficient [Sáenz et al., 2010]. 
3.1.7. Monolayer experiments
Monolayer experiments were performed as described previously [Cañadas et al., 
2011]. Studies were carried out at 25°C using a thermostatted Langmuir-Blodgett 
trough (102M micro Film Balance; NIMA Technologies, Coventry, UK) equipped 
with an injection port and magnetically stirred. The trough is equipped with two 
symmetrical movable barriers controlled by an electronic device. A concentrated 
solution (1 mg/ml) of rat LES dissolved in CHCl3:CH3OH 3:1 (v/v) was used for 
monolayer experiments. The subphase employed was buffer B. For insertion 
studies, monolayers were formed by spreading increasing amounts of LES (1mg/
mL) at the air-water interface to reach initial surface pressures from 0 to 13 mN/m. 
After organic solvent evaporation, the monolayer was allowed to stabilize for a few 
minutes before injection into the subphase a CL amount equivalent to 12mol % with 
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respect to LES, without disturbing the lipid monolayer. Then, CL-induced changes 
in the monolayer surface pressure at constant surface area were measured.
3.1.8. Interfacial adsorption
The effect of CL on the ability of either rat LES or rat NPS to adsorb and spread 
onto at an air-water interface was analyzed with a Wilhelmy-like highly sensitive 
surface microbalance coupled to a small teflon dish. MLVs of rat LES or NPS (266 
nmol) were injected into the hypophase chamber of the Teflon dish, which contained 
1.5ml of buffer A containing 2.5 mM CaCl2 (Figure 3.1). Interfacial adsorption 
was measured following the change in surface pressure (π) as a function of time. 
The surface pressure (π) is a parameter that represents the ability of pulmonary 
surfactant to adsorb and spread onto an air-liquid interface and is related to the 
surface tension (γ) by the following expression: π= γ0-γ, where γ0 is the surface 
tension of the clean air-water interface and γ that of the surface covered by the lipid 
monolayer. Thus, when surfactant spreads and adsorbs onto the air-water interface, 
the surface tension reaches the equilibrium value (25mN/m), which corresponds to 
a surface pressure value of 47mN/m (π= γ0-γ= 72-25=47mN/m) [Zuo et al., 2008; 
Cañadas and Casals, 2012].
Figure 3.1. Adsorption of MLVs composed of surfactant membranes onto 
an air-water interface. This results in the formation of an interfacial monolayer 
which lowers the surface tension of water molecules located at the interface, 
which is reflected in an increase in the surface pressure, π. The surface pressure 
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is defined as: π= γ0-γ, where γ0 is the surface tension of water at the air-liquid 
interface (72 mN/m) and γ is the surface tension in the presence of the phospho-
lipid monolayer.   
3.1.9. Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry (DSC) is a technique which allows to determine 
the thermodynamic properties of temperature-induced phase transitions. In DSC 
experiments, the sample to study and a reference material (a material which does 
not undergo a phase transition within the desired temperature range, usually the 
buffer in which the sample is reconstituted) are simultaneously heated or cooled 
at identical and predetermined rates. If the sample undergoes a temperature-
induced phase transition, the sample will release or absorb heat. This fact results in 
a difference of temperature between the sample and the reference cell. To correct 
this, the instrumental control system will supply more (or less) heat. 
Figure 3.2. DSC thermogram 
for a two-state endothermic 
process. Tm is the phase 
transition temperature, ΔT1/2 is 
the temperature width at half-
height of the peak, and ΔH is the 
enthalpy of the thermodynamic 
event
Biological membranes undergo a temperature-induced phase transition from a 
relatively ordered crystalline-like state (gel phase (Lβ)) to a relatively disordered fluid-
like state (liquid-crystalline phase (Lα)). The properties of the gel-to-liquid phase 
transition of different lipid mixtures can be therefore studied by DSC.
The registered parameter in a DSC scan is the excess heat capacity (Cp) of a 
sample according to the reference cell as a function of temperature. Endothermic 
transitions are represented as positive peaks. Three thermodynamic parameters 
can be directly determined from the thermogram (Figure 3.2). Firstly, the phase 
transition temperature, Tm, represents the temperature at which the gel-to-liquid 
crystalline phase transition is half complete. Secondly, the relative cooperativity of 
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a phase transition is related to the sharpness of the transition peak, which is given 
by the temperature width at half-height, ΔT1/2. Finally, the enthalpy of the transition 
(ΔH) can be calculated by integrating the area below the thermogram [Cañadas and 
Casals, 2013]. 
Calorimetric measurements were performed in a Microcal VP differential scanning 
calorimeter (Microcal Inc., Northampton, MA, USA) at a heating rate of 0.5°C/min. 
MLVs of lipid extract of pulmonary surfactant (1 mM), containing or not different 
molar percentages of CL (3, 6, 12 mol %) and hydrated in buffer B, were loaded in 
the sample cell of the microcalorimeter with 0.7 ml of buffer B in the reference cell. 
Three calorimetric scans were recorded from each sample between 15 and 65°C. 
The standard Microcal Origin software was used for data acquisition and analysis. 
The excess heat capacity functions were obtained after subtraction of the buffer-
buffer base line.
3.1.10. Fluorescence emission anisotropy measurements
Steady-state fluorescence emission anisotropy measurements were carried out as 
described previously [Sáenz et al., 2007] in a SLM-Aminco AB2 spectrofluorimeter 
equipped with Glam prism polarizers and a thermostated cuvette holder (Thermo 
Spectronic, Waltham, MA, USA) (± 0.1 °C), using 5x5 mm path-length quartz 
cuvettes. MLVs of LES containing or not increasing molar percentages of CL (3, 
6, 12 mol %) were mixed with 1,6-diphenyl-1,3,5-hexatriene (DPH) (Molecular 
Probes Inc, Eugene, OR, USA) at a probe/phospholipid molar ratio of 1:200 (final 
phospholipid concentration of 1 mg·ml−1). DPH concentration was determined 
measuring its absorbance at 350 nm, using a molar extinction coefficient in methanol 
of 88000 M-1.cm-1. Excitation and emission wavelengths were set at 360 and 430 
nm, respectively. For each sample, fluorescence emission intensity data in parallel 
and perpendicular orientations, with respect to the exciting beam, were collected 
10 times each and then averaged. Background intensities in DPH-free samples as a 
result of the vesicles were subtracted from each recording of fluorescence intensity. 
Anisotropy, r, was calculated according to Eq.3.2:
where III and I are the parallel and perpendicular polarized intensities measured 
with the vertically polarized excitation light and G is the monochromator grating 
correction factor.
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3.1.11. Binding studies
Tryptophan fluorescence emission spectra of SP-A were measured in the absence 
or the presence of increasing amounts of CL in buffer B plus CaCl2 150µM. SP-A 
samples (with and without CL) and blank samples (CL alone) were excited at 295 
nm and emission spectra recorded from 300 to 400 nm. 
The apparent dissociation constant, Kd, for the SP-A/CL complex was obtained 
by analyzing the tryptophan fluorescence change when 10 μg/ml (15 nM) of SP-A 
reacted with various concentrations of CL. Each titration data point was performed 
in separated samples, and tryptophan fluorescence emission was monitored 10 
minutes after CL addition.
The change in the fluorescence of SP-A at 337 nm and 25 ºC was monitored as a 
function of CL concentration and the titration data were analyzed by nonlinear least-
squares fitting to the Hill equation 3.3:
(3.3)
where ΔF is the change in fluorescence intensity at 337 nm relative to the intensity of 
free SP-A; ΔFmax is change in fluorescence intensity at saturating CL concentrations; 
Kd is the apparent equilibrium dissociation constant; [CL] is the molar concentration 
of free CL; and n is the Hill coefficient.
3.2. EXPERIMENTS WITH MOUSE AND RAT ALVEOLAR 
MACROPHAGES
3.2.1. Isolation of rat alveolar macrophages by bronchoalveolar 
lavage and culturing.
Bronchoalveolar lavages (BALs) of lungs obtained from male Sprague Dawley rats 
(Charles River, USA) were performed with 40 ml of phosphate buffered saline (PBS, 
pH 7.4) containing 0.2 mM EDTA to obtain AMs. Rats were anesthetized with an 
intraperitoneal injection of ketamine (80 mg/kg) and xylazine (10 mg/kg). BALs from 
three rats were pooled and collected by centrifugation for 7 min at 250 g. After 
washing twice with sterile PBS, cells were resuspended in RPMI supplemented with 
ΔF ΔFmax = L[ ]
n L[ ]n +Kd( )
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FBS (10% v/v), 100 U/ml penicillin, 100 μg/ml streptomycin and glutamine 2 mM. 
Then, cells were poured into 100 cm2 culture plates and allowed to adhere for 90 
min at 37ºC in a humidified atmosphere of 5% CO2 in air. After that, supernatants 
were discarded and cells were washed with PBS to remove non-adherent cells. 
Cell purity was assessed by staining of CD11c to carry out the analysis by flow 
cytometry. Cellular population consisted of >88% alveolar macrophages.
3.2.2. Culture conditions of mouse alveolar macrophage cell line.
Two different types of alveolar macrophages were employed to study the anti-
inflammatory action of CL: murine MH-S AMs [Mbawuike and Herscowitz, 1989] 
(Figure 3.3), acquired from the American Type Culture Collection (ATCC) (Manassas, 
VA, USA), and primary rat AMs isolated and cultured as described before. MH-S cells 
were cultured in RPMI 1640 with HEPES and glutamine (Gibco, Invitrogen, Auckland, 
NZ) and supplemented with fetal bovine serum (FBS) (10% v/v) (decomplemented 
at 56°C for 30 minutes) (Biochrom) antibiotic (penicillin/streptomycin) at 1% v/v 
(Lonza, Basel, Switzerland). Cell growth was performed in 100 mm dishes (TPP, 
Switzerland) maintaining the cells at a concentration of 1.105 and 2.105 cells/ml in 
an incubator at 37º C and in a humidified atmosphere of 5 % CO2. MH-S cells were 
scraped every 2-3 days. In any case 35 cellular passes were exceeded.
Figure 3.3. Morphology of MH-S cells by light microscopy.
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3.2.3. Stimulation of MH-S or rat alveolar macrophages.
MH-S cells (3.105 per well) or rat AMs (1.105 per well) in RPMI containing FBS (5 % 
v/v) were seeded on 24-well plates or 96-well plastic dishes respectively. Cells were 
incubated O/N at 37º C in a humidified atmosphere of 5% CO2 in air.
AMs were preincubated with CL vesicles for 18 hours and subsequently, stimulated 
with s-LPS extracted from E. coli serotype (B5:O55) (Sigma-Aldrich, St. Louis, 
MO) or zymosan A (Sigma-Aldrich, St. Louis, MO), in order to determine the anti-
inflammatory effect of endocytosed CL vesicles. Moreover, we studied the effect of 
the co-administration of CL with the proinflammatory stimulus (LPS or zymosan).
To measure proinflammatory markers in the supernatants of cell cultures (TNF-α 
secretion) and protein levels of iNOS in cell lysates, cells were incubated for 6h at 
37ºC, 5% CO2 whereas 10-30 minutes to determine phosphorylation of proteins 
involved in TLR4- or TLR2-elicited signaling events. 
To determine the role of CL vesicles on the expression of certain genes induced by 
LPS, MH-S cells (5x105 cells per well) were seeded in 6-well plates (TPP) in 2 ml of 
RPMI medium containing FBS (5% v/v). Macrophages were then stimulated with 1 
µg/ml of s-LPS for 1h.
3.2.4. Cell viability assays 
The effect of CL vesicles on MH-S AMs viability was determined by propidium 
iodide exclusion assay:
Propidium iodide exclusion assay
AMs were maintained in the absence or presence of different amounts of CL vesicles 
for 24 hours. AMs were scrapped, centrifuged (200g, 10 min, 4°C) to remove the cell 
culture medium, resuspended in 0.5 ml of PBS and treated for 5 minutes with 50 µg/
ml propidium iodide (Sigma Aldrich, St. Louis, MO). Propidium iodide is a waterproof 
dye which is excluded from viable cells. However, it is able to penetrate the non-
viable cells with damaged plasma membrane and to intercalate into DNA bases, 
thereby increasing its fluorescence. The permeability of the plasma membrane to 
propidium iodide (was determined by flow cytometry (BD Biosciences FACScalibur). 
The fluorescence of propidium iodide was determined in the FL-2 channel using 
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Cell Quest Pro software.
3.2.5. Immunofluorescence microscopy 
MH-S cells were seeded as described in section 3.2.3, in wells containing a round 
cover slide previously irradiated with UV light to allow sterilization. CL vesicles were 
fluorescently labeled with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine 
perchlorate (DiIC18) (Invitrogen, Carlsbad, CA), in a molar ratio of 200:1 
phopholipid:probe. CL (dissolved in chloroform/methanol 2:1 (v/v)) was mixed 
with DiIC18 (dissolved in methanol) and dried as described in section 8. The dry 
lipid film was hydrated in 1 ml PBS for 1 h at 10°C in a Thermomixer (Eppendorf, 
Hamburg, Germany) with constant stirring. Then, CL was sonicated as explained 
in section 3.1.5 and added to the cells at a final concentration of 7 nmol/ml for 
increasing preincubation times (see Figure 4.1.3 in section 1 of results). Cells were 
washed with PBS and fixed in paraformaldehyde (PFA) (3.8% p/v) for 30 minutes. 
After that, wells were blocked with PBS containing FBS (10%v/v) for one hour and 
incubated with anti-mouse CD14 antibody developed in rat (1:100) (eBioscience, 
San Diego, CA) for one hour. Cells were washed with PBS and incubated for 30 
minutes with a secondary anti-rat FITC-conjugated antibody (AbD Serotec). After a 
final washing step, cover slides were mounted on slides with Mowiol containing 1 
µg/ml 4’,6-diamidino-2-phenylindole (DAPI) to stain cell nuclei. Micrographs were 
taken on a Leica TCS SP2 Confocal system (Leica Camera AG, Solms, Germany).
3.2.6. Quantification of TNF-α release.
Secretion of TNF-α was determined in culture supernatants of AMs by enzyme-
linked immune sorbent assay (ELISA) kits (BD Biosciences, NJ, USA). Firstly, 
wells of a Maxisorp® polystyrene plate (Nunc, Rochester, NY, USA) were coated 
overnight at 4ºC with a primary antibody against TNF-α. After washing with PBS-
Tween-20 0.05% (v/v), the plate was blocked with PBS-FBS 10% (v/v) for one hour 
at room temperature to prevent non-specific binding. Then, wells were washed 
and incubated with the samples or TNF-α standards for two hours. After washing, 
the plate was incubated with a biotinylated detection antibody against TNF-α and 
streptavidin-horseradish peroxidase conjugate for one hour. Subsequently, wells 
were washed to remove unbound antibody and tetramethylbenzidine (TMB) was 
used as substrate. The reaction was stopped with H2SO4 and the absorbance of 
the plate at 450 nm was read on a plate reader ELISA DIGISCAN (Asys Hitech 
GmbH, Eugendorf, Austria).
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3.2.7. Cell lysates and Western-Blot.
Once the time of phosphorylation (Akt, MAPKs, IkBα) or induction of protein levels 
(iNOS) has elapsed, the culture medium was removed and the plate containing the 
cells was rapidly frozen in liquid nitrogen. Then, a lysis buffer with the following 
composition was added: 10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 
mM EDTA, Triton X-100 0.2% , 1 mM benzamidine , aprotinin, 200 µg/ml leupeptin 
200 µg/ml and 1 mM PMSF. For experiments in which phosphorylated proteins 
were analyzed, the buffer employed to perform cells lysates also contained the 
following phosphatase inhibitors: 20 mM β-glycerophosphate, 10 mM NaF, 10 mM 
sodium pyrophosphate and 2 mM orthovanadate. Cells were gently scraped and 
the content was transferred into an eppendorf. Samples were centrifuged (10000g, 
10 min, 4°C) to remove genomic DNA. Finally, the supernatants were collected 
and the amount of protein was quantified using the bicinchoninic acid (BCA) 
assay. Subsequently, a loading buffer with the following composition was added to 
samples: 80 mM Tris HCl pH 6.8, 10% glycerol, 2% SDS, 0.1 % bromophenol blue 
and 5 % β-mercaptoethanol.
An amount of total protein present in the cell lysate of 6μg was loaded on 
polyacrylamide gels at 10%. Proteins were transferred to a PVDF membrane. 
Once the transfer was completed, membranes were blocked with PBS-Tween 
0.1 % and skim milk (2.5% p/v) for 1 hour at room temperature with continuous 
stirring. All primary antibodies used were obtained from cell signaling: anti-iNOS 
(1:1000), GAPDH (1:10000), P-Erk (1:1000), Total Erk (1:2000), P-p38 (1:1000), total 
p38 (1:2000) P-Akt (1: 1000), total Akt (1:2000) and P-ikBα (1:1000). The secondary 
antibody used was anti-rabbit Ig-G coupled SIGMA peroxidase (1:5000). Bands 
corresponding to the protein of interest were detected using ECL substrate (Millipore) 
and quantified using Quantity One software program (Biorad).
3.2.8. Determination of total protein amount by Bicinchoninic acid 
(BCA) assay
The principle of BCA assay relies on the formation of a Cu2+-protein complex 
under basic conditions, followed by reduction of the Cu2+ to Cu1+ by cysteine, 
tryptophan, tyrosine and peptide bonds [Wiechelman et al., 1988]. The extent of 
reduction is correlated with protein content. BCA forms a purple-blue complex with 
Cu1+ in alkaline environments, thus providing a basis to monitor the reduction of 
alkaline Cu2+ by proteins [Smith et al., 1985]. To develop this assay, 10 µl of each 
cell lysate were mixed with 80 µl of the working reagent supplied in the BCA Kit 
for Protein Determination (Sigma) in 96-well polystyrene microplates (Nunc). The 
working reagent was prepared mixing 50 parts of BCA basic solution (reagent A) 
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with 1 part of 4% (w/v) copper (II) sulfate pentahydrate solution (reagent B). The 
plate was incubated for 30 minutes at 37ºC, and absorbance was read at 570 nm in 
a microplate reader (Asys Hitech). The protein concentration in each cell lysate was 
calculated from a bovine serum albumin standard curve.
3.2.9. Gene expression analysis by quantitative real-time polymerase 
chain reaction (qPCR)
MH-S AMs were seeded as described in section 3.2.3. CL vesicles were co-
administered with LPS or preincubated with cells for 18 hours before the stimulation 
with LPS. Afterthat, culture medium was removed, cells were washed and trypsinized. 
Samples were centrifuged at 200g for 10 minutes. Subsequently, supernatants were 
discarded and pellets were washed with PBS. Cell pellets were stored at -80ºC until 
RNA extraction.
RNA extraction was performed employing High Pure RNA Isolation kit (Roche 
Diagnostics, Basel, Switzerland), according to the manufacturer’s instructions. Briefly, 
cell pellets were resuspended in 200µl of PBS, then 400 µl of lysis/binding buffer 
were added to each sample and mixed by vortexing. Samples were transferred to a 
high pure filter tube coupled to a collection tube, which retain RNA into membrane. 
Residual DNA contaminations were removed adding to the samples 1.8 U/µl 
deoxyribonuclease I (DNase I) and incubating for 15 minutes at room temperature. 
Bound RNA was washed several times with different buffers given in the kit to 
eliminate salts, proteins, cellular impurities and inhibitory contaminants. RNA was 
finally recovered in 50 µl of elution buffer, quantified in a Spectrophotometer ND-
1000 (NanoDrop Technologies, Wilmington, DE, USA) and stored at -80ºC. 
cDNA synthesis was performed with the High-Capacity cDNA Archive Kit (Applied 
Biosystems) following the supplier’s instructions. The reaction was developed in 50 
µl of volume containing 1.25 µg RNA as input, random primers, deoxynucleotide 
triphosphate (dNTP) mix, 1.25U/µl MultiScribeTM reverse transcriptase, reverse 
transcription buffer and nuclease-free water. Samples were mixed with reagents 
by pipetting and incubated for 10 minutes at 25ºC (primers annealing), for 2 hours 
at 37ºC (cDNA synthesis) and for 5 minutes at 85ºC (enzyme inactivation) in a 
thermomixer (Eppendorf, Hamburg, Germany). Finally, cDNA was stored at -20ºC 
until PCR was performed.
Quantitative RT-PCRs were performed using PCR primers and Taqman MGB probes 
(FAM dye-labeled) for the genes cited in Table 3.1 which are products acquired from 
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Assays-on-demand (Aplied Biosystems, Life Technologies, USA).
Target gene Gene name Gene expression assay
GAPDH glyceraldehyde-3- 
phosphate 
dehydrogenase
Mm99999915_g1
CXCL10 C-X-C motif chemokine 
10
Mm01345163_g1
IL1-β Interleukin 1-β Mm00434228_m1
IL1-β Tumor Necrosis Factor α Mm00443258_m1
NOS2 Nitric Oxide Synthase 2 Mm00440502_m1
COX2 cyclooxygenase 2 Mm00478474_m1
Table 3.1. Gene expression assays used in qPCRs performed using predesig-
ned primers.
Reactions were developed in 10 µl of final volume using 0.5 µl of gene expression 
assay, 2 µl of 1:10 diluted cDNA, TaqMan Gene Expression master mix (Applied 
Biosystems) and nuclease-free water. Reactions were carried out in an ABI PRISM 
7900 HT-Fast (Applied Biosystems). The amplification program was: 10 minutes 
at 95ºC, followed by 40 cycles of denaturation for 15 seconds at 95ºC and primer 
annealing and extension for 1 minute at 60ºC. Assays were performed in triplicates. 
Data were analyzed using the 2-ΔΔCT method [Livak and Schmittgen, 2001], and 
results were normalized to the expression levels of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH).
3.3. EXPERIMENTS WITH HUMAN EPITHELIAL CELLS AND 
RESPIRATORY SYNCYTYAL VIRUS (RSV).
3.3.1. Culture conditions of human epithelial cells (A549 and HEp2 
cell line)
We employed two epithelial human cell lines: A549 alveolar epithelial cells (Figure 
3.4) [Giard et al., 1973] and HEp-2 epithelial cells (Figure 3.5) [Moore et al., 1955]. 
Both cell lines were acquired from the ATCC and cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 4 mM glutamine, 100 U/ml penicillin, 
100 U/ml streptomycin (Lonza Group Ltd, Basel, Switzerland) and FBS (10% v/v) 
(Linus, Madrid, Spain) at 37ºC and 5% CO2.
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Figure 3.4. Morphology of A549 AECs by light microscopy.
Figure 3.5. Morphology of HEp-2 cells by light microscopy.
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3.3.2. Cell viability assays.
We analyzed the effect of increasing amounts of CL vesicles on the viability of A549 
AECs employing wst-1 reagent:
Wst-1 reagent
WST-1 assay is based on the cleavage of the tetrazolium salt WST-1 in viable cells 
only, leading to the formation of a soluble formazan salt, which absorbance can be 
read at 450 nm. A549 AECs were maintained in the absence or presence of different 
amounts of CL vesicles for 24 hours. Five minutes before the end of the experiment, 
WST-1 diluted 1:40 was added to the cell culture. Finally, the supernatants were 
transferred into a 96-well microplate and the absorbance was measured at 450/600 
nm using microplate reader (Asys Hitech GmbH, Eugendorf, Austria).
3.3.3. RSV propagation and purification.
The Long strain of human RSV was grown in HEp-2 cells seeded in DMEN 
containing FBS (2% v/v). RSV was purified from cell culture supernatants employing 
polyethylene glycol to allow precipitation and then, were centrifugated in a 30-45% 
discontinuous sucrose gradient in TNE buffer (10 mM Tris-HCl, pH 7.5, 100 mM 
NaCl, 1 mM EDTA) [Mbiguino and Menezes, 1991].
For this purpose, HEp-2 cells were plated at a cellular density of 5.106 cells in 
P100 plate (TPP) in DMEN-FBS (10% v/v) and grown overnight at 37ºC. Then, cells 
were infected at a multiplicity of infection (moi) of 0.5 plaque-forming units (pfu) 
per cell in DMEM-FBS (2%v/v). After 48 hours of infection, cells were scrapped 
and homogenized three times using a syringe coupled to a needle. Subsequently, 
ten P150 plates of HEp-2 cells were infected with the virus obtained from the first 
plate diluted in DMEM-FBS (2% v/v). After 48 hours of infection, supernatants were 
collected and cells were gently scrapped. Both were mixed and homogenized 
three times with a syringe coupled to a needle. After that, a centrifugation step 
was performed (4000g, 20 min, 4ºC) to clarify the mix. In the following step, 50% 
polyethylene glycol 6000 was added to the supernatant to a final concentration 
of 10%. The mix was maintained for 90 minutes at 4ºC with soft swelling. Then, 
it was centrifuged (4000g, 20 min, 4ºC). The pellets obtained were resuspended 
in TNE buffer and homogenized five times with a syringe coupled to a needle 
and sonicated three times for 10 seconds. Samples were added into a 30-45% 
discontinuous sucrose gradient in TNE buffer and centrifuged (150000g, 90 min, 
4ºC). We observed a white band corresponding to RSV, placed between the 30% 
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and 45% sucrose solutions, which was recovered. Finally, RSV was aliquoted and 
stored in liquid N2. Viral titers were determined by plaque assay in layered HEp-2 
cells, as it is described in the following section.
3.3.4. Determination of viral titers.
A549 AECs were seeded at 5.105 cells per well in 6-well plates (TPP) in 2 ml of DMEM-
FBS (10% v/v) and grown overnight at 37ºC. In experiments aiming to determine the 
effect of the coadministration of CL with RSV, cells were mock-infected (with sucrose) 
or infected with RSV (moi=3) in DMEM-FBS (2% v/v) in the absence or presence 
of varying amounts of CL vesicles and/or pulmonary surfactant components for 
90 minutes. Then, cells were maintained in the absence or presence of CL for 24 
hours (post-infection period) at 37ºC in a humidified atmosphere containing 5% 
CO2 in air. In order to analyze the intracellular effect of CL on viral replication, cells 
were preincubated for 18h with CL and then, cells were washed with PBS and 
infected with RSV for 24 hours. Afterthat, supernatants were collected to infect 
HEp-2 monolayers.
HEp-2 cells were seeded the day before at 1.2.106 cells per well in 6-well plates 
(TPP) in 2 ml of DMEM-FBS (10% v/v) and maintained overnight at 37ºC in a 
humidified atmosphere containing 5% CO2 in air. A549 AECs culture supernatants 
were diluted in DMEM-FBS (2% v/v) (10-1 to 10-3) to infect HEp-2 monolayers. 
A549 AECs were incubated at 37ºC for 90 minutes to allow virus adsorption. After 
that, 3 ml of 0.7% low melting-point agarose (Conda, Madrid, Spain) in DMEM-FBS 
(2% v/v) were added into each well. Plates were maintained at 4ºC for 30 minutes 
to allow agarose solidification. Afterthat, plates were incubated at 37ºC for 5 days 
to allow RSV replication. 
To visualize viral plaques, HEp-2 monolayers were firstly fixed with PBS-PFA (4% 
p/v) for 45 minutes. Then, the agarose blocks were removed, cell monolayers were 
also fixed with methanol, washed twice and blocked with PBS-BSA 1% (p/v) for 
30 minutes at room temperature to avoid non-specific binding. Subsequently, 
wells were washed, and incubated for 1 hour with a pool of monoclonal antibodies 
(dilution 1:50) which recognize the two major RSV glycoproteins (2F, 47F, 56F, 
021/1G, 021/2G) [Martínez et al., 1997]. Then, wells were washed three times and 
incubated with an anti-mouse IgG HRP-linked whole antibody (1:500) (Amersham 
Biosciences, Buckinghamshire, UK) for one hour. Finally, RSV-forming plaques 
were revealed using 3-amino-9-ethylcarbazole (Sigma). Viral titer was calculated 
employing the next equation, Eq 3.4:
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where T is the viral titer (pfu/ml), N corresponds to the number of viral plaques 
obtained, D is the dilution factor of the assayed infected-supernatant, and V 
represents the volume of culture supernatant used to infect cells expressed in ml.
3.3.5. Gene expression analysis by quantitative real-time polymerase 
chain reaction (qPCR)
A549 AECs were seeded at a cellular density of 5.105 cells per well in 6-well plates 
in 2 ml of DMEM-FBS 10% (v/v) and maintained overnight at 37ºC. Next day, the 
culture medium was removed, cells were washed and then, mock-infected (with 
sucrose) or infected with RSV (moi=3) in the presence or absence of CL (7nmol/
ml) for 90 minutes. In experiments aiming to elucidate the anti-inflammatory action 
of endocytosed CL vesicles, cells were preincubated with CL for 24h and then, 
washed with PBS and then infected with RSV.  Afterthat, fresh medium was added 
and cells were maintained at 37ºC for 24 hours. Then cells were trypsinized, washed 
with PBS and stored at -80ºC.
RNA was isolated from cellular pellets using ReliaPrep RNA Cell Miniprep System 
(Promega, Madison, WI, USA) according to the manufacturer´s instructions. Briefly, 
250 µl of lysis buffer (BL+TG) were added to each cellular pellet and mixed well by 
vortexing and pipetting. Then, isopropanol was added to the samples and mixed 
by vortexing for 5 seconds. After that, samples were transferred to a minicolumn 
coupled to a collection tube and centrifugated (30 seconds, 14000 g, 25ºC). The 
resulting eluate was discarded. Total RNA will be retained into the minicolumn 
membrane. After a washing step, the membrane of the minicolumns was treated 
with DNAse I (Promega, Madison, WI, USA) for 15 minutes to remove potential 
contaminations with DNA.
After several washing steps, RNA was eluted in 40μl of RNase-free water by 
centrifugation (2min, 14000g, 25ºC). Total RNA extracted was measured at 260 nm 
in a spectrophotometer Biophotometer Plus (Eppendorf, Hamburg, Germany) and 
stored at -80ºC.
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cDNA synthesis was performed as described in section 3.2.9.
To perform Quantitative RT-PCRs we used PCR primers and Taqman MGB 
probes (FAM dye-labeled) for the genes cited in Table 3.2 which were acquired 
from Assays-on-demand (Aplied Biosystems, Life Technologies, USA). A Custom 
Taqman Gene Expression Assay (Aplied Biosystems, Life Technologies, USA) 
was employed for amplification and quantification of the RSV Nucleoprotein 
N (forward primer: 5´CATGATTCTCCGATTGTGGGATGA 3´; reverse primer: 5´ 
TCACGGCTGTAAGACCAGATCTAT 3´; probe: 5´ CCCCTGCTGCCAATTT 3´.
Target gene Gene name Gene expression assay
ACTB β-actin Hs99999903_m1
DDX58 (RIG-I) Dead (Asp-Glu-Ala-Asp) 
box polypeptide 58
Hs00204833_m1
TLR3 Toll-like receptor 3 Hs01551078_m1
TNF-α Tumor Necrosis Factor α Hs01113624_g1
ISG15 Interferon stimulated 
Gene 15
Hs01921425_s1
Table 3.2. Primers and probes used to carry out qPCR assays.
To develop PCR reaction, a mix of a total volume of 50µl for each sample containing 
the following components was prepared: Gene expression assay (2.5µl), cDNA (3µl) 
and 5x Pyrotaq probe qPCR mix plus (Cultek) (15µl) and nuclease free PCR water 
(29.5µl) (Promega, Madison, WI, USA). PCR reactions were performed in triplicate 
(15µl/PCR tube) on a StepOne sequence detection system (Aplied Biosystems, 
Life Technologies, USA). Samples were subjected to the following amplification 
program: 94ºC for 3 minutes, followed by 35 cycles 94ºC for 30 seconds (DNA 
denaturation), 45 seconds at 65ºC (primer annealing) and 45 seconds at 72ºC 
(DNA chains extension). Finally, samples were maintained at 72ºC for 2 minutes. 
ACTB was used as an endogenous control. Experiments were analyzed using the 
comparative CT (ΔCCT) method for relative quantifications. 
3.3.6. Flow cytometric analysis of RSV binding to A549 cells. 
A549 cells were cultured in plastic Petri dishes with DMEN-FBS 10% (v/v). The day 
on which the experiment will be performed, the culture medium was removed, cells 
were washed once with PBS plus EDTA 1 mM and then, cells were incubated with 
10ml of PBS-EDTA for 10 min at 37ºC and 5% CO2 to allow cells detachment from 
the Petri dish. Subsequently, PBS-EDTA was removed and cells were recovered 
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using 5ml of PBS- FBS 2% (v/v). After cell counting, 5.105 cells were placed into 
each eppendorf and centrifuged at 3000 rpm for 5 minutes in a minifuge. From here, 
the whole process was carried out at 4ºC. Then, supernatant was discarded and 
celular pellet was resuspended in 2 ml of DMEN-FBS 2% (v/v) in the presence or 
absence of RSV (moi 3) containing or not CL (7 and 25 nmol/ml). Cells were incubated 
on a rotating wheel for 45 min. Afterthat, cells were incubated with primary mouse 
antibody against G glycoprotein of RSV for 30 min and, successively, anti-mouse Ig 
labeled with FITC. Finally, cells were fixed with PFA 1% in PBS. The Fluorescence of 
cells was determined in a Becton Dickinson FASCalibur cytometer using CellQuest 
software. PBS-FBS 2% (v/v) was used for washes carried out between steps and 
for dilutions of antibodies. This protocol is based on [Martínez and Melero, 2000].
3.4. EXPERIMENTS WITH MURINE EPITHELIAL CELLS AND 
HAEMOPHILUS INFLUENZAE (NTHi).
3.4.1. Culture conditions of murine epithelial cells (MLE-12 cell line)
We used the murine cell line MLE-12 which expresses some features of normal 
type II alveolar epithelial cells [Wikenheiser et al., 1993]. MLE-12 cells were cultured 
under the same conditions described for A549 cell line (section 3.3.1).
3.4.2. Adhesion experiments of NTHi to pneumocytes MLE-12
Murine pneumocytes MLE-12 were infected with NTHi (108 c.f.u per well) in the 
absence or the presence of different concentrations of CL (7 and 27 mol/ml) for 30 
minutes at 37ºC and 5% CO2. Infection was carried out in Hank´s medium (0.137 
M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1 
mM MgSO4, 4.2 mM NaHCO3). After infection, culture medium was removed and 
washed 5 times with PBS, lysed with 300 μl of PBS-saponin 0.025% for 10 min at 
room temperature, and serial dilutions were plated on Brain heart infusion (BHI)-
agar. Next day, we proceed to c.f.u counting [López-Gómez et al., 2012].
3.4.3. Experiments of internalization of NTHi into pneumocytes  
MLE-12 
A similar protocol to that described above for adhesion experiments was performed. 
However, cells were infected with NTHi for 2h and then, they were incubated with 
RPMI-FBS 10% (v/v) containing gentamicin (200μg/ml) in order to kill extracellular 
bacteria. After three washing steps, pneumocytes were lysed according to the 
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protocol described for adhesion experiments. Then, cellular lysates were serial 
diluted for c.f.u counting on BHI-agar plates [López-Gómez et al., 2012].
3.4.4. Analysis of Akt phosphorylation by western-blot
Pneumocytes were infected with NTHi (108 c.f.u per well) in the absence or the 
presence of CL (7 and 27 nmol/mL) for 1h at 37ºC and 5% CO2. Then, cells were 
lysed in a buffer with the following composition: 10 mM HEPES pH 7.9, 1.5 mM 
MgCl, 10 mM KCl, 0.5 mM EDTA, Triton X-100 0.2%, 1 mM benzamidine, aprotinin, 
200 µg/ml leupeptin 200 µg/ml and 1 mM PMSF. To determine phosphorylated 
Akt, we carried out a western blot of cellular lysates according to the protocol 
described in section 3.2.7. Specific anti-bodies were used in order to detect P-Akt 
and GAPDH. Finally, membranes were incubated with a rabbit secondary antibody 
coupled to SIGMA peroxidase. Bands were detected using ECL substrate (Millipore) 
and quantified using Quantity One software program (Biorad).
3.5. STATISTICS
Data are shown as means ± SE. Statistical comparisons were made using one-
way ANOVA followed by Bonferroni test. p values <0.001 or <0.05 were considered 
statistically significant. All statistical calculations were performed using SIGMAPLOT.
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4.1. ANTI-INFLAMMATORY EFFECT OF CARDIOLIPIN IN 
ALVEOLAR MACROPHAGES STIMULATED WITH BACTERIAL AND 
FUNGAL MOLECULAR PATTERNS
4.1.1. INTRODUCTION
Cardiolipin is an anionic phospholipid having a head group (glycerol) that is esterified 
to two phosphatidylglyceride backbone fragments rather than one. This structure, 
combined with its four acyl chains makes CL unique among phospholipids [Paradies 
et al., 2014]. CL is present in the outer membrane of Gram-negative bacteria and 
the membrane of Gram-positive bacteria (~10 and ~25%, respectively) [Barák and 
Muchová, 2013]. In eukaryotic cells, CL is preferably found in the inner mitochondrial 
membrane (~20 %) [Krebs et al., 1979; Zinser et al., 1991 Paradies et al., 2014]. 
Nevertheless, CL is also present in the outer mitochondrial membrane (~5%) and 
is enriched at contact sites between the inner and outer membrane [Daum 1985; 
Zinser et al., 1991; Kroon et al., 1997]. Nevertheless, high levels of CL have been 
found in the bronchoalveolar lavage of human and mice with pneumonia. CL found 
in BAL could proceed from dying host cells as well as from bacterial membranes. 
The analysis of the acyl chain composition of these CLs (longer and unsaturated) 
suggest that they are presumably from the host [Ray et al., 2010]. The biological 
function of CL in the alveolar fluid is unknown. It has been previously reported 
that POPG, an anionic surfactant phospholipid, plays a key role in the alveolar 
space modulating inflammation induced by respiratory pathogens (Mycoplasma 
pneumoniae) [Kandasamy et al., 2011] or pathogen-associated molecular patterns 
such as [bacterial lypopolisaccharide (LPS)] [Kuronuma et al. 2009] or TLR2 ligands 
such as Pam3Cys [Kandasamy et al., 2011; Kuronuma et al., 2009]. 
We hypothesize that the secretion of low amounts of CL might modulate the 
inflammatory response of AMs and protect the host from the inflammatory response 
elicited as a consequence of the infection, that when it turns into aberrant, could 
damage lung tissues. However, high amounts of CL might be harmful for lung 
surfactant. Upon its secretion, CL could act in the extracellular medium and also be 
internalized by AMs and type II pneumocytes.
Therefore, the proposal of the present study was to determine the effect of 
extracellular and intracellular low concentrations of CL vesicles (≥0.07 nmol/ml) on 
the immune response of AMs stimulated with two pathogen-associated molecular 
patterns, to elucidate whether the action of CL is specific or not for a particular 
proinflammatory stimulus.
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4.1.2. EXPERIMENTAL DESIGN
To study the potential immunoregulatory role of CL vesicles on the LPS or zymosan-
elicited immune response, CL small unilamellar vesicles were coadministered with 
smooth bacterial LPS from E.Coli (1µg/ml) or zymosan A from S.Cerevisiae (50µg/ml) 
to MH-S murine AMs or rat AMs (Figure 4.1.1, t=0, co-addition CL-LPS). Alternatively, 
cells were previously incubated with CL vesicles for 18h and subsequently, washed 
with PBS and then stimulated with LPS (1µg/ml) or zymosan (50µg/ml) (Figure 4.1.1, 
t=18h, preincubation with CL). This preincubation time was long enough to ensure 
CL endocytosis by AMs, demonstrated with confocal microscopy experiments 
shown bellow (Figure 4.1.3). 
Figure 4.1.1. Experimental design.
 4.1.3. RESULTS
 4.1.3.1. Determination of the size and stability of cardiolipin 
vesicles. 
We determined the hydrodynamic diameter of CL vesicles obtained upon sonication 
and analyzed the stability of these vesicles at 25ºC by Dynamic Light Scattering 
(DLS) technique after 30 min, 1h, 2h, 4h and 24h. Figure 4.1.2 shows DLS analysis 
of CL vesicles in buffer Tris 20 mM pH= 7.4 containing NaCl 150 mM. Two minutes of 
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sonication were enough to obtain a homogeneous population of CL small unillamelar 
vesicles (SUVs) with 50 nm of hydrodynamic dyameter (volume adjustment). The 
size of the vesicles was maintained at least for 24h.
Figure 4.1.2. DLS analysis  of the hydrodynamic diameter of CL vesicles obtai-
ned after 2 minutes of sonication (50nm,volume adjustement). CL SUVs were 
stable for 24h. The Y axis represents the relative volume of scattered light and 
the X axis shows the hydrodynamic diameter of the particles present in the so-
lution.
 4.1.3.2. Alveolar macrophages are able to internalize cardiolipin 
SUVs.
CL is secreted to the alveolar fluid from dying host cells during infection [Ray et 
al., 2010].  Once there, CL could modify the activation state of AMs acting in the 
extracellular medium but also at the intracellular level if AMs were able to internalize 
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this phospholipid as it has been described for lung surfactant membranes 
[Agassandian and Mallampalli, 2013]. Therefore, we conducted confocal microscopy 
experiments in order to determine wheter CL is endocytosed by MH-S AMs. Then, 
cells were incubated for different times (10min, 30 min, 4h and 18h) in the presence 
of CL SUVs labeled with DiIC18 probe (200:1 phospholipid: probe molar ratio). Cells 
were fixed with paraformaldehyde, plasma membranes were labeled with anti-
CD14 and FITC-conjugated secondary antibody whereas cell nuclei were stained 
with DAPI. Figure 4.1.3 indicates that after 10 minutes of CL addition, most of CL 
SUVs were located in the plasma membrane because they co-localized with the 
macrophage membrane receptor, CD14. After 30 minutes of preincubation, CL 
SUVs are beginning to be endocytosed by AMs and after 18 hours, the endocytosis 
of CL SUVs was maximal. From Figure 4.1.3, we can conclude that AMs are able to 
internalize CL SUVs. 
(legend continued on next page
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Figure 4.1.3. Cardiolipin internalization by MH-S AMs. Images taken by 
confocal microscopy of MH-S cells incubated with CL SUVs (7nmol/ml) labeled 
with DiIC18 (in a 200:1 phospholipid: probe molar ratio) (in red) for 10 minutes 
to 18 hours, fixed, labeled with anti-CD14 antibody (in green) and stained with 
DAPI (1µg/ml) (in blue). After 10 minutes of incubation with CL, CL co-localized 
with CD14 at the cellular membrane. Nevertheless, note that after 30 minutes 
of incubation, CL SUVs were being endocytosed by the cells. CL endocytosis 
increased over time, being maximal at 18 hours.
 4.1.3.3. Cardiolipin vesicles do not impair cell viability at the  
concentrations tested.
MH-S cells were incubated in the absence or presence of different doses of CL (7, 
27 and 70 nmol/ml) for 24 hours. Cell viability was assessed by propidium iodide 
exclusion assay by flow citometry. We assessed that cell viability was not impaired 
at the concentrations of 7-70 nmol/ml of CL and these concentrations were used in 
the following experiments.
Figure 4.1.4. Cardiolipin vesicles do not affect viability of MH-S cells at 7-70 
nmol/ml concentrations as determined by propidium iodide exclusion assay. 
Dose-dependent effect of CL vesicles on cell viability was evaluated after 24 
hours of incubation with CL vesicles. Results are represented as means ± S.E 
from three different cell cultures with at least three biological replicates.
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4.1.3.4. Cardiolipin inhibits LPS-elicited proinflammatory markers.
During Gram-negative sepsis, AMs produce large quantities of proinflammatory 
cytokines in response to LPS. One of the most important is TNF-α, that triggers 
an array of immune responses against invading pathogens [Lin and Yeh, 2005]. To 
examine whether extracellular, endocytosed CL vesicles or both, were capable of 
modulating the activation state of AMs stimulated with LPS, we first studied the 
effect of CL on LPS-induced TNF-α release. In Figure 4.1.5A, CL vesicles were co-
administered with LPS to MH-S cells. In Figure 4.1.5B, cells were incubated in the 
absence or presence of different amounts of CL for 18h to ensure its endocytosis and 
then, cells were stimulated or not with bacterial LPS. As it is shown in Figure 4.1.5, 
basal TNF-α levels were almost undetectable, and were not affected by CL vesicles. 
Co-addition of CL vesicles with LPS (Figure 4.1.5A) as well as the preincubation 
with CL before the addition of LPS (Figure 4.1.5B), diminished LPS-induced TNF-α 
secretion by AMs in cell culture supernatants, in a dose-dependent manner. 
Figure 4.1.5.  Low amounts of CL inhibited LPS-induced TNF-α release in a 
dose-dependent manner. LPS and CL were simultaneously added to MH-S cells 
(n=6) (A). MH-S cells were preincubated with CL for 18h and then, treated with 
LPS (1 µg/ml) for 6h (n=9) (B). TNF-α levels were measured by ELISA. Data are 
expressed as percentages of LPS-induced TNF-α release ± S.E in the absence 
of CL. Basal TNF-α secretion was 8 ± 1 pg/ml, and the average LPS-induced 
TNF-α secretion in the absence of CL was 483 ± 26 pg/ml (*** p<0.001 vs LPS). 
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The next step was to study whether CL vesicles were able to inhibit the production 
of another relevant proinflammatory marker, inducible nitric oxide synthase. The 
expression of this enzyme is activated in rodent macrophages in response to an 
appropriate stimulus such as LPS or proinflammatory cytokines. iNOS produce 
nitric oxide (NO) which contributes to pathogen killing [Jorens et al., 1995]. We 
observed, as expected, that LPS increased iNOS protein levels. Concerning to the 
effect of CL, similarly to what we have observed for TNF-α, co-administration of CL 
vesicles and LPS (Figure 4.1.6A) or endocytosis of CL vesicles before LPS addition 
(Figure 4.1.6B), diminished iNOS protein expression induced by LPS in a dose-
dependent manner. Nevertheless, we noticed that inhibitory effect of CL was less 
pronunciated when CL vesicles had been endocytosed. The co-administration of 
CL with LPS significantly reduced iNOS protein levels at lower concentrations of CL 
(≥ 0.07nmol/ml) than CL vesicles preincubated with cells before LPS addition, when 
a concentration of 7 nmol/ml was necessary to diminish iNOS production. 
Figure 4.1.6. Low amounts of CL vesicles inhibited LPS-induced iNOS 
expression in a dose-dependent manner. LPS and CL were co-administered to 
MH-S cells and maintained at 37ºC for 6h (n=6) (A). MH-S cells were preincubated 
with CL for 18h and subsequently, stimulated with LPS (1 µg/ml) and maintained 
at 37ºC for 6h (n=9) (B). iNOS protein levels were measured by western-blot and 
quantified by densitometry. Data are expressed as percentages of LPS-induced 
iNOS protein levels ± S.E in the absence of CL. (*p<0.050; *** p<0.001 vs LPS). 
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We then investigated if CL vesicles were able to modify the expression of another 
LPS-induced proinflammatory genes. To that end, we studied by qPCR the mRNA 
expression of nitric oxide synthase 2 (NOS2), cyclo-oxygenase 2 (COX2), C-X-C 
motif chemokine 10 (CXCL10), interleukin 1 beta (IL1-β) and TNF-α in MH-S AMs. 
CL and LPS were co-administered to the cells or incubated with CL for 18 hours 
before the stimulation with LPS. 
All these proteins encoded by these genes are important mediators of the 
inflammatory response. NOS2 is the gene that encodes iNOS protein, which is 
the responsible of NO production, as described above [Jorens et al., 1995]. COX-
2 is the enzyme responsible of the synthesis of the proinflammatory mediators 
called prostaglandins. COX2 is expressed at very low levels in basal conditions 
and strongly induced by proinflammatory stimuli such as LPS [Barrios-Rodiles et 
al., 1999]. CXCL10 is a chemokine that plays an important role in the recruitment 
of immune cells to the site of inflammation [Liu et al., 2011]. IL1-β and TNF-α are 
proinflammatory cytokines commonly produced by LPS-activated macrophages 
[Meng and Lowell, 1997].
As we can observe in Figures 4.1.7 to 4.1.11, LPS-elicited the expression of all 
these proinflammatory genes in MH-S AMs after 1 hour of treatment. Basal mRNA 
production was not affected by CL vesicles. Nevertheless, we demonstrated that 
CL vesicles in both cases (co-addition with LPS or incubation previous to LPS 
addition) diminished the mRNA expression of these proteins after LPS exposure. 
Interestingly, in this case, the inhibitory effect of CL vesicles was greater when they 
had been endocytosed by AMs before LPS treatment.
(legend continued on next page
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Figure 4.1.7. CL vesicles (7nmol/ml) reduced LPS-induced NOS2 mRNA 
expression in MH-S AMs. LPS and CL vesicles were co-administered to MH-S 
cells (A) or cells were incubated with CL (18h) before LPS exposure (B). NOS2 
mRNA levels were detected by q-PCR and normalized to GAPDH levels. Data 
are expressed as percentages of LPS-induced NOS2 expression ± S.E in the 
absence of CL. (*** p<0.001 vs LPS). 
Figure 4.1.8. CL vesicles (7nmol/ml) reduced LPS-induced COX2 mRNA 
expression in MH-S AMs. LPS and CL vesicles were co-administered to MH-S 
cells (A) or cells were incubated with CL (18h) before LPS exposure (B). COX2 
mRNA levels were detected by q-PCR and normalized to GAPDH levels. Data 
are expressed as percentages of LPS-induced COX2 expression ± S.E in the 
absence of CL. (*** p<0.001 vs LPS). 
(legend continued on next page
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Figure 4.1.9. CL vesicles (7nmol/ml) reduced LPS-induced IL1-β mRNA 
expression in MH-S AMs. LPS and CL vesicles were co-administered to MH-S 
cells (A) or cells were incubated with CL (18h) before LPS exposure (B). IL1-α 
mRNA levels were detected by q-PCR and normalized to GAPDH levels. Data 
are expressed as percentages of LPS-induced IL1-β expression ± S.E in the 
absence of CL. (*** p<0.001 vs LPS)
Figure 4.1.10. CL vesicles (7nmol/ml) reduced LPS-induced CXCL10 mRNA 
expression in in MH-S AMs. LPS and CL vesicles were co-administered to MH-S 
cells (A) or cells were incubated with CL (18h) before LPS exposure (B). CXCL10 
mRNA levels were detected by q-PCR and normalized to GAPDH levels. Data 
are expressed as percentages of LPS-induced CXCL10 expression ± S.E in the 
absence of CL. (*** p<0.001 vs LPS).
(legend continued on next page
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Figure 4.1.11. CL vesicles (7nmol/ml) reduced LPS-induced TNF-α mRNA ex-
pression in MH-S AMs. LPS and CL vesicles were co-administered to MH-S 
cells (A) or cells were incubated with CL (18h) before LPS exposure (B). TNF-α 
mRNA levels were detected by q-PCR and normalized to GAPDH levels. Data 
are expressed as percentages of LPS-induced TNF-α expression ± S.E in the 
absence of CL. (*** p<0.001 vs LPS).
 4.1.3.5. Cardiolipin inhibits LPS-elicited signaling pathways
LPS recognition by TLR4 elicits signal transduction pathways that leads to the 
transcription of genes encoding several proinflammatory mediators such as those 
that we have studied above (NOS2, COX2, TNF-α, IL1-β and CXCL10). Several 
studies have identified signal transduction pathways that are activated by LPS, 
including activation of NF-kB and activation of MAPKs, including Erk, c-Jun 
N-terminal kinase and p38 [Medzhitov and Janeway, 2000]. 
Therefore, we next investigated the influence of CL in signaling pathways triggered 
by LPS. In experiments shown in Figures 4.1.12A, 4.1.13A and 4.1.14A, CL and LPS 
were co-administered to the cells. In Figures 4.1.12B, 4.1.13B and 4.1.14B, AMs 
were incubated 18h in the absence or presence of increasing doses of CL vesicles 
and were then stimulated with LPS. Then, cell lysates were electrophoresed and 
immunoblotted. After 10 (Akt and MAPKs) or 30 (ikB-α) minutes of the addition of 
LPS, we could appreciate an increment of the 
(legend continued on next page
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Figure 4.1.12. Low amounts of CL inhibit LPS-elicited Akt phosphorylation in 
a dose-dependent manner. MH-S cells were stimulated with LPS for 10 minutes 
in the presence and absence of extracellular (n=18) (A) or endocytosed CL (n=12) 
(B). Phosphorylated Akt was detected by western blot, quantified by densitometry 
and normalized to total Akt. LPS-induced Akt phosphorylation in the absence of 
CL was considered as 100%. Data are expressed as mean percentages ± S.E. 
(***p<0.001 vs LPS).
Phosphorylated forms of the proteins Akt (Figure 4.1.12), Erk (Figure 4.1.13), p38 
(Figure 4.1.14) and ikB-α, which is a NF-kB inhibitor, and whose phosphorylation 
promotes its proteasome degradation, activating NF-kB (Figure 4.1.15). As it is 
shown in Figures 4.1.7 to 4.1.10, CL reduced LPS-elicited phosphorylation of all 
these proteins. Thus, these results agreed with the reduction that we have observed 
in the expression of the proinflammatory mediators studied above.
Figure 4.1.13. Low amounts of CL vesicles inhibited LPS-elicited Erk 
phosphorylation in a dose-dependent manner. MH-S cells were stimulated 
with LPS for 10 minutes in the absence or presence of extracellular (n=8) (A) or 
endocytosed (n=8) CL vesicles (B). Phosphorylated Erk was detected by western 
blot, quantified by densitometry and normalized to total Erk. LPS-induced 
phosphorylation in the absence of CL was set at 100%. Data are expressed as 
mean percentages ± S.E. (**p<0.001 vs LPS).
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Figure 4.1.14. Low amounts of CL vesicles inhibited LPS-elicited p38 
phosphorylation in a dose-dependent manner. MH-S cells were stimulated 
with LPS for 10 minutes in the absence or presence of extracellular (n=9) (A) 
or endocytosed (n=8) (B) CL. Phosphorylated p38 was detected by western 
blot and quantified by densitometry. LPS-induced p38 phosphorylation in the 
absence of CL was set at 100%. Data are expressed as mean percentages ± 
S.E. (***p<0.001 vs LPS).
Figure 4.1.15. Cardiolipin inhibited LPS-induced IκBα phosphorylation. MH-S 
cells were preincubated with different amounts of CL vesicles for 18h and then, 
stimulated or not with LPS (1µg/ml) for 30 minutes. After that time, cells were 
lysed and cellular lysates were analyzed by western-blot. One representative 
experiment is shown.
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4.1.3.6. Cardiolipin inhibits LPS-elicited signaling in primary rat 
alveolar macrophages.
To verify that the anti-inflammatory action of CL was not specific of the cell line 
MH-S, we conducted some experiments using AMs isolated from the lungs of male 
Sprague-Dawley rats. Vesicles of CL and LPS (1µg/ml) were co-administered to 
rat AMs. We obtained similar results to those obtained with MH-S macrophages. 
In Figure 4.1.16, we could observe that LPS-elicited Akt and Erk phosphorylation 
were strongly diminished in the presence of increasing amounts of CL vesicles (≥ 
0.7nmol/ml). Thus, this allow us to conclude that the anti-inflammatory action of CL 
is not restricted to the MH-S cell line.
Figure 4.1.16. Cardiolipin inhibits LPS-induced signaling in primary rat AMs. 
Rat alveolar macrophages were stimulated with LPS (1µg/ml) in the absence or 
presence of the indicated doses of CL vesicles. Akt (A) and Erk (B) phosphorylation 
levels were detected by western-blot. LPS-induced phosphorylation in the 
absence of CL was set at 100%. Data are expressed as mean percentages ± 
S.E. (n=3) (*** p<0.001 vs LPS).
4.1.3.7. Cardiolipin immunomodulatory effect is not restricted to the 
LPS response.
 In order to elucidate whether the immunomodulatory effect of CL was specific or 
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not of the LPS-elicited inflammatory response through TLR4 receptor, we decided 
to investigate the anti-inflammatory action of CL in zymosan-stimulated MH-S AMs. 
Zymosan is an insoluble preparation of Saccharomyces cerevisiae cell wall which 
is known to activate macrophages via TLR2.  TLR2 cooperates with TLR6 and 
CD14 to orchestrate the innate immune response against zymosan [Ozinsky et al., 
2000]. Zymosan is also recognized by Dectin-1, a phagocytic receptor expressed 
on macrophages and dendritic cells, which collaborates with TLR2 and TLR6 
enhancing the immune responses triggered by the recognition of zymosan by each 
receptor [Gantner et al., 2003]. 
With the aim of analyzing the effect of CL on zymosan-stimulated MH-S AMs, we 
incubated the cells in the absence or presence of increasing doses of CL vesicles 
for 18 hours. Then, cells were washed and fresh culture medium was added. AMs 
were stimulated or not with zymosan (50µg/ml) for 6h to determine production of 
proinflammatory markers (TNF-α secretion and iNOS protein levels).  
As we could appreciate in Figure 4.1.17, the preincubation of the cells with vesicles 
of CL before stimulation with zymosan, reduced zymosan-induced production of 
TNF-α and iNOS.
(legend continued on next page
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Figure 4.1.17. Endocytosis of cardiolipin vesicles inhibited TNF-α release and 
iNOS protein expression. MH-S cells were preincubated with CL at the indicated 
concentrations for 18h. After that time, cells were stimulated with zymosan (50µg/
ml) for 6h (A, B). iNOS protein levels were detected by western blot, quantified by 
densitometry and normalized to GAPDH levels (n=4) (A). TNF-α levels in culture 
supernatants were assessed by ELISA (n=4) (B). Data are expressed as mean 
percentages of iNOS protein levels (A) or zymosan-induced TNF-α release (B) 
± SE. One representative image of iNOS is shown (C). (***p<0.001 vs zymosan).
We then analyzed the effect of CL vesicles on zymosan-elicited Erk phosphorylation. 
CL and zymosan were co-administered to AMs (Figure 4.1.18A) and alternatively 
CL for 18 hours before zymosan addition (Figure 4.1.18B). As it is shown in Figure 
4.1.18, in MH-S cells, stimulation with zymosan (50μg/ml) for 10 minutes led to 
a significant increase in Erk phosphorylation levels, whereas the presence of CL 
vesicles reduced their phosphorylation.
Figure 4.1.18. CL vesicles reduced zymosan-induced Erk-phosphorylation 
in a dose-dependent manner in MH-S AMs. Zymosan and CL vesicles were 
simultaneously added to MH-S cells (A) or incubated with CL (18h) before 
zymosan addition (B). Erk phosphorylation was detected by western-blot after 
ten minutes of zymosan exposure.  Zymosan-induced phosphorylation in the 
absence of CL was set at 100%. Data are expressed as mean percentages ± 
S.E. (n=3). (*p< 0.050,*** p< 0.001 vs zymosan).  
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We next studied CL effect on zymosan-induced Akt phosphorylation. CL was added 
to AMs simultaneously to zymosan (50µg/ml). As we could appreciate in Figure 
4.1.19, CL inhibited zymosan-elicited Akt phosphorylation.
Figure 4.1.19. Low amounts of CL vesicles inhibited zymosan-elicited Akt 
phosphorylation. CL vesicles were added to MH-S cells simultaneously to zy-
mosan (50 µg/ml). Akt phosphorylation was detected by western-blot after ten 
minutes of zymosan exposure. Zymosan-induced phosphorylation in the absen-
ce of CL was set at 100%. Data are expressed as mean percentages ± SE, (n=3). 
(***p<0.001 vs zymosan).
Altogether, the results described in section 4.1.3.7, allow us to conclude that CL 
vesicles were able to inhibit zymosan-elicited innate immune response in AMs 
as it happened when LPS is used as stimulus. Therefore, the anti-inflammatory 
action of CL vesicles is not specific of a particular proinflammatory stimulus (LPS), 
suggesting that CL could act as a potential broad spectrum treatment to counteract 
inflammatory processes caused by bacterial and fungal pathogens.
4.1.4. DISCUSSION
In the present part of results, we examined the anti-inflammatory effect of low 
amounts of CL on the activation state of MH-S AMs stimulated with LPS or 
zymosan. We have studied the immunomodulatory action of CL by two different 
experimental approaches: CL was co-administered with the proinflammatory 
stimuli or preincubated with AMs for 18 hours before stimulation in order to allow 
CL endocytosis. 
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First, we conducted confocal microscopy experiments to determine whether 
AMs could endocyte the CL vesicles obtained after sonication which present a 
hydrodynamic diameter of 50 nm (Figure 4.1.2). In Figure 4.1.3, we could appreciate 
that the endocytosis process began almost 30 minutes after the addition of CL SUVs 
and increased with preincubation time, being maximal at 18 hours (Figure 4.1.3). This 
result is consistent with previous information about CL internalization by alveolar 
cells. In this line, Ray and co-workers cultured mouse type II lung epithelial cells in the 
presence of CL for 2 hours and they found that these cells are able to internalize CL 
through the P-type ATPase transmembrane lipid pump, ATP8B1. ATP8B1 binds and 
internalizes CL from extracellular fluid employing a basic residue-enriched motive 
[Ray et al., 2010]. Interestingly, it has been described in several cellular models 
[mouse peritoneal macrophages RAW 264.7, human monocytes THP1 treated with 
phorbol 12-myristate 13-acetate, primary human monocyte derived macrophages 
and mouse peritoneal macrophages] that internalization of liposomes composed of 
CL and dioleoylphosphatidylcholine (DOPC) occurs through phagocytosis after 1 
hour of incubation. Otherwise, they proved that RAW 264.7 cells engulfed two- to 
fourfold more CL-presenting mitochondria than control mitochondria. They found 
that the enhanced phagocytosis in the presence of CL was dependent on a member 
of the subclass B of scavenger receptors, CD36 [Balasubramanian et al., 2015]. 
Either, when CL was co-administered with or preincubated with cells 18 hours 
before LPS-driven stimulation, CL was proved to block LPS-induced signaling 
pathways (PI3K, MAPK, NF-κB) as it inhibited phosphorylation of Akt (Figure 
4.1.12), Erk (Figure 4.1.13), p38 (Figure 4.1.14) and IκB-α phosphorylation (Figure 
4.1.15). Moreover, CL was also effective in attenuating LPS-induced TNF-α release 
(Figure 4.1.5) and TNF-α mRNA expression (Figure 4.1.11) as well as iNOS protein 
levels (Figure 4.1.6) and its mRNA expression (Figure 4.1.7). Finally, CL was able 
to diminish the mRNA expression of several proinflammatory markers induced by 
LPS such as COX2 (Figure 4.1.8), IL1-β (Figure 4.1.9) and CXCL10 (Figure 4.1.10) 
in MH-S AMs. This strong immunomodulatory action of CL was not restricted to a 
single cell type, since the addition of CL vesicles simultaneously to LPS was also 
capable of attenuating ERK and Akt phosphorylation in rat primary AMs (Figure 
4.1.16).
We also have also demonstrated that CL vesicles (co-administered or preincubated 
for 18 hours), inhibited zymosan-induced Akt (Figure 4.1.19) and Erk phosphorylation 
(Figure 4.1.18A). Internalized CL vesicles diminished Erk phosphorylation (Figure 
4.1.18B), iNOS protein levels and TNF-α secretion elicited by zymosan (Figure 
4.1.17). These results provide evidence that CL is also capable of modulating 
innate immune responses triggered by proinflammatory stimuli distinct to LPS and 
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mediated by different types of TLR.
The mechanism underlying the anti-inflammatory action of CL is unknown and 
subject of ongoing research. We hypothesize that in the extracellular medium, CL 
could bind to and block one or more receptors involved in the cellular response to 
LPS or zymosan. Intracellular immunomodulatory effect is assured because AMs 
were preincubated with CL for 18h to ensure CL endocytosis. After preincubation, 
cells were washed. Then, fresh medium was added and cells were stimulated. Thus, 
intracellularly, we hypothesize that CL modifies the expression of cellular receptors 
involved in AMs response to the proinflammatory stimuli cited above, promotes the 
endocytosis of TLR4 and/or TLR2 receptors or its accessory molecules or maybe 
disrupts lipids rafts, that were found to be essential for LPS-signaling [Olsson and 
Sundler, 2006]. It is likely to be involved more than one of the proposed mechanisms.
In the literature there are few data about the role of CL on the immune response. 
Nevertheless, Balasubramanian and co-workers, according to our results, reported 
that CL attenuates inflammatory response in macrophages stimulated with LPS. 
However, they described that CL action occurs exclusively through an extracellular 
mechanism. 
The binding of LPS to MD-2 at the cell surface is necessary for TLR4 activation [Park 
et al., 2009]. Therefore, due to the similar molecular structure of CL and the lipid A 
of LPS, Balasubramanian and co-workers decided to carry out competitive binding 
experiments. They proved that CL, but not phosphatidylcholine or phosphatidylserine, 
was capable of inhibiting LPS binding to MD-2 [Balasubramanian et al., 2015]. 
Thus, according to the experiments cited above, these investigators ruled out that 
the anti-inflammatory effect of CL would occur at the intracellular level.
LPS-binding protein is required for LPS recognition by AMs. In this way, LBP 
monomerizes LPS and transfers LPS molecules to CD14 [Wright et al., 1990, Tobias 
et al., 1993]. 
Mueller and co-workers reported that LBP binds CL, thereby blocking LPS-binding 
site [Mueller et al., 2005]. These authors previously found that a synthetic compound 
structurally related to lipid A and CL, failed to induce an inflammatory response 
on immune cells but it possessed a strong antagonistic activity against the LPS 
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response. Furthermore, they found that the addition of CL to the cells 15 minutes 
before LPS exposure, potently inhibited TNF-α secretion by human mononuclear 
cells and macrophages in vitro. This time of preincubation is short and most of the 
CL vesicles were probably outside the cells, as we have determined by confocal 
microscopy for the cells we used (Figure 4.1.3). This finding is consistent with our 
results, in which we observed that the co-administration of CL with LPS reduced 
LPS-elicited inflammation. These investigators postulated that CL binds to LBP and 
compete with LPS for the same binding site inhibiting LPS-elicited inflammatory 
response. The proposed mechanism is reasonable because the LPS-binding region 
of LBP contains several positive charged amino acids [Lamping et al., 1996], which 
are a good target for anionic phospholipids such as CL. 
According to the action mechanism proposed by Mueller and colleagues for CL, 
Bochkov and co-workers showed that 1-palmytoil-2-arachnidonoyil-sn-glycerol-
3-phosphorylcholine oxidation products (oxPAPC), phospholipid that is not found 
in healthy humans and is produced only at the sites of inflammation, inhibits LPS 
signaling by blocking the binding of LPS to LBP and CD14 in endothelial cells. In 
addition, they demonstrated that oxPAPC is capable of protecting mice challenged 
with a lethal dose of LPS [Bochkov et al., 2002]. We further proved the effect of CL 
vesicles once endocytosed by AMs. Under such circumstances, it was not possible 
that CL competes with LPS for LBP on AMs surface because CL vesicles were 
inside the cells.
Taking into account the information obtained from our experiments, we cannot 
assume that CL inhibitory action is based exclusively on the CL-LBP interaction 
because we have also stimulated AMs with zymosan, a TLR2 ligand independent 
of LBP to trigger the inflammatory response and we have found that CL inhibited 
inflammation. 
Given that the integrity of lipid rafts is a requisite for the activation of the LPS-
response [Triantafilou et al., 2002, Finberg and Kurt-Jones, 2006; Ruysschaert et 
al., 2015], we hypothesize that CL could bind to CD14 as described for POPG 
[Kuronuma et al. 2009], impairing the recruitment directed by CD14 of TLR4 and/or 
TLR2 and/or its associated molecules into lipid rafts [Finberg and Kurt-Jones, 2006; 
Ruysschaert et al., 2015]. Thus, this could be another possible mechanism involved 
in the anti-inflammatory effect of CL. 
Previous studies demonstrated the immunomodulatory action of POPG, an anionic 
phospholipid present in the composition of pulmonary surfactant. POPG has been 
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demonstrated to bind to CD14 and MD-2 thus inhibiting LPS-elicited NO and TNF-α 
production from rat and human AMs and U937 cells [Kuronuma et al., 2009]. POPG 
impairs LPS response by disrupting LBP-CD14 function [Hashimoto et al., 2003]. In 
addition, POPG inhibits the production of inflammatory mediators triggered by TLR2 
activation by Micoplasma pneumoniae [Kandasamy et al., 2011]. As CL is another 
anionic phospholipid, it might be blocking TLR4 and TLR2 responses through similar 
mechanisms of those described for POPG. However, our work describes a strong 
immunomodulatory action of CL that occurs to a much lower relation phospholipid: 
LPS to that described for POPG [Hashimoto et al., 2003; Kuronuma et al., 2009].
Interestingly, Hashimoto and co-workers found that the acyl chain structure of 
phospholipids was determinant for a phospholipid to present or not anti-inflammatory 
properties on LPS-elicited response. Thus, they studied the anti-inflammatory effect 
of different molecular species of phosphatidylglycerol on NF-κB activation using 
murine bone marrow immortalized cells expressing TLR4 and MD-2. DPPG did not 
show an inhibitory effect, while POPG and DOPG did. Thus, they concluded that 
the presence of unsaturated bonds on the acyl chain structure is mandatory for a 
phospholipid to display anti-inflammatory action. The transfer of a phospholipid 
to LBP or CD14 from fluid phospholipid vesicles occurs more readily than the 
transference from those with a lower degree of fluidity. CL vesicles as well as POPG 
and DOPG vesicles are very fluid and we propose that this could be an additional 
reason to justify their strong anti-inflammatory properties [Hashimoto et al., 2003].
Balasubramanian and co-workers discarded an intracellular immunomodulatory 
action of CL. They studied CL internalization in wild type primary and knockout 
mouse peritoneal macrophages for CD36. They observed that in CD36-deficient 
cells, CL internalization was minimal referred to wild type cells. Interestingly, CL 
inhibited LPS-elicited production of cytokines in wild type and CD36-deficient 
cells. This suggests that CD36 and CD36-mediated internalization are not required 
for CL anti-inflammatory action [Balasubramanian et al., 2015]. Nevertheless, in 
our experiments to study the intracellular action of CL, AMs were incubated in 
the presence or absence of CL for 18 hours and then, the culture medium was 
removed. After washing and adding fresh culture medium, cells were stimulated 
with LPS or zymosan. We observed the inhibitory action of CL at very low amounts 
of phospholipid (≤ 0.07 nmol/ml). Therefore, we suggest that the small amount of CL 
internalized in CD36-deficient cells [Balasubramanian et al., 2015], could be enough 
for CL to exert its intracellular anti-inflammatory action. 
On the other hand, as we cited above, Ray and co-workers demonstrated that 
ATP8B1 is a CL import protein which regulates CL levels in the lung fluid. Therefore, 
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ATP8B1 could be another receptor mediating CL internalization. Nevertheless, they 
performed their experiments using AECs, in which ATP8B1 expression is higher 
compared to macrophages or fibroblasts [Ray et al., 2010].
Recently, it has been described that P4-ATPases, among which it is found ATP8B1, 
attenuate LPS-induced TLR4 signaling by mediating endocytic retrieval of TLR4 
[van der Mark et al., 2017]. P4-ATPases are integral membrane proteins which 
translocate phospholipids from the exoplasmic leaflet to the cytoplasmic leaflet to 
create phospholipid asymmetry [Sebastian et al., 2012] and to initiate the biogenesis 
of transport vesicles [Sebastian et al., 2012; van der Mark et al., 2013; Lopez-
Marques et al., 2014]. These proteins function as a heterodimer with a member of 
CDC50 family (β-subunit) and the P4-ATPase (α-subunit) [Katoh Y and Katoh M, 
2004; van der Mark et al., 2013]. 
When LPS bind to TLR4 receptor complex on the cell surface, induces an early 
response dependent on MyD88 that results in the production of proinflammatory 
cytokines (TNF-α, IL-1β and IL-6) [Lee et al., 2012]. Consequently, TLR4 is internalized 
and signals from the endosomal compartment in a MyD88-independent manner. 
This develops type I IFN response, which dampens the inflammatory reaction and 
is critical to counteract an ongoing infection [Kagan et al., 2008; Zanoni et al., 
2011]. These investigators found that depletion of CDC50A in THP1 cells leads 
to a hyperactivation of the early LPS response as demonstrated by high levels of 
TNF-α, IL-1β and IL-6 release, increased MAPK signaling and sustained NFκB- 
activation. On the other hand, they observed that in CDC50A-depleted cells TLR4 
internalization is impaired, leading to a defective IFN response. Similar results were 
obtained when they used depleted cells of P4-ATPases ATP8B1 and ATP11A [van 
der Mark et al. 2017]. 
CDC50A was detected in intracellular vesicles whereas ATP8B1 and ATP11A are 
mainly located in the plasma membrane of THP1 cells. The preferred substrate of 
these P4-ATPases is phosphatidylserine [Paulusma et al., 2008; Lopez-Marques 
et al., 2014; Takatsu et al., 2014]. Interestingly, Ray and co-workers proved that 
ATP8B1 bound CL through a basic residue enriched-motive [Ray et al., 2010]. 
Nevertheless, recently it has been described that ATP8B1 could bind PC, a non-
anionic PL [Takatsu et al., 2014].
Van der Mark and co-workers propose that ATP8B1 and ATP11A mediate local 
clustering at the plasma membrane of PS or another PLs which are prone to induce 
curvature which enhances the binding of proteins involved in the generation of 
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vesicles which are involved in TLR4 endocytosis [Van der Mark et al., 2017]. 
On the other hand, Cighetti and co-workers described the ability of a synthetic 
bacterial lipid A mimetic, structurally related to CL, to induce specifically CD14 
internalization without changes in cell surface expression of TLR4-MD2 complex. 
Therefore, CD14 internalization would lead to the disruption of the cellular response 
to LPS [Cighetti et al., 2014].
We hypothesize that CL could promote TLR4 and/or CD14 internalization through 
the P4-ATPase complex, thus promoting signaling through endosomal TLR4 which 
counteract the inflammatory response of MyD88-dependent signaling.
Scavenger receptors are classified as subclass A (SR-AI and SR-AII) or subclass B 
which includes CD36 and SR-BI/SR-BII [Thorne et al., 2007]. SR-A, expressed on 
the surface of AMs, is well known in the context of atherosclerosis by its capability to 
bind and internalize modified low density lipoproteins [Winther et al., 2000; Michael 
et al., 2015]. In addition, it has been described that SR-A recognizes several PAMPs 
among which are found LPS and zymosan [Mukhopadhyay and Gordon, 2004, 
Hollifield et al., 2007]. Recent studies have postulated that LPS stimulation promotes 
an association between TLR4 and SR-A which is required for optimal LPS-induced 
activation of the TLR4-mediated NF-κB pathway [Yu et al., 2012]. Given that SR-A 
bind lipids, we thought that CL could form an inactive complex with SR-A impairing 
the development of the immune response following LPS or zymosan exposure. 
Otherwise, Balasubramanian and co-workers incubated serial dilutions of PC or 
CL with the extracellular domain of CD36 and CD204 (SR-A). They found that 
neither CD36 nor CD204 recognize PC, whereas CD36 but not CD204, recognizes 
CL. In addition, using blocking antibodies, they discarded SRBI/II and proposed 
CD36 as the putative receptor that mediates the phagocytosis of CL liposomes 
[Balasubramanian et al., 2015].
The peroxisome proliferator-activated receptor γ (PPARγ) is known to be highly 
expressed in AMs [Ricote et al., 1998]. PPARγ ligands are unsaturated fatty acids, 
15-deoxy-delta-12,14-prostaglandin J2, 15-Hydroxyeicosatetraenoic acid, acid 
components of oxidized low-density lipoprotein, 9- and 13-hydroxyoctadecadienoic 
[Varga et al., 2011]. PPARs activate gene expression by binding to specific DNA 
response elements in target genes as heterodimers with the retinoid X receptors 
[IJpenberg et al., 1997]. PPARs activated by appropriate ligands, release the 
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corepressor and binds to coactivator molecules [Glass and Ogawa, 2006]. 
It has been described that mice with deficiency in lysosomal acid lipase, and as 
a consequence, low levels of fatty acid, exhibited an inflammatory phenotype 
which was counteracted by PPAR-γ agonists [Lian et al., 2005]. In macrophages/
monocytes, PPARγ ligands suppressed the upregulation of iNOS, TNF-α, IL-1β, 
IL-12, and matrix metallopeptidase 9 [Ricote et al., 1997; Jiang et al., 1998; Welch 
et al., 2003]. Several reports have suggested that PPARs inhibit the expression of 
proinflammatory genes by interference with signal-dependent activation of NF-κB, 
AP-1, C/EBP, STAT and NF-AT. PPARs can inhibit inflammatory gene expression 
through different mechanisms such as competition for a limiting pool of coactivators, 
direct interaction with the subunits of NF-κB (p65 and p50) and c-Jun or modulation 
of p38 MAPK activity [reviewed in Ricote et al., 2007]. We hypothesize that CL could 
act as a ligand for PPARγ inhibiting LPS or zymosan-elicited inflammatory response.
Yui and Yamazaki studied the effect of CL on peritoneal macrophages growth and 
activation state [Yui and Yamazaki, 1991]. They first examined the effect of increasing 
doses of CL on cell viability after 3 days of preincubation with CL. They found that 
≤ 40µg/ml (27nmol/ml) had no toxic effects on macrophages and that 40µg/ml of 
CL was the optimal concentration to induce growth. Nevertheless, they observed 
that 80µg/ml (54 nmol/ml) impaired cell viability. We also conducted experiments 
to determine AMs viability one day after preincubation with different doses of CL 
(7, 27 and 70 nmol/ml) (Figure 4.1.4). In our case, we did not detect loss of cell 
viability, even at the highest concentration tested, probably due to a shorter time 
of incubation or the cellular type. In discrepancy with our results, Yui and Yamazaki 
observed that pretreatment of macrophages with low amounts of CL (7 to 14 nmol/
ml) for one to three days, enhanced macrophage TNF-α release induced by LPS in 
vitro. Nevertheless, they found that higher amounts of CL (27 nmol/ml) completely 
suppressed TNF-α release. These investigators failed to elucidate the mechanism 
underlying CL action. In agree with us, Yui and Yamazaki proposed that the inhibitory 
action of CL is not specific of a single PAMP since they obtained similar results in 
macrophages treated with a whole pathogen, Enterococus faecalis.
In summary, data shown in this part of results demonstrates that small amounts of CL 
have an extracellular and also intracellular anti-inflammatory effect. The intracellular 
effect was demonstrated by incubating CL with cells for 18 hours followed by 
washing and adding fresh culture medium, where cells were stimulated with LPS 
or zymosan. Furthermore, we have found that all signaling pathways activated after 
exposure to these PAMPs were inhibited in the presence of CL. This fact suggests 
that the molecular target for the inhibition exerted by CL is TLR itself and/or one 
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or more of its associated proteins, but not molecules involved in downstream 
pathways. Moreover, we have found that the anti-inflammatory effect of CL occurs 
in murine MH-S AMs and also in primary rat AMs. 
It has been proposed that recognition of oxidized phospholipids by the host could 
be an endogenous feedback mechanism that helps to limit the damage caused by 
inflammation in the context of severe Gram-negative bacterial infection [Bochkov et 
al., 2002]. Since CL is released, probably from host membranes, to the alveolar fluid 
during infection [Ray et al., 2010], we hypothesize that this might be a protective 
mechanism developed by the host to control bacterial- and fungal-induced 
inflammatory responses. Furthermore, the anti-inflammatory action of CL should 
be considered in order to design new antibacterial and antifungal therapies based 
on CL.
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4.2. ANTIVIRAL AND IMMUNOMODULATORY EFFECTS OF 
CARDIOLIPIN VESICLES AGAINST RESPIRATORY SYNCYTIAL 
VIRUS
4.2.1 INTRODUCTION
Respiratory syncytial virus (RSV) is the main cause of lower respiratory tract 
infections such as pneumonia and bronchiolitis in the elderly, immunocompromised 
individuals and children under the age of two [Collins and Mellero, 2011].
In the bronchoalveolar lavage of mice and humans with pneumonia high levels of 
cardiolipin were found [Ray et al., 2010]. CL could be released to the alveolar fluid 
by dying host cells. There, lung surfactant components, viral particles and vesicles 
of CL could interact among them. 
In this thesis, we have previously demonstrated the strong anti-inflammatory action 
of low doses of CL vesicles (≥ 0.7nmol/ml) on alveolar macrophages in response to 
LPS or zymosan. Moreover, it was recently published that anionic phospholipids, 
such as POPG and PI, present in lung surfactant, inhibit RSV replication and the 
subsequent cytokine production [Numata et al., 2010; Numata et al., 2013a; Numata 
et al., 2013b, Numata M et al., 2015]. Taking into account this prior information, we 
hypothesized that CL could act as a defense factor at low concentrations, protecting 
the host from RSV infection. 
Therefore, the purpose of this study was to examine the effect of low doses of 
cardiolipins on viral replication and immune response of human AECs infected with 
RSV. In addition, we also studied the mechanism underlying CL action on RSV 
infection and the potential effects of the presence of native pulmonary surfactant 
on CL antiviral action.
4.2.2 EXPERIMENTAL DESIGN
To study the effect of CL on viral replication and the inflammatory response, AECs 
were mock-infected (with sucrose) or infected with human RSV (Long strain) at a 
multiplicity of infection (moi) of 3 plaque forming units (pfu) per cell in the absence 
or presence of CL vesicles. CL vesicles were added simultaneously to RSV infection 
(t=0) or were preincubated with cells for 18h before RSV infection (t=18h) to allow 
endocytosis of CL vesicles and evaluate the intracellular effect of CL.
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RSV replication was evaluated determining 1) virus titers by plaque assay of infected 
supernatants in layered HEp-2 cells and 2) mRNA levels of the N nucleoprotein of 
RSV by qPCR. Expression of RSV-induced inflammatory markers was also evaluated 
by qPCR
Figure 4.2.1. Experimental design.
4.2.3. RESULTS
 4.2.3.1. Cardiolipin does not impair cell viability at the tested 
concentrations.
Human AECs (A549 cell line) were seeded as described in the materials and methods 
section. Next day, cells were preincubated in the presence or absence of increasing 
amounts of CL (0.7, 7, 14 and 27 nmol/ml) for 24 hours. To determine cell viability, 
we performed a colorimetric assay using the compound WST-1 as described in the 
materials and methods section. This reagent is a tetrazolium salt which is reduced 
to formazan in the presence of mitochondrial dehydrogenases. The absorbance of 
reduced tetrazolium could be read at 450 nm. The higher activity of mitochondrial 
enzymes is correlated with increased cell viability. We assessed that cell viability 
was not impaired at the concentrations of CL used (7 to 27 nmol/ml) (Figure 4.2.2).
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Figure 4.2.2. Cardiolipin does not affect AECs viability at the tested concen-
trations. AECs (5.105 per well) were seeded and maintained at 37ºC O/N. Then, 
cells were treated with different amounts of CL (0, 7, 14, and 27 nmol/ml) for 24 
hours. Cell viability was determined by WST-1 assay. Cell viability in the absence 
of CL was set at 100%. Data are expressed as the mean ± S.E (n=2).
 4.2.3.2. Cardiolipin inhibits viral replication.
To study CL action on RSV replication, cells were infected with RSV (moi 3 pfu/
cell) in the absence or presence of increasing amounts of CL (0.7, 3.5, 7 nmol/ml) 
for 90 minutes at 37ºC. Subsequently, fresh medium was added and cells were 
maintained at 37ºC for 24 hours, in the absence or presence of CL. Viral titer in 
culture supernatants was determined by plaque assay in layered HEp-2 cells. As it 
is depicted in Figure 4.2.3 and Table 4.2.1, CL vesicles were able to reduce viral titer 
in culture supernatants of RSV-infected AECs.
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Figure 4.2.3 and table 4.2.1. Cardiolipin reduces viral titer in supernatants of 
AECs. HEp2 cells (1.2x106) were seeded in 6-well plates and infected for 90 
minutes at 37ºC with a series of dilutions (10-1 to 10-3) of supernatants from 
RSV-infected AECs that have been treated with or without CL (0.7, 3.5 or 7 nmol/
ml). After infection, 3 ml of 0.7% agarose in 2% FBS DMEN were added to each 
well. Plates were maintained at 4ºC for 30 minutes to allow agarose solidification. 
Then, cells were incubated at 37ºC for 5 days to perform plaque quantification. 
The results are presented as means (± SEM) from three different RSV-infected 
AEC cultures. (* p<0.050 vs RSV; **p<0.010 vs RSV).
We further analyzed the CL effect on viral replication by quantifying mRNA levels 
of the N nucleoprotein of RSV by qPCR. N nucleoprotein is essential for RSV 
encapsidation by coating the entire viral RNA genome to form the ribonucleoprotein 
complex [Collins et al., 2013]. N nucleoprotein expression was quantified by qPCR 
in AECs infected with RSV (moi 3 pfu/cell) in the absence or presence of CL (7 
nmol/ml) for 90 minutes and maintained at 37ºC for 0, 4, and 24 h post-infection. 
Figure 4.2.4 shows that CL was able to reduce N nucleoprotein expression after 
90 minutes of infection. This inhibitory effect was maintained in the post-infection 
period (4h or 24h). These results suggest that CL action takes place in the early 
stages of infection. We hypothesized that CL vesicles might inhibit RSV uptake by 
AECs. CL vesicles might block RSV attachment to the epithelium surface and/or 
inhibit the endocytosis of RSV.
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Figure 4.2.4. Cardiolipin vesicles inhibit RSV N nucleoprotein expression in 
AECs infected with RSV. CL vesicles (7 nmol/ml) were added to AECs and si-
multaneously infected with RSV (moi of 3 pfu/cell) in 2% FBS DMEN for 90 min 
at 37ºC. After that, cells were maintained in the absence or presence of CL vesi-
cles (7 nmol/ml) for 0, 4 or 24 hours at 37ºC. Then, RNA was then extracted from 
cellular pellets for qPCR analysis. The results are presented as means (± SEM) 
from three different RSV-infected AEC cultures. (*** p<0.001).
 4.2.3.3. Cardiolipin inhibits RSV attachment to the epithelium 
surface. Cardiolipin acts at lower dose than POPG. 
RSV uptake by epithelial cells is a two-step process that firstly involves the binding 
of viral G and F proteins by electrostatic interaction with glycosaminoglycans 
(GAGs) of the cell surface. The second step, directed by F protein, implies the fusion 
of viral envelope with the cellular plasma membrane [Krusat and Streckert, 1997; 
Hallak et al., 2000]. There is also evidence of entry by clathrin-mediated endocytosis 
although endosomal acidification is not required [Collins et al., 2013]. Therefore, 
endocytosis involves the same fushion mechanism with the endosomal membrane 
than with the plasma membrane. In the cytoplasm, genome transcription occurs 
and it is encapsidated with N nucleoprotein and associated with the polymerase 
complex to form nucleocapsides. Finally, nucleocapsides are transported to the 
plasma membrane and virions will be released by budding (see Figure 1.8 of the 
introduction) [Fearns and Dewal, 2016]. 
In order to understand how the vesicles of CL inhibit viral replication, we investigated 
the ability of CL to inhibit RSV attachment to the cell surface. AECs in suspension 
were infected with RSV in the presence and absence of CL, and cells were analyzed 
for attached virus by FACScan, using a mouse antibody against G glycoprotein and 
subsequently with fluorescent phycoerythrin-conjugated antibody directed against 
N
 e
xp
re
ss
io
n 
as
 %
 o
f R
SV
-in
du
ce
d
 ***
0
20
40
60
80
100
120
Infection and post-infection at 37 ºC
4h
 
0h
 
24h
 
CL - + - + + - 
 ***  ***
IV. RESULTS AND DISCUSSION
141
mouse IgG. Binding experiments were performed at 4ºC. The results presented in 
Figures 4.2.5A and 4.2.5B demonstrate significant binding of the RSV to the cell 
surface in the absence of CL. The addition of CL markedly inhibited the adhesion of 
viral particles to the cell surface, being almost completely suppressed at 25 nmol/ml 
of CL (fluorescence intensity similar to mock samples). We conclude that CL exerts 
its antiviral action by inhibiting viral particles attachment to the cell surface. As a 
result, RSV fusion to the cell membrane and replication will be impaired.
Figure 4.2.5. Cardiolipin inhibits RSV binding to AECs. (A) CL effects upon cell 
surface binding of RSV. Suspensions of AECs were incubated with RSV (moi of 
3 pfu/cell) for 1 hour in the presence and absence of CL. Then, the cells were 
treated with a mouse antibody against RSV G glycoprotein and subsequently 
with a phycoerythrin-conjugated antibody directed against mouse IgG. All incu-
bations were performed at 4ºC. Finally, the cells were fixed with PBS-PFA 1% 
and analyzed by flow citometry. A representative FACScan is shown in which 
cells were not infected with virus (mock), infected with virus alone (RSV) or in-
fected with virus and CL (RSV + CL). (B) Summary of FACScan data from three 
independent experiments. (***p<0.001 vs RSV infection in the absence of CL).
 4.2.3.4. Cardiolipin acts at lower dose than POPG. 
We next determined viral particles adhesion to the cell surface in comparison 
with POPG, an anionic surfactant phospholipid which is capable of disrupting 
viral attachment to epithelial cells surface [Numata et al., 2013a, Numata et al., 
2013b].  AECs were infected at 4ºC for 90 minutes and then RNA was extracted 
from cellular pellets. RNA of N nucleoprotein from viral particles attached to AECs 
surface was analyzed by qPCR. As we could see in Figure 4.2.6, CL vesicles from 
a concentration of 7 nmol/ml markedly suppressed N nucleoprotein RNA detection 
in AECs, whereas in the case of POPG occurs at 25 nmol/ml. We can conclude that 
CL inhibits RSV attachment to the epithelium surface at lower dosis than POPG.
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Figure 4.2.6. Cardiolipin inhibits RSV adhesion to AECs to a higher extent than 
POPG. Different amounts of CL or POPG vesicles were added to AECs and si-
multaneously infected with RSV (moi of 3 pfu/cell) for 90 min at 4ºC. After that, 
cells were washed and cellular pellets were collected (0h post-infection). The 
results are presented as means (± SEM) from three different RSV-infected AEC 
cultures. (**p<0.010; *** p<0.001 vs RSV).
 4.2.3.5. Cardiolipin vesicles inhibit the expression of RSV-
induced infection markers in alveolar epithelial cells.
We have demonstrated the strong inhibitory action of low amounts of CL on RSV 
replication in AECs. We would expect that if less viral particles are able to bind and 
enter cells in the presence of CL, the inflammatory response induced by RSV will 
be reduced. Moreover, we have previously described in part 1 of results that CL is 
able to inhibit LPS and zymosan-elicited signaling and the production by AMs of 
several proinflammatory markers (TNF-α, IL1-β, CXCL10, iNOS (NOS2) and COX2). 
Thus the role of low amounts of CL vesicles on the inflammatory response of AECs 
after RSV infection was investigated. AECs were mock-infected (with sucrose) or 
infected with RSV (moi 3 pfu/cell) in the absence or presence of CL vesicles (7 nmol/
ml) for 90 minutes at 37 ºC. After that, cells were maintained 24 hours at 37 ºC in the 
absence or presence of CL vesicles (7 nmol/ml).
Then, we quantified by q-PCR the mRNA expression of certain molecules that are 
upregulated during RSV infection. These are the main cellular receptors for RSV 
(RIG-I and TLR3), IFN-induced gene 15 (ISG15) and TNF-α.
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RIG-I and TLR3 are the main RSV-receptors and sense double-stranded RNA 
(dsRNA). RIG-I is a cytosolic RNA helicase, whereas TLR3 is transmembrane 
protein found in the cell surface or in endosomal compartments [Yu and Levine, 
2011]. ISG15 is the earliest IFN-induced gene after RSV infection and encodes an 
ubiquitin-like protein that promotes an antiviral state [Kunzi et al., 2003]. TNF-α is a 
proinflammatory cytokine that contributes to RSV clearance but an excessive TNF-α 
secretion exacerbates illness by causing lung damage [Rutigliano and Graham, 
2004]. The expression of all of these molecules have been demonstrated to be up-
regulated during RSV infection in human A549 or murine MLE-15 epithelial cells 
[Liu et al., 2007; Martínez et al., 2007; Moore et al., 2008]. ISG15 and TNF-α play a 
key role in the development of an inflammatory response against RSV. Despite of a 
controlled inflammatory response is necessary for virus clearance, an exacerbated 
inflammation results in tissue injury.
Figure 4.2.7 shows that RIG-I, TLR3, ISG15 and TNF-α expression were up-
regulated in RSV-infected AECs. The presence of CL vesicles drastically decreased 
RSV-elicited expression of all these markers. 
(legend continued on next page
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Figure 4.2.7. CL vesicles inhibited RSV-induced TNF-α (A), TLR3 (B), ISG15 
(C) and RIG-I (D) expressions. Vesicles of CL (7 nmol/ml) were added to A549 
AECs and simultaneously infected with RSV (moi of 3 pfu/cell) for 90 min at 
37ºC. After a post-infection period of 24 hours in the presence or absence of CL, 
RNA was extracted from cellular pellets for qPCR. The results are presented as 
means (± SEM) from three different RSV-infected AEC cultures and expressed 
as percentages of RSV-induced expression in the absence of CL. (***p<0.001 vs 
RSV). 
 4.2.3.6. Cardiolipin antiviral action is preserved regardless of 
the presence of pulmonary surfactant components.
Given that the alveolar epithelium is covered by surfactant membranes and that the 
main surfactant protein, SP-A, binds CL vesicles (section 4 of results), we decided 
to study whether the inhibitory effect of CL could be blocked by the presence of 
surfactant components. To this end, we studied CL antiviral action in the presence or 
absence of either rat native pulmonary surfactant (NPS), purified surfactant protein 
SP-A, or MLVs prepared from the lipid extract of NPS (LES), a fraction containing 
phospholipids, cholesterol and the hydrophobic surfactant proteins SP-B and SP-
C. Note that NPS contains both LES components and SP-A, which is attached to 
surfactant membranes. Cells were infected with RSV (moi 3 pfu/cell) in the absence 
or presence of CL (7 nmol/ml), NPS (250µg/ml), LES (250µg/ml), SP-A (100µg/ml) 
and combinations thereof for 90 minutes at 37ºC. Then, 2ml of 2% FBS DMEN and a 
new dose of the components mentioned above were added. Cells were maintained 
for 24 hours at 37ºC. Finally, viral replication was evaluated determining viral titers 
in culture supernatants of infected AECs by plaque assay in layered HEp-2 cells. 
Figure 4.2.8 shows that either NPS, LES nor SP-A exhibited any effect on RSV 
replication. Importantly, NPS, LES and SP-A did not block the antiviral action of CL 
vesicles. 
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Figure 4.2.8. Rat native pulmonary surfactant (NPS) nor the hydrophobic 
fraction of lung surfactant (LES) or SP-A inhibited viral titer in supernatants of 
RSV-infected A549 AECs. The presence of NPS nor SP-A or LES did not impair 
or ameliorate CL antiviral action. HEp2 cells (1.2x106 per well) were seeded in 
6-well plates and infected for 90 minutes at 37ºC with a series of dilutions (10-1 
to 10-3) of RSV-infected supernatants from A549 AECs that have been treated 
or not with CL (7 nmol/ml), NPS (250 µg/ml), LES (250 µg/ml), SP-A (100 µg/ml) 
or combinations thereof. After infection, 3 ml of 0.7% agarose in 2% FBS DMEN 
were added to each well. Plates were maintained at 4ºC for 30 minutes to allow 
agarose solidification. Then cells were incubated at 37ºC for 5 days to perform 
plaque quantification. The results are presented as means (± SEM) from three 
different RSV-infected AEC cultures. (***p<0.001 vs RSV). 
 4.2.3.7. Internalized vesicles did not affect viral replication but 
inhibit TNF-α production in RSV-infected A549 AECs.
We next investigated whether internalized CL vesicles were capable of inhibiting 
viral replication in AECs in order to determine whether intracellular CL is capable 
of modulating host inflammatory responses elicited by RSV infection. The cells 
were incubated in the presence or absence of CL (3.5, 7.0 and 28 nmol/ml) for 
18h at 37ºC and then infected with RSV for 24h. We evaluated viral replication in 
culture supernatants by plaque assay in layered HEp-2 cells (Figure 4.2.9A) and 
by quantifying mRNA levels of RSV N nucleoprotein expression (Figure 4.2.9B). 
As it is shown in Figure 4.2.9, internalized CL vesicles did not reduce viral titers in 
culture supernatants of infected-AECs (A) nor inhibited mRNA production of the N 
nucleoprotein (B). Altogether, these results indicate that CL, once internalized into 
the cells, was not able to inhibit viral replication.
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Figure 4.2.9. Internalized CL vesicles failed to inhibit RSV replication in A549 
AECs. A549 cells were preincubated with CL SUVs (3.5, 7 or 28 nmol/ml) for 18 
hours, and then infected with RSV (moi of 3 pfu/cell) for 24 hours. (A) Internalized 
CL vesicles did not decrease RSV titers in culture supernatants of infected cells 
(n=3). (B) Internalized CL vesicles did not reduce the expression of the mRNA of 
RSV N nucleoprotein. The results are presented as means (± SEM) from three 
different RSV-infected AEC cultures and expressed as percentages of RSV-indu-
ced expression in the absence of CL.
We have previously demonstrated in this thesis that endocytosed CL vesicles inhibit 
the production of several proinflammatory markers by AMs stimulated with either LPS 
or zymosan (part 1 of results). Thus, we investigated whether internalized vesicles 
of CL (7 and 28 nmol/ml) were also capable of modulating RSV-induced expression 
of TNF-α in AECs. TNF-α is the principal mediator of RSV-induced inflammation 
[Rutigliano and Graham, 2004]. AECs were preincubated with 7 or 28 nmol/ml of CL 
vesicles for 18 hours. Subsequently, the culture medium was removed, cells were 
washed and mock-infected or infected with RSV for 24 hours. After that, the mRNA 
expression of TNF-α was quantified by qPCR. Figure 4.2.9 shows that the effect 
of endocytosed CL vesicles was dependent on the dose because CL exhibited 
an anti-inflammatory effect at 28 but not at 7nmol/ml. Note that, CL when was 
co-added with RSV was able to decrease TNF-α expression at a lower amount of 
phospholipid (7 nmol/ml) due to the ability of extracellular CL vesicles to block virus 
binding to the cell surface and therefore, virus entry and cellular responses to RSV 
infection (Figure 4.2.7A).
Therefore, the results presented in this section indicate that intracellular CL is not 
able to inhibit RSV replication but is capable of modulating the proinflammatory 
response of AECs infected with RSV.
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Figure 4.2.10. Internalized vesicles of CL inhibited RSV-induced TNF-α mRNA 
but dependent on the dose. AECs were preincubated or not with CL vesicles (7 
or 28 nmol/ml) for 18h and then, they were mock-infected (with sucrose) or in-
fected with RSV (moi of 3 pfu/cell) for 90 min at 37ºC. After 24 hours, RNA was 
extracted from cellular pellets for qPCR. The results are presented as means (± 
SEM) from three different RSV-infected AEC cultures and expressed as percen-
tages of RSV-induced TNF-α expression in the absence of CL. (***p<0.001 vs 
RSV).
4.2.4. DISCUSSION
The role of CL on the immune response has been poorly studied. Our recent data 
shown in part 1 of results, provide strong evidence that low doses of this phospholipid 
(≥0.7nmol/ml) play a key role in modulating the innate immune response of alveolar 
macrophages stimulated with bacterial LPS or fungal zymosan. The purpose of the 
present study was to investigate the action of CL on RSV replication in AECs and 
the inflammatory response as a consequence of the infection. We analyzed the 
action of extracellular CL vesicles by addition of CL simultaneously with RSV, and 
the action of intracellular CL vesicles, which were endocytosed by AECs previously 
to RSV infection.
Our results highlight the strong antiviral action of extracellular vesicles of CL at low 
doses of phospholipid (7nmol/ml). When was present in the extracellular medium, 
CL inhibited RSV replication in a dose-dependent manner (Figures 4.2.3 and 4.2.4) 
and the RSV-elicited immune innate response (Figure 4.2.7). The fact that mRNA 
levels of N nucleoprotein were reduced immediately after 90 minutes of infection 
(0h post-infection) in the presence of CL (7nmol/ml) and that this inhibitory effect 
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was maintained over time (4 and 24h post-infection) (Figure 4.2.4), suggests that CL 
action occurs in an early stage of infection.
 It is known that RSV uptake by epithelial cells consists of a two-step process that 
involves firstly, the attachment of viral G and F protein to the cell and secondly, it 
is required the fusion of RSV membrane with the plasma membrane directed by F 
protein of RSV. After fusion, RSV replicates in the cytosol of the host cells surface 
[Krusat and Streckert, 1997; Hallak et al., 2000]. First, we investigated whether CL 
action takes place by blocking the binding of viral particles adhesion to the cell 
surface. 
We first conducted flow cytometry assays to examine the direct binding of RSV to 
AECs and its inhibition by CL (7 and 25 nmol/ml) at 4°C (Figures 4.2.5A and 4.2.5B). 
In these experiments, we observed a dose-dependent CL inhibition of RSV binding 
to the surface of epithelial cells. At 7 and 25 nmol/ml, CL inhibited the binding of 
RSV to cells by greater than 50% and 80 %, respectively. 
We further compared the effect of CL with POPG on RSV adhesion to the AECs 
surface. To that end, we determined the presence of N nucleoprotein in AECs 
incubated with RSV at 4ºC for 90 minutes in the presence or absence of different 
amounts of CL or POPG vesicles (0, 0.7,7,10, and 25 nmol/ml) (Figure 4.2.6). At this 
temperature, is only detected RSV adhesion because the fusion process required a 
physiological temperature (37ºC). We found that CL was more effective than POPG 
in blocking RSV adhesion to the cell surface. CL inhibitory effect occured in a dose-
dependent fashion from a CL concentration of 7 nmol/ml, whereas the inhibitory 
effect of POPG start to be detected at 25 nmol/ml. At this concentration, CL showed 
80% of inhibition. Numata and co-workers used saturating concentrations of PI 
and POPG (260 and 130 nmol/ml), respectively. At saturating concentrations, PI 
and POPG produce almost the same degree of inhibition [Numata et al., 2013a]. 
Experiments reported by Numata and co-workers were performed at a moi of 1, 
however, our experiments were performed at a moi of 3. Under these experimental 
conditions we found a CL saturating effect at around 10 nmol/ml indicating that CL 
is more efficient than other acidic phospholipids such as POPG and PI. 
In order to elucidate whether CL could act once endocytosed by the cells as an 
antiviral agent, we performed experiments to determine the effect of intracellular 
CL on viral replication. To that end, CL vesicles were preincubated with the cells 
for 18 hours before infection. After that, culture medium was removed and cells 
were washed. Then, fresh culture medium was added and cells were infected with 
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RSV. Results obtained by determining viral titer of infected culture supernatants and 
mRNA expression of N nucleoprotein of RSV, indicated that once endocytosed, CL 
was not able to inhibit RSV replication inside AECs (Figure 4.2.9).
Thereby, altogether, results depicted in Figures 4.2.5, 4.2.6 and 4.2.9 allow us to 
conclude that CL acts exclusively in the extracellular medium by blocking viral 
particles attachment to the cell surface. CL vesicles could be able to directly bind 
to RSV particles or well to bind and block receptors involved in RSV binding to the 
cell surface. Our results are in agree with those reported in the literature for other 
anionic phospholipids such as POPG and PI [Numata et al., 2010; Numata et al., 
2013a; Numata et al., 2013b; Numata el al., 2015]. 
Glycosaminoglycans are negatively charged linear polymers of repeating 
disaccharide units produced by mammalian cells and some bacteria [Yamada and 
Kawasaki, 2005], most of them linked to transmembrane proteins. In the cellular 
surface, GAGs act as viral receptors, and GAGs deficiency impairs RSV uptake 
by epithelial cells. RSV F and G proteins seem to bind to the cell surface through 
electrostatic interactions with negatively charged GAGs and subsequently, fusion 
occurs and the enter of ribonucleoprotein complex [Krusat and Streckert, 1997; 
Hallak et al., 2007]. CL as well as POPG and PI are negatively charged phospholipids 
that could compete with GAGs for RSV binding, trapping RSV and blocking its entry 
into the cells.
In the alveolar fluid, CL vesicles might be in contact with lung surfactant components, 
thereby, we analyzed the effect of native pulmonary surfactant (NPS) and its isolated 
components on CL antiviral action. 
We found that neither NPS (250 µg/ml), nor LES (250 µg/ml) nor SP-A (100 µg/ml) 
showed any antiviral effect at the concentrations tested (Figure 4.2.8). NPS and 
LES contain acidic phospholipids (PI and PG) but their distribution in surfactant 
membranes might impede effective binding of RSV particles. PI and POPG present 
in the composition of NPS are probably masked by other surfactant components 
and maybe, due to this reason, was not able to exert its antiviral properties [Numata 
et al., 2010; Numata et al., 2013a; Numata et al., 2013b]. 
Importantly, we found that, the antiviral action of CL was not affected by the presence 
of NPS, LES or SP-A (Figure 4.2.8). We found that SP-A is able to bind to CL with 
high affinity (section 4 of the results). However, our data indicate that SP-A binding 
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to CL did not interfere with CL antiviral action. Of note, it has been reported that 
co-administration of RSV and SP-A reduced viral titers in the lung of SP-A deficient 
mice [Levine et al., 1999]. However, there are controversial results with respect the 
activiral actions of SP-A [Hickling et al., 2000].
Finally, we analyzed the action of intracellular or extracellular CL on RSV-elicited 
inflammatory response in AECs. As we expected, if less viral particles are able to 
replicate inside the cells in the presence of extracellular CL vesicles, the immune 
innate response will be reduced. Figure 4.2.7 shows that extracellular CL vesicles 
(7 nmol/ml) reduced RSV-induced expression of RIG-I, TLR3, ISG15 and TNF-α. 
With respect to endocytosed CL, we found that intracellular CL is able to reduce 
RSV-elicited TNF-α expression but at a higher phospholipid concentration (28nmol/
ml) than extracellular CL vesicles (7nmol/ml). The mechanism that underlies the 
anti-inflammatory action of endocytosed CL vesicles is different of that described 
for extracellular CL vesicles, whose anti-inflammatory action is a consequence of a 
decreased replication of the virus inside AECs [Figure 4.2.10].
When RSV is recognized by TLR3, this receptor induces downstream signaling 
through its adaptor protein, MyD88. MyD88 elicits signaling pathways such as IRAK 
(IL-1 receptor-associated kinase)-1/4, TRAF6 (TNF receptor associated factor 6), 
IRF (interferon regulatory factor), and/or NF-κB [Yamamoto et al., 2003; Takeda and 
Akira, 2015]. These signals may lead to the production of various cytokines such 
as type I IFN (IFN-α and -1β) and proinflammatory cytokines such as TNF-α, IL-1, 
IL-6, and IL-8 [Yamamoto et al., 2003; McGettrick and O’Neill, 2004; Takeda and 
Akira, 2015]. We hypothesize that endocytosed CL vesicles could act regulating 
transcription factors that block some steps of the signaling pathways cited above 
thus producing a decrease in the RSV-elicited inflammatory response.
In summary, our results highlight the antiviral and anti-inflammatory action of low 
amounts CL vesicles on RSV infection. Interestingly, we found that CL is more 
effective than acidic phospholipids such as POPG in inhibiting viral docking to 
the cell surface. CL antiviral properties have not been demonstrated before and 
suggest that low dose of CL could be used as a promising therapy against RSV, 
which causes serious illness in children, elderly individuals and people with chronic 
cardiopulmonary diseases.
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4.3. CARDIOLIPIN PROTECTS AGAINST NON-TYPABLE 
HAEMOPHILUS INFLUENZAE INFECTION OF MLE-12 MURINE 
ALVEOLAR EPITHELIAL CELLS.
4.3.1. INTRODUCTION
Non-typable Haemophilus influenzae is a non-capsulated Gram-negative present 
as a commensal in the nasopharynx of the vast majority of healthy individuals. 
However, when it moves in to the lower respiratory tract it causes disease. NTHi is 
the main cause of exacerbations in patients with underlying inflammatory diseases, 
such as chronic obstructive pulmonary disease (COPD) [Murphy et al., 2004; 
Moghaddam et al., 2011]. NTHi is also a leading cause of otitis media, sinusitis and 
pneumonia, often following viral respiratory infection [Murphy, 2003]. A proposed 
mechanism through which NTHi causes chronical infections is due to its ability to 
be internalized and survive inside airway epithelial cells. NTHi is able to survive into 
late endosomes in a non-replicative state but maintaining an active metabolism. The 
internalization mechanism requires lipid rafts and citoskeleton integrity, as well as 
Akt phosphorylation mediated PI3K [Morey et al., 2011; López-Gómez et al., 2012].
Cardiolipin is present in the outer membrane of Gram-negative bacteria and the 
membrane of Gram-positive bacteria (around 10 and 25%, respectively) [Barák and 
Muchová., 2013]. Nevertheless, NTHi lacks of CL in the composition of its membrane 
[Ray et al., 2010]. In eukaryotic cells, CL is mainly located in the inner mitochondrial 
membrane (around 20 %) [Krebs et al., 1979; Zinser et al., 1991 Paradies et al., 
2013]
Recently, it has been described that in mice and humans with pneumonia, CL is 
released to the alveolar fluid presumably from the host [Ray et al., 2010]. It has been 
shown that anionic phospholipids, such as phosphatidylglycerol, limit the immune 
response and infection in the alveoli [Kuronuma et al., 2009; Kandasamy et al., 2011]. 
Moreover, in the present doctoral dissertation we have proved the anti-inflammatory 
action of CL against bacterial and fungal molecular patterns on murine AMs and its 
antiviral and anti-inflammatory properties on human AECs infected with RSV. 
Taking into account this prior information, the purpose of this study was to investigate 
whether CL protects against bacterial infection of AECs by NTHi.
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4.3.2. EXPERIMENTAL DESIGN
We infected murine AEC cell line MLE-12 with two different strains of NTHi: one 
isolated from otitis media (NTHi 375) and the other from COPD (NTHi 86-028NP) 
patients. Murine MLE-12 AECs were mock-infected or infected with NTHi (108 c.f.u/
ml) in the presence or absence of CL (7 and 27 nmol/ml) at 37ºC and 5% CO2.
We first evaluated adhesion of NTHi to AECs. With this purpose, cells were infected 
for 30 minutes, lysed with PBS-saponin and serial dilutions were plated on agar-
BHI for colony counting. We then evaluated invasion of AECs by NTHi. With this 
aim, AECs were infected for 2h, followed by treatment with gentamicin in order to 
kill extracelullar bacteria. Then, cells were lysed and serial dilutions were plated on 
agar-BHI for colony counting.
To detect Akt phosphorylation, after incubation with NTHi for 1h, cell culture medium 
was discarded, wells were washed and cell lysates were obtained for western-blot.
All these procedures are detailed in the materials and methods section.
Figure 4.3.1. Experimental design.
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4.3.3. RESULTS 
 4.3.3.1. Cardiolipin inhibits NTHi internalization into epithelial 
cells without affecting bacterial adhesion to the cell surface.
First, we analyzed the potential effect of CL on bacterial adhesion and invasion in 
murine MLE-12 AECs (Figure 4.3.2). Our results indicated that the co-administration 
of CL with NTHi reduced bacterial invasion whereas we did not observe changes 
in adhesion. In both bacterial strains (otitis and COPD), the inhibitory effect on 
invasion was dose-dependent. From these experiments we can conclude that CL 
action might take place at the intracellular level because  CL did not interfere with 
NTHi docking to the cell surface. Thereby, the next step was to analyze the effect 
of CL on NTHi-elicited Akt phosphorylation, a signal needed for NTHi internalization 
into the epithelium [López-Gómez et al., 2012].
Figure 4.3.2. Cardiolipin inhibited invasion (pink bars) but not adhesion (grey 
bars) of NTHi COPD (A) or otitis (B) in MLE-12 cells. CL was added simulta-
neously with NTHi to the cells. To carry out adhesion and invasion experiments 
cells were infected with NTHi for 30 minutes or 2 hours respectively. Data show 
the percentage of viable bacteria referred to control (infected cells in the absence 
of CL). Data are expressed as mean percentages ± S.E. (*** p<0.001 vs control; 
*p<0.050 vs control).
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 4.3.3.2. Cardiolipin inhibits NTHi-induced Akt-phosphorylation
Results depicted in Figure 4.3.2 suggest an effect of CL on intracellular signaling. 
Since, we have demonstrated that CL strongly inhibited LPS- and zymosan-
elicited Akt phosphorylation in murine and rat AMs (part 1 of results), we decided 
to investigate the effect of CL on NTHi-induced Akt phosphorylation. We analyzed 
NTHi-induced Akt phosphorylation in the presence or absence of CL vesicles (7 or 
27 nmol/ml). Results shown in Figure 4.3.3 proved that CL is able to inhibit basal as 
well as NTHi-elicited Akt phosphorylation.
Figure 4.3.3. Low amounts of CL vesicles inhibit NTHi-elicited
 Akt phosphorylation. Cardiolipin vesicles were coadministrated with NTHi 
COPD (A) or otitis (B) to the cells for 1 hour. Phosphorylated Akt was detected by 
western blot and quantified by densitometry. NTHi-induced Akt phosphorylation 
in the absence of CL was considered as 100%. Data are expressed as mean 
percentages ± S.E. (### p<0.001 vs control; ## p<0.010 vs control; ***p<0.001 
vs NTHi).
4.3.4. DISCUSSION
Non-typable Haemophilus influenzae is a Gram-negative bacteria which exists 
as a commensal of the nasopharynx but it can cause opportunistic infections in 
immunocompromised individuals. NTHi has been considered an extracellular 
pathogen but there is compelling evidence indicating that NTHi is able to invade 
epithelial cells [Virji et al., 1991; Swords et al., 2000]. Considering that intracellular 
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localization of NTHi favors its persistence [López-Gómez et al., 2012], finding a 
molecule able to inhibit NTHi invasion of the epithelium would be crucial to counteract 
NTHi persistent or chronic infection. As depicted in Figure 4.3.2, the co-administration 
of CL vesicles with NTHi, inhibited NTHi internalization into murine pneumocytes 
without affecting bacterial adhesion to the cell surface. This fact reveals that the 
mechanism underlying to the protective effect of CL on NTHi infection compared to 
RSV infection is different. We have proved in the present thesis that CL inhibits viral 
replication through an extracellular mechanism by impairing viral particles docking 
to the cell surface (part 2 of results). In the case of NTHi infection, CL may be acting 
inside the cell blocking a key step of the intracellular signaling required for NTHi 
invasion. In fact, in this thesis, we proved that incubation of the cells in the presence 
of CL vesicles for 18 hours before LPS addition was as effective as coadministration 
of CL with LPS, which indicates that CL anti-inflammatory action takes place in the 
extracellular medium and also after its endocytosis as it is demonstrated in part 1 
of results, Figure 4.1.3. 
Given that NTHi internalization requires the phosphorylation of the serine-threonine 
kinase Akt mediated by PI3K [López-Gómez et al. 2012], we decided to analyzed CL 
action on NTHi-induced Akt phosphorylation. For both NTHi strains used isolated 
from patients suffering otitis and COPD, we found that CL inhibited NTHi-elicited 
Akt phosphorylation [Figure 4.3.3]. As we hypothesized in part 1 of Results, CL 
maybe directly blocking PI3K, another protein needed for Akt phosphorylation or 
some receptors upstream of these molecules.
NTHI binds to a variety of receptors on the host cell membrane. Among them, 
are found, Platelet-activating factor receptor (PAF-R), the betaglucan receptor 
and integrins α5 and β1. NTHi adhere to and enter to human epithelial cells via 
an interaction of lipooligosaccharide (LOS), a molecule similar to LPS, with PAF-R 
[Ketterer et al., 1999; Swords et al., 2000]. In fact, it was demonstrated that PAFR 
expression is upregulated in the respiratory epithelium of smokers and COPD 
patients. This enhaces NTHi and Streptococcus pneumoniae adherence to the 
surface of bronchial epithelium [Swords et al., 2001]. In addition to PAFR, the 
β-glucan receptor (Dectin-1) also mediates NTHi internalization into the cells. Ahrén 
et al. found that adherence and phagocytosis of NTHI by monocytes, eosinophils 
and A549 AECs were both inhibited by the Dectin-1 antagonist laminarin [Ahrén et 
al., 2001]. However, our results indicated that NTHi adhesion to the cell surface is 
not affected by CL. Therefore, it is unlikely that PAF-R and Dectin-1 are potential 
targets for CL.
López-Gómez and co-workers demonstrated that integrin α5 is needed both for 
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NTHi adhesion to and internalization into the host epithelial cells. However, β1 
integrin inactivation, by gene silencing or blocking antibodies, leads to intact NTHi 
adhesion but impairs NTHi invasion [López-Gómez et al., 2012]. Moreover, integrin 
activation elicits several signaling pathways including src, Rac1, PI3K-Akt and 
microtubules stabilization and polymerization [Caswell et al., 2009; Huveneers and 
Danen., 2009]. Pharmacological inhibition of these pathways results in a diminished 
NTHi internalization [Morey et al., 2011; López-Gómez et al., 2012]. Since our results 
show that CL inhibits NTHi invasion but not adhesion to the epithelium surface and 
NTHi-induced Akt phosphorylation is inhibited by CL, it is possible that CL might 
target β1 integrin or its downstream signaling patways.
Many pathogens seek refuge inside host cells during infection. CL, due to its ability 
to inhibit bacterial internalization into pneumocytes, may lead to clinical benefits in 
persistent infections by NTHi or another bacteria that manipulate PI3K, Akt and/or 
microtubules reorganization to invade pneumocytes.
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4.4. CARDIOLIPIN EFFECTS ON PULMONARY SURFACTANT
4.4.1. INTRODUCTION
Cardiolipin is present in the outer membrane of Gram-negative bacteria and the 
membrane of Gram-positive bacteria (around 10 and 25%, respectively) [Barák and 
Muchová, 2013]. In eukaryotic cells, CL is mainly located in the inner mitochondrial 
membrane (~ 20 %) [Krebs et al., 1979; Zinser et al., 1991; Paradies et al., 2013]. 
Nevertheless, CL is also present in the outer mitochondrial membrane (~ 5%) and 
is enriched at contact sites between the inner and outer membrane [Daum 1985; 
Zinser et al., 1991; Kroon et al., 1997]. Unlike most naturally occurring phospholipids, 
CL is composed of two 1,2-diacylphosphatidate moieties esterified to the 1- and 
3-hydroxyl groups of a glycerol. This results in a phospholipid with a small anionic 
headgroup and a large hydrophobic moiety formed by four acyl chains [Lewis and 
McElhaney, 2009; Unsay et al., 2013] (Figure 4.4.1).
The chemical structure of CL confers this phospholipid the tendency to form 
nonlamellar structures involved in membrane processes [Dahlberg, 2007; Unsay et 
al., 2013]. In fact, in the mitochondria, CL is essential for the production of ATP by 
oxidative phosphorylation. In addition, it participates in apoptosis and mitochondrial 
fusion and fission processes [Claypool and Koehler, 2012; Mayr, 2015; Kagan et al., 
2017; Maguire et al., 2017]. The relevance of CL in cellular function is demonstrated 
by the existence of several pathologies associated with deficiency in CL biosynthesis 
and/or remodeling of their acyl chains [Acehan et al., 2012; Claypool and Koehler, 
2012; Lu et al., 2016]. Despite its key role on cell function, molecular effects of 
CL on pulmonary surfactant membranes properties and function remains largely 
unknown.
Recently, it has been described 
that patients and mice with 
pneumonia present high levels 
of CL in the alveolar fluid. The 
chemical structure of CLs found 
in the bronchoalveolar fluid 
of these individuals is typical 
mammalian CL. This fact led 
to virtually rule out a bacterial 
origin. These investigators 
have also proved that high 
concentrations of CL impaired 
lung function, decreasing 
4.4.1. Cardiolipin molecular structure. 
Taken from Unsay et al., 2013.
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compliance and increasing lung elastance and resistance [Ray et al., 2010].
Considering this prior information, the aim of this study was to investigate whether 
CL released from dying host cells to the alveolar fluid during infection could damage 
pulmonary surfactant membranes hampering its surface activity function. 
4.4.2. EXPERIMENTAL DESIGN
We investigated the effect of CL on the function and physical properties of surfactant 
membranes employing different biophysical techniques (Figure 4.4.2). To determine 
CL action on surfactant function. To that end, we performed different experimental 
approaches: 1) CL was incorporated into lipid preparations of surfactant containing 
SP-B and SP-C (LES) at increasing molar ratios (0, 3, 6 and 12%) and mixed LES/
CL multilamellar vesicles (MLVs) were prepared; 2) Small unilamellar vesicles of CL 
(SUVs) were prepared as described in materials and methods, and injected ten 
minutes before or co-inyected with MLVs of LES or NPS.
Moreover, we characterized the effect of CL incorporated into LES on the physical 
properties of LES by two different experimental techniques: DPH anisotropy and 
differential scanning calorimetry which provide information about lipid membrane 
order and membrane fluidity, respectively. Finally, we evaluated the ability of CL to 
insert into LES monolayers.
Figure 4.4.2. Experimental design used in this work. (MLVs: Multilamellamelar 
Vesicles; SUVs: Small Unilamellamelar Vesicles; DSC: Diferential Scanning Calo-
rimetry; DPH:  1, 6-Diphenyl-1, 3, 5-hexatriene). 
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4.4.3. RESULTS
 4.4.3.1. Surfactant inhibition by cardiolipin
To study CL effect on the ability of pulmonary surfactant to adsorb onto and spread 
at the air/liquid interface, we recorded the interfacial adsorption kinetics of NPS 
or LES in the absence or presence of CL injected simultaneously to surfactant 
(Figure 4.4.3A and 4.4.3B, blue symbols) or before surfactant injection into the 
aqueous subphase (1.5ml) (Figure 4.4.3A and 4.4.3B, pink symbols). LES MLVs 
quickly adsorbed to the air/liquid interface increasing the surface pressure up to an 
equilibrium value of 47 mN/m (Figure 4.4.3A, black symbols) as previously shown 
[Sáenz et al., 2007; Sáenz et al., 2010]. When CL and LES were simultaneously 
injected into the aqueous subphase, the maximum surface pressure and the 
adsorption rate decreased (Figure 4.4.3A, blue symbols), indicative of a CL-induced 
slight inhibition of the ability of surfactant membranes to adsorb onto and spread at 
an air/liquid interface. Nevertheless, when CL vesicles were injected into the aqueous 
subphase before LES injection, CL strongly inhibited surfactant adsorption (Figure 
4.4.3, pink symbols). This inhibition must be due to competitive adsorption since CL 
vesicles showed interfacial activity (Figures 4.4.3A and 4.4.3B, purple symbols). On 
the other hand, co-injection of CL did not affect the interfacial adsorption of NPS 
(Figure 4.4.3B, blue symbols), whereas preinjection of CL strongly hampered the 
adsorption of NPS (Figure 4.4.3B, pink symbols). 
In Figure 4.4.3C, we can appreciate that NPS (white bar) as well as LES (gray bar) 
in the absence of CL reached the equilibrium surface pressure after 30 minutes. CL 
co-inyected into the aqueous subphase prevented LES (gray zig-zag pattern bar) 
but not NPS (white zig-zag pattern bar) to attain the equilibrium surface pressure. 
However, when CL was inyected into the aqueous subphase10 minutes before 
prevent both, NPS (white balls pattern bar) and LES (white balls pattern bar) to reach 
the equilibrium surface pressure. This indicate that SP-A present in NPS protects 
NPS membranes from inhibition when NPS and CL vesicles were co-inyected. 
Nevertheless, SP-A was not able to avoid NPS inhibition when CL was inyected 
previously in the aqueous subphase.
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Figure 4.4.3. Inhibitory effect of CL on the interfacial adsorption of (A) LES or 
(B) NPS.  Surface adsorption was assayed at a phospholipid concentration of 
180 nmol/ml in the absence (•) and presence of CL (27 nmol/ml) simultaneously 
injected in the subphase with surfactant (•) or injected in the aqueous subphase 
before surfactant injection (•). Pure CL vesicles adsorbed onto the clean air-
liquid interface (•). Data are expressed as means ± SE of three experiments. (C) 
Comparison of the equilibrium surface pressure attained after 30 min by NPS 
(white bar) and LES MLVs (gray bar), in the absence and presence of CL co-
inyected with NPS or LES (zig-zag pattern) or CL injected into the subphase 
before NPS or LES injection (balls pattern). *** (p<0.001); * (p < 0.050) with respect 
to the control without CL.
Given that CL is miscible with DPPC [Sennato et al., 2015], the major surfactant 
phospholipid [Casals and Cañadas, 2012], and DPPE [Sennato et al., 2005], we 
next evaluated whether CL incorporation in surfactant membranes would alter their 
ability to adsorb onto an air/liquid interface at different molar percentages (6 and 12 
%). The presence of increasing molar percentages of CL decreased the maximum 
surface pressure in a dose-dependent manner (Figure 4.4.4A and 4.4.4B), which 
indicates that the presence of CL in the composition of LES membranes inhibited 
the ability of surfactant membranes to adsorb onto and spread at an air/liquid 
interface. This effect may be due to a disturbing effect of CL on the structure of 
surfactant membranes.
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Figure 4.4.4. Incorporation of CL into LES vesicles inhibited their ability to ad-
sorb onto and spread at an air/liquid interface. (A) Effect of the amount of CL 
incorporated into surfactant membranes on the adsorption kinetics of LES MLVs 
(180 µM PL): (•) 0 mol %; (•) 6 mol % ; and 12 mol % (•). Data are expressed as 
means ± SE of three experiments. (B) Effect of the amount of CL incorporated in 
LES MLVs on the maximum surface pressure attained after 30 min. *** (p<0.001); 
* (p < 0.050) with respect to the control without CL.
 4.4.3.2. SP-A binds cardiolipin
SP-A is able to bind to a broad spectrum of ligands existing on the surface of microbes, 
such as LPS on Gram-negative bacteria, glycoprotein on fungi, lipoarabinomannan 
on mycobacteria, phospholipids on Mycoplasma, and glycoproteins on viral surface 
[Wright, 2005]. Since SP-A prevents surfactant inhibition by co-inyected CL [Figure 
4.4.3B], it is conceivable that SP-A could bind free CL vesicles in the aqueous 
subphase preventing their interaction with surfactant membranes or their adsorption 
to the air- liquid interface. To test this hypothesis, we studied the ability of SP-A to 
bind CL employing fluorescence spectroscopy.
To that end, we recorded the intrinsic fluorescence emission spectrum of 15 nM SP-A 
in Tris-HCl 5mM buffer pH=7.4, containing NaCl 150 mM and CaCl2 150 µM using 
295 nm excitation, before and after addition of increasing amounts of CL (Figure 
4.4.5A). The emission spectrum of SP-A was characterized by a maximum at 338 
nm (Figure 4.4.5A), due to the contribution of two conserved tryptophan residues 
located at positions 191 and 213 of the globular C-terminal domain [Casals et al., 
1993]. The addition of increasing amounts of CL resulted in a significant decrease 
in the amplitude of the emission spectrum of SP-A, without changes in its maximum 
emission wavelength (Figures 4.4.5A and 4.4.5B). This indicates that SP-A binds to 
CL. Figure 4.4.5B shows the intensity data from titration of 15 nM SP-A with CL at 
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338 nm. By fitting the titration data to equation 3.3, a Kd value of 2.2 ± 0.4 nM was 
obtained. These results allow us to suggest that SP-A present in NPS would bind to 
CL free vesicles protecting surfactant membranes from inhibition.
Figure 4.4.5. SP-A is able to bind cardiolipin vesicles. (A) Fluorescence emis-
sion spectra of SP-A (15 nM) recorded in the absence (black line) or the presence 
increasing amounts of CL (0 to 20 nM, colored lines) at 25 °C in 5 mM Tris-HCl 
buffer (pH 7.4) containing 150 mM NaCl and 150µM of CaCl2. (B) Fitting of the 
equilibrium binding titration data expressed as F/F0, where F0 is the observed 
intensity of pure SP-A and F, the intensity of SP-A in the presence of increasing 
amounts of CL. Results are means ± SE of three independent experiments (B).
 4.4.3.3. Cardiolipin is able to insert into surfactant monolayers
Next, we determined whether CL is capable of inserting into LES monolayers by 
measuring the increase in the lipid monolayer surface pressure at a given initial 
pressure (Figure 4.4.6). An increase in pressure (π) indicates that CL is able to insert 
into the monolayer. Given that CL incorporation into LES membranes impairs their 
proper interfacial adsorption, we determined whether CL present in the alveolar 
fluid could be incorporated into surfactant membranes.
To carry out these experiments, the monolayer of LES was formed by spreading 
LES dissolved in chloroform:methanol (2:1) and allowing its total evaporation. Once 
the monolayer was formed, the pressure increases due to the presence of lipids at 
the interface. A certain amount of lipid was deposited (different each time), therefore 
different pressure values were reached for each amount of lipid. Then, CL was 
injected into the subphase and the variation of the surface pressure as a function 
of time was monitored. As we can observe, the surface pressure increased in the 
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presence of CL. When the monolayer is formed, CL was injected into the aqueous 
subphase. This increase is lower as the amount of LES deposited in the subphase 
increased. That is why, as the amount of LES increased, less CL molecules fit in 
the interface until no more could be incorporated. By plotting the surface pressure 
increase induced by the insertion as a function of initial surface pressure (Δπ = πe - 
πi), the maximum insertion pressure (MIP) for CL could be obtained by extrapolation 
of the regression line to a surface pressure increase equal to zero. This pressure 
indicates the maximum πi above which no more CL molecules were able to penetrate 
into a LES membranes and increase surface pressure.
We have obtained a MIP value of 28 mN/m for CL insertion into LES monolayers. 
Considering that the estimated lateral pressure for a biological membrane is around 
30 mN/m [Marsh, 1996]. Our data suggest that CL could be capable of inserting into 
LES membranes.
Figure 4.4.6. CL is capable of inserting into LES monolayers. LES monolayers 
were formed by spreading different amounts of a concentrated solution of LES 
(1 mg/ml) at the air-water interface of the subphase buffer (5 mM Tris buffer, pH 
7.4, 150 mM NaCl and 0.175 mM CaCl2) to give the indicated initial surface 
pressures (0 to 13 mN/m). Then, CL was injected into the subphase and CL-in-
duced changes in the monolayer surface pressure at constant surface area were 
measured using a thermostated Langmuir-Blodgett trough. Straight line was ob-
tained by linear regression of the experimental data. Results are means ± SE of 
three independent experiments.
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4.4.3.4. Cardiolipin effect on the physical properties of surfactant 
membranes in the absence and presence of SP-A.
Given that the incorporation of CL into LES membranes strongly inhibited their 
interfacial adsorption (Figure 4.4.4), we evaluated the effect of CL on the physical 
properties of LES membranes. To that end, we studied the thermotropic properties 
of LES membranes. LES MLVs exhibited an endothermic transition with a gel/liquid 
crystalline transition temperature, Tm, of approximately 44.4 ± 0.2ºC and a transition 
enthalpy of 2.7 ± 0.1 kcal/mol (Figure 4.4.7A and Table 4.4.1). As the amount of CL 
incorporated into LES MLVs increased, both the Tm and the transition enthalpy 
decreased (Table 4.4.1). This indicates that CL fluidizes surfactant membranes and 
decreases van der Waals interactions among adjacent surfactant lipid molecules. 
Figure 4.4.7B shows that, in the presence of CL, the emission anisotropy of DPH 
decreases. The lack of changes in the fluorescence of the probe in the presence 
of CL (data not shown) allows us to infer that CL decreases the lipid order of LES. 
Given that SP-A prevents surfactant inhibition by co-inyected CL vesicles as 
described above, we evaluated the potential protective effect of SP-A against CL 
incorporation in LES membranes. Figure 4.4.7 shows that SP-A (2.5 wt % SP-A) 
did not counteract the effect of CL 6 mol % on either the thermotropic properties 
(Figure 4.4.7A) or the lipid order (Figure 4.4.7B) of LES membranes.
Figure 4.4.7. Cardiolipin effect on the surfactant membranes thermotropic be-
havior (A) and lipid order (B) in the absence or presence of SP-A. (A) DSC scans 
of mixed MLVs of LES containing increasing molar percentages of CL were re-
corded : 0 mol % (—), 3% mol (—), 6 mol % (—), 12 mol % (—) and 6 mol %. 
Dashed line shows that addition of 2.5 % SP-A (w/w) to the samples containing 
6 mol % CL did not alter DSC trace. Calorimetric scans were performed at a 
scanning rate of 0.5ºC/min. Data shown are the means of three thermograms 
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± S.E. (B) CL in the absence (•) diminished the lipid order of  LES membranes. 
This effect was not reverted by SP-A (•) The emission anisotropy of DPH was 
measured with excitation at 360 nm and emission at 430 nm. Data shown are the 
means of three independent measurements. All measurements were performed 
at 25 ± 0.1ºC. * (p < 0.05) between LES in the absence and presence of CL.
4.4.5. DISCUSSION
Cardiolipin is a unique phospholipid with a dimeric structure, having four acyl 
chains and potentially carrying two negative charges [Haines, 2009]. CL is present 
in bacterial membranes [Barák and Muchová, 2013] and in eukaryotic organisms, 
where it is mainly found in the inner [Krebs et al., 1979; Zinser et al., 1991 Paradies 
et al., 2013] but also in the outer mitochondrial membrane [Daum 1985; Zinser et al., 
1991; Kroon et al., 1997]. CL is typically a minor component of pulmonary lavage 
fluid and comprises only ~1–2% of surfactant [Ray et al., 2010; Agassandian and 
Mallampali, 2013]. Ray and Co-workers determined that in human and mice with 
pneumonia, CL levels were increased in the bronchoalveolar lavage. CL acyl chain 
composition appeared to be from human rather than bacterial origin. They have 
also demonstrated that in a mouse model of bacteria-induced lung injury, high 
concentrations of CL impaired lung function, decreasing compliance and increasing 
lung elastance and resistance. Moreover, these investigators have demonstrated that 
incorporation of CL into infasurf, a commercial apoprotein-containing surfactant, 
hampered the surface tension-lowering ability of this surfactant in vitro [Ray et al., 
2010]. 
Therefore, the aim of this work was to characterize the mechanism by which CL 
inhibits surfactant function and to evaluate the protective role of SP-A against CL-
induced surfactant inactivation.
 In this work, we determined that CL vesicles slightly inhibit the surface adsorption 
of surfactant preparations lacking SP-A (LES) by competitive adsorption (Figure 
4.4.3A) and by fluidization of surfactant membranes (Figure 4.4.4). CL vesicles 
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ΔH (kcal/mol ºC) Tm (ºC)
LES 2.7 ± 0.1 44.4 ± 0.2
+ CL (3% mol) 2.40 ± 0.02 43.4 ± 0.1
+ CL (6% mol) 1.3 ± 0.1 43.8 ± 0.2
+ CL (12% mol) 1.18 ± 0.09 34 ± 2
+ CL (6% mol) + SP-A 1.4 ± 0.1 44.4 ± 0.3
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(Figures 4.4.3A) as many biologic molecules, including tissue and blood proteins, 
inflammation specific proteins and fatty acids among others, adsorb to the air-water 
interface and compete with lung surfactant for the interface [Wang and Notter, 1998; 
Taeusch et al., 2005; Zasadzinski et al., 2005; Zuo et al., 2008]. As we could see in 
Figure 4.3A, free CL vesicles in the aqueous subphase delayed the adsorption of 
LES at the air-water interface (Figure 4.4.3A). This effect is similar to that observed 
for fibrinogen and albumin via competitive adsorption by Gunasekara and co-
workers [Gunasekara et al., 2007]. 
In addition to competitive adsorption, CL molecules could be incorporated into 
LES membranes inhibiting their function in a similar way to that determined for 
C-reactive protein [Sáenz et al., 2010].
Results shown in Figure 4.4.4 demonstrate that incorporation of CL molecules in 
LES vesicles (Figure 4.4.5) hampers their ability to adsorb onto and spread at an air-
liquid interface. When CL is incorporated in LES MLVs, its bulky structure impeded 
DPPC packing [Ray et al., 2010].
 Sennato and co-workers studied the interaction of PC, PE and CL using mixed 
monolayers of saturated DPPC or DPPE in the presence or absence of fully 
unsaturated CL. They found that DPPC, the main surfactant phospholipid [Cañadas 
and Casals, 2012], was miscible with CL whereas DPPE did not. Moreover, they 
pointed that the different behavior is due to the polar head, because they proved 
that unsaturated egg PC is also miscible with CL [Sennato et al., 2005]. CL is also 
miscible with POPG and DPPG [Wydro, 2013].
Given that CL is miscible with DPPC and repulsions occur between DPPC and CL 
molecules [Sennato et al., 2005], van der Walls interactions between phospholipids 
decrease. This fact agrees with the increase of fluidity and decrease of lipid order 
of LES membranes as amount of CL incorporated into LES membranes increased 
(Figure 4.4.7 and Table 4.4.1). By containing a high proportion of unsaturated acyl 
chains (more than 95%) [Niemelä et al. 2006] or maybe by establishing interactions 
with surfactant components, CL may render the membranes more fluid and less 
ordered. 
In agreement with the results shown in Figure 4.4.7 and Table 4.4.1, it has been 
described that the fluidity of pure L-α-phosphatidylcholine from egg (EPC) 
membranes increased with the CL concentration. Moreover, they proved that CL also 
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increased the fluidity of membranes mimicking the mitochondrial outer membrane 
composition and decreased their mechanical stability, indicating that CL decreases 
the packing of the membranes [Unsay et al. 2013]. 
Our data suggest that CL could be incorporated into LES membranes (Figure 4.4.6). 
Nevertheless, further experiments should be conducted to insure it. We propose that 
CL might be incorporated into surfactant membranes during surfactant recycling by 
type II pneumocytes [Agassandian and Mallampali, 2013] or directly, due to the 
fusion of CL vesicles with those of surfactant, since CL vesicles fuse in the presence 
of calcium [Ortiz et al., 1999].
Another focus of this study was to investigate SP-A´s effect on surfactant inhibition 
by CL. SP-A is able to bind a broad spectrum of ligands and is mainly involved 
in the immune innate defense in the alveoli [Wright, 2005]. We proved that NPS, 
which contains SP-A, is not inhibited when co-inyected with CL SUVs in the air/
liquid subphase (Figure 4.4.3B). These data allow us to hypothesize that SP-A could 
counteract the slight inhibitory effect observed in the case of LES, probably due to 
the ability of SP-A to accelerate surfactant adsorption [Schürch et al., 1992; Casals, 
2001]. It is well known that adding non-surface active hydrophilic polymers to the 
subphase provides a depletion attraction between surfactant aggregates and the 
interface, which can overcome the steric and electrostatic resistance to adsorption 
induced by serum and albumin among other substances [Zasadzinski et al., 2005; 
Lu et al., 2000; Taeusch et al., 1999]. SP-A is a natural hydrophilic polymer which 
can enhance adsorption to eliminate surfactant inactivation by CL as it is described 
for serum [Zasadzinski et al., 2005]. 
In addition, SP-A binding to CL (Figure 4.4.5) might block CL interaction with 
surfactant membranes as it has been described in our research group for beta-
glucan (unpublished data) or impairs CL incorporation into LES as it has been 
reported for CRP [Sáenz et al., 2010]. 
On the other hand, we proved that when CL is incorporated into LES membranes, 
SP-A did not revert effect on CL´s effects on LES physical properties (Figure 4.4.7). 
It has been described that SP-A promotes solid/fluid phase coexistence in model 
surfactant membranes lacking colesterol (DPPC/POPG/PA) which ameliorates 
membranes physical properties and their surfactant activity. Nevertheless, phase 
coexistence is characteristic of LES both in the presence as in the absence of SP-A 
[Sáenz et al., 2007].
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In summary, our results highlight an inhibitory action for CL at high doses on 
lung surfactant function. CL action takes place by two different mechanisms: (i) 
competitive adsorption, in which CL competes with surfactant for the air-liquid 
interface, (ii) a fluidizing effect of CL on surfactant membranes. Furthermore, we 
proved that SP-A is able to counteract the slight inhibitory effect caused by free CL 
vesicles in the aqueous subphase but if CL forms part of the composition of LES, 
SP-A did not revert CL effect on LES physical properties 
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V. CONCLUSIONS
The research presented in this doctoral thesis highlights the dual effect of cardiolipin 
(CL) in the alveolus in function of the dose. Low amounts of CL are beneficial for 
the host, acting as an anti-infectious and anti-inflammatory agent, whereas higher 
doses are harmful, affecting lung surfactant function and cell viability. The results 
compiled in this thesis allow us to conclude that:
1. CL vesicles either simultaneously added with the proinflammatory stimulus 
 or preincubated with cells before stimulation present a strong 
 immunomodulatory effect at low doses on the inflammatory response of 
 alveolar macrophages. We have proved that the anti-inflammatory action of 
 CL is not restricted to a particular stimulus, and occurs both extra- and intra- 
 cellularly likely by different mechanisms. On the surface of alveolar 
 macrophages, CL might impair LPS or zymosan binding to their respective 
 receptors. Once internalized by cells, CL might modify the expression of 
 cellular receptors and molecules involved in cell response. 
2.  Extracellular CL vesicles exert antiviral and anti-inflammatory properties 
 against RSV infection of human alveolar epithelial cells (AECs). CL antiviral 
 action is carried out exclusively in the extracellular medium, whereas its 
 anti-inflammatory properties were preserved once endocytosed by AECs. 
 In the extracellular medium, CL inhibits RSV replication and the subsequent 
 inflammatory response by interfering with viral particles docking to the cell 
 surface. Moreover, we proved that CL antiviral action is maintained in the 
 presence of lung surfactant components.
3.  The co-administration of CL vesicles with non-typable Haemophilus influenzae 
 (NTHi) inhibits NTHi internalization by murine AECs without affecting bacterial 
 adhesion to the cell surface. CL action occurs via inhibition of Akt 
 phosphorylation, a mechanism necessary for bacterial invasion of the   
 epithelium.
4.  Higher doses of CL than those used in experiments with cells exert an 
 inhibitory action on lung surfactant function. CL action takes place by two 
 different mechanisms: (i) competitive adsorption, in which CL competes with 
 surfactant for the air-liquid interface; and (ii) a fluidizing effect of CL on 
 surfactant membranes. Furthermore, we proved that surfactant protein Ç  
 A is able to counteract the slight inhibitory effect caused by free CL vesicles 
 in the aqueous subphase but did not show any effect when CL forms part of 
 the composition of surfactant vesicles. 
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